<SEC-DOCUMENT>0001144204-17-036847.txt : 20170714
<SEC-HEADER>0001144204-17-036847.hdr.sgml : 20170714
<ACCEPTANCE-DATETIME>20170714165245
ACCESSION NUMBER:		0001144204-17-036847
CONFORMED SUBMISSION TYPE:	PRE 14A
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20170714
FILED AS OF DATE:		20170714
DATE AS OF CHANGE:		20170714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AmpliPhi Biosciences Corp
		CENTRAL INDEX KEY:			0000921114
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				911549568
		STATE OF INCORPORATION:			WA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		PRE 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37544
		FILM NUMBER:		17965932

	BUSINESS ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		804-827-2524

	MAIL ADDRESS:	
		STREET 1:		3579 VALLEY CENTRE DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGETED GENETICS CORP /WA/
		DATE OF NAME CHANGE:	19940331
</SEC-HEADER>
<DOCUMENT>
<TYPE>PRE 14A
<SEQUENCE>1
<FILENAME>v470849_pre14a.htm
<DESCRIPTION>PRE 14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A
INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proxy
Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934</FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Amendment No. )</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 2in">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3in"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant</P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a Party other than
        the Registrant</P></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Wingdings">o</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">x</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preliminary Proxy
        Statement</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Confidential,
        for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Definitive Proxy Statement</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Definitive Additional
        Materials</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Soliciting Material
        Pursuant to &sect;240.14a-12</P></TD></TR>
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMPLIPHI BIOSCIENCES CORPORATION </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Registrant as Specified In Its
Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B></B></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name of Person(s) Filing Proxy Statement
if Other Than the Registrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment of Filing Fee (Check the appropriate
box)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>
</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">x</P></TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No fee required.</P>

</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fee computed on
        table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</P></TD></TR>
<TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 1in">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of each class of securities to which
transaction applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Aggregate number of securities to which
transaction applies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Per unit price or other underlying value
of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state
how it was determined):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Proposed maximum aggregate value of transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Total fee paid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">
</TD>
    <TD STYLE="width: 0.25in">
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fee paid previously
        with preliminary materials.</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
</TD>
    <TD>
        <P STYLE="font: 10pt Wingdings; margin: 0pt 0">o</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check box if any
        part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
        paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Amount Previously Paid:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Form, Schedule or Registration Statement
No.:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Filing Party:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date Filed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: red"><B>PRELIMINARY PROXY STATEMENT,
SUBJECT TO COMPLETION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMPLIPHI BIOSCIENCES
CORPORATION </B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3579 Valley Centre Drive, Suite 100<BR>
San Diego, California 92130<BR>
<BR>
<B>NOTICE OF ANNUAL MEETING OF SHAREHOLDERS</B><BR>
<B>TO BE HELD ON SEPTEMBER 7, 2017</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Dear Shareholder:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32pt">You are cordially invited
to attend the 2017 Annual Meeting of Shareholders of AmpliPhi Biosciences Corporation, a Washington corporation (&ldquo;AmpliPhi&rdquo;
or the &ldquo;Company&rdquo;). The meeting will be held on Thursday, September 7, 2017 at 8:00 a.m. local time at the offices of
Cooley LLP located at 4401 Eastgate Mall, San Diego, California 92121 for the following purposes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">&nbsp;</P>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">1.</TD><TD STYLE="text-align: justify">To elect two Class II Directors of the Company.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify">Approval of the issuance by the Company of 523,210 shares of common stock to certain former holders
of the Company&rsquo;s Series B convertible preferred stock (the &ldquo;Holders&rdquo;), pursuant to the terms of that certain
First Amendment to Common Stock Issuance Agreement, dated June 27, 2017, by and among the Company and the Holders.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify">Approval of an amendment to the AmpliPhi Biosciences Corporation 2016 Equity Incentive Plan to,
among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 800,000 shares.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify">Ratification of the Audit Committee&rsquo;s selection of Ernst &amp; Young LLP as the Company&rsquo;s
independent registered public accounting firm for the fiscal year ending December 31, 2017.</TD></TR></TABLE>



<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify">To conduct any other business properly brought before the meeting.</TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These items of
business are more fully described in the Proxy Statement accompanying this Notice.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The record date for the meeting is July 12, 2017. Only shareholders
of record at the close of business on that date may vote at the meeting or any adjournment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border: Black 1pt solid"><B>Important Notice
Regarding the Availability of Proxy Materials for the 2017 Annual Meeting of Shareholders to be held on September 7, 2017 at 8:00
a.m. local time at the offices of Cooley LLP located at 4401 Eastgate Mall, San Diego, California 92121<BR>
<BR>
The proxy statement and annual report to shareholders are available at<BR>
<I>www.ampliphibio.com/investor-relations.html.</I></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; border-top: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 40%; border-top: white 1pt solid; border-right: white 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By Order of the Board of Directors,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chairman of the Board of Directors</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego, California</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: white 1pt solid; border-left: white 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; border-bottom: white 1pt solid; font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32pt"><B>You are cordially
invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return
the enclosed proxy, or vote over the telephone or the internet as instructed in these materials, as promptly as possible in order
to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) has been
provided for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please
note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you
must obtain a proxy issued in your name from that record holder.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 32pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMPLIPHI BIOSCIENCES CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3579 Valley Centre
Drive, Suite 100<BR>
San Diego, California 92130</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROXY STATEMENT<BR>
FOR THE 2017 ANNUAL MEETING OF SHAREHOLDERS<BR>
TO BE HELD ON SEPTEMBER 7, 2017<BR>
<BR>
QUESTIONS AND ANSWERS ABOUT THESE PROXY MATERIALS AND VOTING<BR>
&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Why am I receiving these materials?
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have sent you these proxy materials
because the Board of Directors (sometimes referred to as the &ldquo;Board&rdquo;) of AmpliPhi Biosciences Corporation (sometimes
referred to as the &ldquo;Company&rdquo;, &ldquo;AmpliPhi&rdquo;, &ldquo;we&rdquo; or &ldquo;us&rdquo;) is soliciting your proxy
to vote at the 2017 Annual Meeting of Shareholders (the &ldquo;annual meeting&rdquo; or the &ldquo;meeting&rdquo;), including at
any adjournments or postponements of the meeting. You are invited to attend the annual meeting to vote on the proposals described
in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may simply complete,
sign and return the enclosed proxy card or follow the instructions below to submit your proxy over the telephone or through the
internet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We intend to mail these proxy materials
on or about&nbsp;July&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 to all shareholders of record entitled to vote at the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>How do I attend
the annual meeting? </B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The meeting will be held on Thursday, September
7, 2017 at 8:00 a.m. local time at the offices of Cooley LLP located at 4401 Eastgate Mall, San Diego, California 92121. Directions
to the annual meeting may be found at <I>www.ampliphibio.com/investor-relations.html</I>. Information on how to vote in person
at the annual meeting is discussed below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Who can vote at the annual meeting?
</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Only shareholders of record at the close
of business on July 12, 2017 will be entitled to vote at the annual meeting. On this record date, there were 8,749,052 shares of
common stock outstanding and entitled to vote.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Shareholder of Record: Shares Registered
in Your Name </I></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If on July 12,
2017 your shares were registered directly in your name with AmpliPhi&rsquo;s transfer agent, Computershare, Inc., then you are
a shareholder of record. As a shareholder of record, you may vote in person at the meeting or vote by proxy. Whether or not you
plan to attend the meeting, we urge you to fill out and return the enclosed proxy card or vote by proxy over the telephone or on
the internet as instructed below to ensure your vote is counted.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Beneficial Owner: Shares Registered
in the Name of a Broker or Bank </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If on July 12, 2017 your shares were held,
not in your name, but rather in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial
owner of shares held in &ldquo;street name&rdquo; and these proxy materials are being forwarded to you by that organization. The
organization holding your account is considered to be the shareholder of record for purposes of voting at the annual meeting. As
a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You
are also invited to attend the annual meeting. However, since you are not the shareholder of record, you may not vote your shares
in person at the meeting unless you request and obtain a valid proxy from your broker or other agent.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>What am I voting on? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There are four matters scheduled for a
vote:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">Election of the two nominees for director named in
this proxy statement;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">Approval of the issuance by the Company of 523,210
shares of common stock to certain former holders of the Company&rsquo;s Series B convertible preferred stock (the &ldquo;Holders&rdquo;),
pursuant to the terms of that certain First Amendment to Common Stock Issuance Agreement, dated June 27, 2017, by and among the
Company and the Holders;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">Approval of an amendment to the AmpliPhi Biosciences
Corporation 2016 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized
for issuance under the plan by 800,000 shares; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">Ratification of the Audit Committee&rsquo;s selection
of Ernst &amp; Young LLP as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December
31, 2017.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What if another matter is properly brought before the meeting?
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors knows of no other matters that will be
presented for consideration at the annual meeting. If any other matters are properly brought before the meeting, it is the intention
of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How do I vote?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may either vote &ldquo;For&rdquo; all the nominees to the
Board of Directors or you may &ldquo;Withhold&rdquo; your vote for any nominee you specify. For each of the other matters to be
voted on, you may vote &ldquo;For&rdquo; or &ldquo;Against&rdquo; or abstain from voting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The procedures for voting are fairly simple:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholder of Record: Shares Registered in Your Name</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a shareholder of record,
you may vote in person at the annual meeting, vote by proxy over the telephone, vote by proxy using the enclosed proxy card or
vote by proxy through the internet. Whether or not you plan to attend the meeting, we urge you to vote by proxy to ensure your
vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">To vote in person, come to the annual meeting and
we will give you a ballot when you arrive.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">To vote using the proxy card, simply complete, sign
and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to us before
the annual meeting, we will vote your shares as you direct.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">To vote over the telephone, dial toll-free 1-800-652-8683
using a touch-tone phone and follow the recorded instructions. You will be asked to provide the control number from the enclosed
proxy card. Your vote must be received by 11:59 p.m. Eastern Time on September 6, 2017 to be counted.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: left">To vote through the internet, go to www.envisionreports.com/APHB
to complete an electronic proxy card. You will be asked to provide the control number from the enclosed proxy card. Your vote
must be received by 11:59 p.m. Eastern Time on September 6, 2017 to be counted.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Beneficial Owner: Shares Registered
in the Name of Broker or Bank</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If you are a beneficial owner of shares
registered in the name of your broker, bank, or other agent, you should have received a voting instruction form with these proxy
materials from that organization rather than from AmpliPhi. Simply complete and mail the voting instruction form to ensure that
your vote is counted. Alternatively, you may vote by telephone or over the internet as instructed by your broker or bank. To vote
in person at the annual meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from
your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>We provide internet proxy voting to allow you to vote your
shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please
be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers
and telephone companies.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How many votes do I have?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On each matter to be voted upon, you
have one vote for each share of common stock you owned as of the close of business on July 12, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What happens if I do not vote? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholder of Record: Shares Registered in Your Name </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a shareholder of record and do not vote by completing
your proxy card, by telephone, through the internet or in person at the annual meeting, your shares will not be voted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Beneficial Owner: Shares Registered in the Name of Broker
or Bank</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you are a beneficial owner and do
not instruct your broker, bank, or other agent how to vote your shares, the question of whether your broker or nominee will still
be able to vote your shares depends on whether the New York Stock Exchange deems the particular proposal to be a &ldquo;routine&rdquo;
matter. Brokers and nominees can use their discretion to vote &ldquo;uninstructed&rdquo; shares with respect to matters that are
considered to be &ldquo;routine,&rdquo; but not with respect to &ldquo;non-routine&rdquo; matters. Under the rules and interpretations
of the New York Stock Exchange, &ldquo;non-routine&rdquo; matters are matters that may substantially affect the rights or privileges
of shareholders, such as mergers, shareholder proposals, elections of directors (even if not contested), and certain corporate
governance proposals, even if management-supported. Accordingly, your broker or nominee may not vote your shares on Proposals 1,
2, or 3 without your instructions, but may vote your shares on Proposal 4 even in the absence of your instruction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What if I return a proxy card or
otherwise vote but do not make specific choices? </B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<DIV STYLE="padding: 0in; border: white 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you return a signed and dated proxy card or otherwise vote
without marking voting selections, your shares will be voted, as applicable: &ldquo;For&rdquo; Proposal 1, the election of both
nominees for director; &ldquo;For&rdquo; Proposal 2, approval of the proposed issuance by the Company of 523,210 shares of common
stock to certain former holders of the Company&rsquo;s Series B convertible preferred stock, pursuant to the terms of that certain
First Amendment to Common Stock Issuance Agreement, dated June&nbsp;27, 2017, by and among the Company and such holders; &ldquo;For&rdquo;
Proposal 3, approval of an amendment to the AmpliPhi Biosciences Corporation 2016 Equity Incentive Plan to, among other things,
increase the aggregate number of shares of common stock authorized for issuance under the plan by 800,000 shares; and &ldquo;For&rdquo;
Proposal 4, ratification of the Audit Committee&rsquo;s selection of Ernst &amp; Young LLP as the Company&rsquo;s independent registered
public accounting firm for the fiscal year ending December 31, 2017. If any other matter is properly presented at the meeting,
your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Who is paying for this proxy solicitation? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will pay for the entire cost of soliciting proxies. In addition
to these proxy materials, our directors and employees and Georgeson LLC may also solicit proxies in person, by telephone, or by
other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies, Georgeson
LLC will be paid its customary fee of approximately $10,000, plus out-of-pocket expenses if it solicits proxies. We may also reimburse
brokerage firms, banks and other agents for the cost of forwarding proxy materials to beneficial owners.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What does it mean if I receive more than one set of proxy
materials? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If you receive more than one set of proxy materials, your shares
may be registered in more than one name or in different accounts. Please follow the voting instructions on the proxy cards in the
proxy materials to ensure that all of your shares are voted.</P>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Can I change my vote after submitting my proxy? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Shareholder of Record: Shares Registered in Your Name </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yes. You can revoke your proxy at any
time before the final vote at the meeting. If you are the record holder of your shares, you may revoke your proxy in any one of
the following ways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>You may submit another properly completed proxy card with a later date.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>You may grant a subsequent proxy by telephone or through the internet.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>You may send a timely written notice that you are revoking your proxy to our Secretary at AmpliPhi Biosciences Corporation,
3579 Valley Centre Drive, Suite 100, San Diego, California 92130.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>You may attend the annual meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.</TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your most current proxy card or telephone or internet proxy
is the one that is counted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Beneficial Owner: Shares Registered in the Name of Broker
or Bank </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If your shares are held by your broker
or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>When are shareholder proposals and director
nominations due for next year&rsquo;s annual meeting? </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; border: white 1pt solid">To be considered
for inclusion in next year&rsquo;s proxy materials, your proposal must be submitted in writing by March __, 2018, to our Secretary
at AmpliPhi Biosciences Corporation, 3579 Valley Centre Drive, Suite 100, San Diego, California 92130. If you wish to submit a
proposal (including a director nomination) that is not to be included in next year&rsquo;s proxy materials, your proposal generally
must be submitted in writing to the same address not fewer than 60 nor more than 90 days prior to the date approved by the Board
of Directors to hold the 2018 Annual Meeting of Shareholders; provided, that if we provide less than 60 days&rsquo; notice of such
date, your proposal (including a director nomination) must be received by our Secretary not later than the tenth day following
the day on which the notice of the date of the 2018 Annual Meeting of Shareholders is mailed or publicly disclosed. Please review
our current bylaws, which contain additional requirements regarding advance notice of shareholder proposals and nominations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>How are votes
counted?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Votes will be counted by the inspector
of election appointed for the meeting, who will separately count, for the proposal to elect directors, votes &ldquo;For,&rdquo;
&ldquo;Withhold&rdquo; and broker non-votes; and, with respect to other proposals, votes &ldquo;For&rdquo; and &ldquo;Against,&rdquo;
abstentions and, if applicable, broker non-votes. Under the rules of the NYSE MKT, abstentions are considered to be votes &ldquo;cast&rdquo;
and will have the same effect as &ldquo;Against&rdquo; votes for each of Proposals 2, 3, and 4. Broker non-votes will not be counted
towards the vote total for any proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What are &ldquo;broker non-votes&rdquo;? </B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As discussed above, when a beneficial owner of shares held in
&ldquo;street name&rdquo; does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed
by the New York Stock Exchange to be &ldquo;non-routine,&rdquo; the broker or nominee cannot vote the shares. These unvoted shares
are counted as &ldquo;broker non-votes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How many votes are needed to approve each proposal?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table summarizes the
minimum vote needed to approve each proposal and the effect of abstentions and broker non-votes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposal</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 33%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposal Description</B></FONT></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 29%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vote Required for Approval</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effect of</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Abstentions</B></FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effect of</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Broker</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Non-Votes</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Election of Directors</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The two nominees receiving the most &ldquo;For&rdquo; votes will be elected to the Board of Directors.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval of the proposed issuance by the Company of 523,210 shares of common stock to certain former holders of the Company&rsquo;s Series B convertible preferred stock, pursuant to the terms of that certain First Amendment to Common Stock Issuance Agreement, dated June&nbsp;27, 2017, by and among the Company and such holders</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares that vote &ldquo;For&rdquo; the proposal must exceed the number of shares that vote &ldquo;Against&rdquo; the proposal.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Against</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None </FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-bottom: 6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approval of an amendment to the AmpliPhi Biosciences Corporation 2016 Equity Incentive Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 800,000 shares</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares that vote &ldquo;For&rdquo; the proposal must exceed the number of shares that vote &ldquo;Against&rdquo; the proposal.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Against</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ratification of the Audit Committee&rsquo;s selection of Ernst &amp; Young LLP as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending December 31, 2017</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares that cast a vote &ldquo;For&rdquo; the proposal must exceed the number of shares that cast a vote &ldquo;Against&rdquo; the proposal.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Against</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What is the quorum requirement?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A quorum of shareholders is necessary to hold a valid meeting.
A quorum will be present if shareholders holding at least a majority of the outstanding shares entitled to vote on a matter and
be counted collectively upon such matter are present at the meeting in person or represented by proxy. On the record date, there
were 8,749,052 shares outstanding and entitled to vote. Thus, the holders of 4,374,527 shares must be present in person or represented
by proxy at the meeting to have a quorum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Your shares will be counted towards the quorum only if you submit
a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting.
Abstentions and broker non-votes will be counted towards the quorum requirement. If there is no quorum, the holders of a majority
of shares at the meeting in person or represented by proxy may adjourn the meeting to another date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>How can I find out the results of the voting at the annual
meeting?</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Preliminary voting results will be announced at the annual meeting.
In addition, final voting results will be published in a current report on Form 8-K that we expect to file within four business
days after the annual meeting. If final voting results are not available to us in time to file a Form 8-K within four business
days after the meeting, we intend to file a Form 8-K to publish preliminary results and, within four business days after the final
results are known to us, file an additional Form 8-K to publish the final results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>What proxy materials are available on the internet?</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proxy statement, Form 10-K and annual report to shareholders
are available at <I>www.ampliphibio.com/investor-relations.html</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposal 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Election Of Directors&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AmpliPhi&rsquo;s Board of Directors is
divided into three classes. Each class consists, as nearly as possible, of one-third of the total number of directors, and each
class has a three-year term. Under our current bylaws, any vacancy occurring on the Board (other than a director removed for cause
by the shareholders) may be filled by the shareholders, the Board or, if the directors in office constitute fewer than a quorum,
by the affirmative vote of a majority of the remaining directors. A vacancy occurring as a result of the removal of a director
for cause may be filled only by a vote of the holders of two-thirds of the shares then entitled to elect the director removed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors presently has six
members. There are two directors in Class II, whose term of office expires in 2017. The two nominees for Class II director are
Wendy S. Johnson and Vijay B. Samant. Each of the Class II director nominees is currently a director of the Company who was previously
elected by the shareholders. If elected at the annual meeting, each of these Class II director nominees would serve until the 2020
Annual Meeting of Shareholders and until her or his successor has been duly elected and qualified, or, if sooner, until the director&rsquo;s
death, resignation or removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Directors are elected by a plurality of
the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors.
Accordingly, the two nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed
proxies will be voted, if authority to do so is not withheld, for the election of the two nominees named below. If any nominee
becomes unavailable for election as a result of an unexpected occurrence, shares that would have been voted for that nominee will
instead be voted for the election of a substitute nominee proposed by the Board of Directors. Each person nominated for election
has agreed to serve if elected. The Company&rsquo;s management has no reason to believe that any nominee will be unable to serve.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Board of Directors Recommends<BR>
a Vote &ldquo;for&rdquo; Each Named Nominee&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
for our current directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 6%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 42%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook<SUP>(2)(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman of the Board</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis Drapeau<SUP>(1)(2)(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">73</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy S. Johnson</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael S. Perry, Ph.D.<SUP>(1)(2)(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay B. Samant<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 1in">_________</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Member of the Audit Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Member of the Compensation Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Member of the Nominating and Corporate Governance Committee.</TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating
and Corporate Governance Committee seeks to assemble a Board of Directors that, as a whole, possesses the appropriate balance of
professional and industry knowledge, financial expertise and high-level management experience necessary to oversee and direct the
Company&rsquo;s business. To that end, the Nominating and Corporate Governance Committee has identified and evaluated nominees
in the broader context of the Board of Directors&rsquo; overall composition, with the goal of recruiting members who complement
and strengthen the skills of other members and who also exhibit integrity, collegiality, sound business judgment and other qualities
that the Nominating and Corporate Governance Committee views as critical to effective functioning of the Board of Directors. The
brief biographies below include information regarding the specific and particular experience, qualifications, attributes or skills
of each nominee that led the Nominating and Corporate Governance Committee to recommend that person as a nominee. However, each
of the members of the Nominating and Corporate Governance Committee may have a variety of reasons why he believes a particular
person would be an appropriate nominee for the Board of Directors, and these views may differ from the views of other members.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominees for Election for a Three-year
Term Expiring at the 2020 Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Wendy S. Johnson </I></B>has served
as a member of our Board of Directors since May 2014. In addition, Ms. Johnson served as our Interim Chief Operating Officer from
September 2014 to January 2017. From 2005 to January 2014, Ms. Johnson served as a venture partner at ProQuest Investments, a venture
capital firm. From 2006 to January 2014, Ms. Johnson served as the President and Chief Executive Officer of Aires Pharmaceuticals,
a ProQuest portfolio company. Prior to joining ProQuest, she served as Senior Vice President, Corporate Development, at Salmedix
Inc., and she held senior business and corporate development positions at WomenFirst Healthcare, Prizm Pharmaceuticals (Selective
Genetics Inc.), Cytel Corp., Synbiotics Corp., and Murex Corp. (Cambridge U.K.). Additionally, Ms. Johnson served as Assistant
Director with the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Ms. Johnson received an
M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School and a B.S. in microbiology from
the University of Maryland. The Nominating and Corporate Governance Committee and the Board of Directors believe that Ms. Johnson&rsquo;s
significant experience in pharmaceutical drug development and business development, as well her strong background in microbiology,
qualifies her to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Vijay B. Samant </I></B>has served
as a member of our Board of Directors since November 2015. Since November 2000, Mr. Samant has served as President and Chief Executive
Officer of Vical, Inc., a developer of biopharmaceutical products for the prevention and treatment of chronic life-threatening
infectious diseases. Prior to joining Vical, he had 23 years of diverse U.S. and international sales, marketing, operations, and
business development experience with Merck. From 1998 to 2000, he was Chief Operating Officer of the Merck Vaccine Division. From
1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business
Affairs and Executive Director of Materials Management. Mr. Samant holds a master&rsquo;s degree in management studies from the
Sloan School of Management at the Massachusetts Institute of Technology, a master&rsquo;s degree in chemical engineering from Columbia
University, and a bachelor&rsquo;s degree in chemical engineering from the University of Bombay, University Department of Chemical
Technology. Mr. Samant has been a member of the board of directors of Vical since 2000, and was a member of the board of directors
of Raptor Pharmaceutical Corporation from 2011 to 2014, and was a member of the board of directors for BioMarin Pharmaceutical
Inc. from 2002 to 2004. Mr. Samant was a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010, a member of the
Board of Trustees for the National Foundation for Infectious Diseases from 2003 to 2012, and a member of the Board of Trustees
for the International Vaccine Institute in Seoul, Korea from 2008 to 2012. The Nominating and Corporate Governance Committee and
the Board of Directors believe that Mr. Samant&rsquo;s significant experience leading biopharmaceutical product development companies,
as well his significant sales, marketing, operations, and business development expertise within the biotechnology and pharmaceutical
industries, qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a brief biography, and
a discussion of the specific experience, qualifications, attributes or skills of each director whose term will continue after the
2017 Annual Meeting of Shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Class III Directors Continuing in Office
Until the 2018 Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Jeremy Curnock Cook </I></B>has served
as a member of our Board of Directors since July 1995 and as Chairman of the Board of Directors since February 1998. From September
2014 to May 2015, he served as our Interim Chief Executive Officer. Mr. Curnock Cook has served as Chairman of International Bioscience
Managers Limited, a corporate and investment advisory firm, since 2000, and also currently serves as Managing Director of Bioscience
Managers Pty Ltd, a medical sciences fund manager. From 1987 to 2000, Mr. Curnock Cook was a director of Rothschild Asset Management
Limited, a corporate and investment advisory company, and was responsible for the Rothschild Bioscience Unit. Mr. Curnock Cook
founded the International Biochemicals Group in 1975, which was sold in 1985 to Royal Dutch Shell, where he served as Managing
Director until 1987. He also serves as a member of the board of directors of Avita Medical Ltd, a publicly traded (ASX:AVH) medical
technology company, Nexus6 Ltd and SeaDragon Ltd. Mr. Curnock Cook received an M.A. in natural sciences from Trinity College, Dublin.
The Nominating and Corporate Governance Committee and the Board of Directors believe that Mr. Curnock Cook&rsquo;s significant
experience as a board member of multiple biotechnology companies qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Paul C. Grint, M.D. </I></B><FONT STYLE="background-color: white">has
served as our Chief Executive Officer since May 2017 and as a member of our Board of Directors since November 2015. Dr. Grint served
on the Compensation Committee of our Board of Directors until his appointment as our Chief Executive Officer. From June 2015 to
May 2017,&nbsp;</FONT>Dr. Grint&nbsp;<FONT STYLE="background-color: white">served as the President and Chief Executive Officer
and on the board of directors of Regulus Therapeutics Inc.,&nbsp;</FONT>a company focused on the discovery and development of microRNA
therapeutics,&nbsp;<FONT STYLE="background-color: white">and served as the Chief Medical Officer of Regulus Therapeutics Inc. from
June 2014 to June 2015. From February 2011 to June 2014, Dr.&nbsp;Grint served as the President of Cerexa, Inc., a wholly owned
subsidiary of Forest Laboratories, Inc., a pharmaceutical company, where he was responsible for the oversight of anti-infective
product development. Before that, Dr.&nbsp;Grint served as Senior Vice President of Research at Forest Research Institute, Inc.,
the scientific development subsidiary of Forest Laboratories, Inc., from January 2009 to February 2011, and as Chief Medical Officer
of Kalypsys, Inc., a biopharmaceutical company, from 2006 to 2008. Dr.&nbsp;Grint also previously served in similar executive level
positions at Pfizer Inc., IDEC Pharmaceuticals Corporation, and Schering-Plough Corporation. Dr. Grint currently serves on the
board of directors of Amplyx Pharmaceuticals, Inc. and of Synedgen, Inc., and served on the board of directors of Illumina Inc.
from April 2005 to May 2013. Dr.&nbsp;Grint received a B.S. in Medical Science from St. Mary&rsquo;s Hospital in London and his
medical degree from St. Bartholomew&rsquo;s Hospital Medical College at the University of London.</FONT> The Nominating and Corporate
Governance Committee and the Board of Directors believe that Dr. Grint&rsquo;s significant experience in leading biotechnology
and pharmaceutical companies, as well his significant experience in drug development and in the biotechnology industry, qualifies
him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Class I Directors Continuing in
Office Until the 2019 Annual Meeting</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Louis Drapeau </I></B>has served as a member of our Board
of Directors since March 2011. Since October 2007 through February 2016, Mr. Drapeau has served in various management positions
of InSite Vision, a traded ophthalmology drug development company that was acquired in October 2015, including Vice President and
Chief Financial Officer and Chief Executive Officer from November 2008 to December 2010. Prior to InSite Vision, he served as Chief
Financial Officer, Senior Vice President, Finance, at Nektar Therapeutics, a biopharmaceutical company, from January 2006 to August
2007. Prior to Nektar, he served as Acting Chief Executive Officer from August 2004 to May 2005 and as Senior Vice President and
Chief Financial Officer from August 2002 to August 2005 for BioMarin Pharmaceutical Inc. Previously, Mr. Drapeau spent 30 years
at Arthur Andersen, including 19 years as an Audit Partner in Arthur Andersen&rsquo;s Northern California Audit and Business Consulting
practice, which included 12 years as Managing Partner. From February 2007 until April 2017, Mr. Drapeau served as a member of the
board of Bio-Rad Laboratories, Inc., a publicly traded pharmaceutical company. Mr. Drapeau currently serves on the board of directors
of Avita Medical Ltd, a publicly traded (ASX:AVH) medical technology company, Mr. Drapeau received a B.S. in mechanical engineering
and an M.B.A. from Stanford University. The Nominating and Corporate Governance Committee and the Board of Directors believe that
Mr. Drapeau&rsquo;s experience with respect to accounting and financial matters qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Michael S. Perry, D.V.M., Ph.D. </I></B>has
served as a member of our Board of Directors since November 2005. Since June 2017 Dr. Perry has served as the Chief Executive Officer
of Avita Medical Ltd, a publicly traded (ASX:AVH) medical technology company, and has been a member of the board of directors of
Avita Medical since February 2013. Since April of 2017 he has also served as a Director and Operating Partner of Bioscience Managers
Pty Ltd., a medical sciences fund manager. From January 2016 to April 2017, Dr. Perry served as Senior Vice President and Chief
Scientific Officer of Global Business Development and Licensing for Novartis AG. From September 2014 to January 2016 he served
as Chief Scientific Officer for the Cell and Gene Therapy Unit of Novartis Pharmaceuticals Corporation and from October 2012 to
September 2014, he served as Global Head of Stem Cell Therapy and Vice President of the Integrated Hospital Care Franchise for
Novartis Pharmaceuticals Corporation. Prior to rejoining Novartis in October 2012, he was a Venture Partner with Bay City Capital,
LLC, a venture capital firm, from 2005 to September 2012. While serving in this capacity, he concurrently served as President and
Chief Medical Officer at Poniard Pharmaceuticals, Inc., a publicly held drug development company, and from 2009 to 2011. Dr. Perry
also previously served as Chief Development Officer of VIA Pharmaceuticals, Inc., a publicly held biotechnology company, from 2005
to 2009. Dr. Perry served as Chairman and Chief Executive Officer of Extropy Pharmaceuticals, Inc., a privately held pediatric
specialty pharmaceutical company, from 2003 to 2005. From 2002 to 2003, he served as President and Chief Executive Officer of Pharsight
Corporation, a publicly held software and consulting services firm. From 2000 to 2002, he served as Global Head of Research and
Development for Baxter Healthcare&rsquo;s BioScience Division (now Baxalta). From 1997 to 2000, Dr. Perry served as President and
Chief Executive Officer of SyStemix Inc. and Genetic Therapy Inc., both wholly-owned subsidiaries of Novartis Pharma. Dr. Perry
served as Vice President of Regulatory Affairs for Novartis from 1994 to 1997. Prior to 1994, Dr. Perry held various management
positions with Syntex Corporation (now Roche), Schering-Plough Corporation (now Merck) and BioResearch Laboratories, Inc. Dr. Perry
received a Doctor of Veterinary Medicine (DVM), a Ph.D. in biomedical science-pharmacology specialty and an Honours B.Sc. in physics
from the University of Guelph in Ontario, Canada. He is also a graduate of the Harvard Business School International Management
Forum. Dr. Perry has served as Adjunct Professor in the Gates Center for Regenerative Medicine at the University of Colorado School
of Medicine, Anschutz Medical Campus since November 2013. He has served as a member of the board of directors of Arrowhead Pharmaceuticals
since December 2011 and on the board of Gamida Cell Ltd. since May 2017. The Nominating and Corporate Governance Committee and
the Board of Directors believe that Dr. Perry&rsquo;s substantial scientific and medical knowledge, investing experience, and operational
and executive experience in the biotechnology and pharmaceutical industries qualifies him to serve on our Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR CLEAR="ALL">
<B>INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE </B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Independence of The Board of Directors&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required under the NYSE MKT listing
standards, a majority of the members of a listed company&rsquo;s Board of Directors must qualify as &ldquo;independent,&rdquo;
as affirmatively determined by the Board of Directors. Our Board of Directors consults with the Company&rsquo;s counsel to ensure
that the Board&rsquo;s determinations are consistent with relevant securities and other laws and regulations regarding the definition
of &ldquo;independent,&rdquo; including those set forth in pertinent listing standards of NYSE MKT, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Consistent with these considerations, after
review of all relevant identified transactions or relationships between each director, or any of his or her family members, and
the Company, its senior management and its independent auditors, the Board has affirmatively determined that all of our directors
are independent directors within the meaning of the applicable NYSE MKT listing standards, other than Dr. Grint and Ms. Johnson.
In making this determination, the Board found that none of these directors or nominees for director had a material or other disqualifying
relationship with the Company. The Board concluded that Dr. Grint and Ms. Johnson are not independent directors within the meaning
of the applicable NYSE MKT listing standards rules given their roles as Chief Executive Officer and former Interim Chief Operating
Officer, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Board Leadership
Structure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors
has a Chairman, Jeremy Curnock Cook, who has authority, among other things, to call and preside over board meetings, to set meeting
agendas and to determine materials to be distributed to the Board. Accordingly, the Chairman has substantial ability to shape the
work of the Board of Directors. We have a separate chair for each committee of the Board. As a general policy, the Board believes
that separation of the positions of Chairman and Chief Executive Officer reinforces the independence of the Board of Directors
from management, creates an environment that encourages objective oversight of management&rsquo;s performance and enhances the
effectiveness of the Board of Directors as a whole. As such, Dr. Grint serves as our Chief Executive Officer while Mr. Cook serves
as our Chairman of the Board of Directors but is not an officer. We expect and intend the positions of Chairman of the Board of
Directors and Chief Executive Officer to continue to be held by separate individuals in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Role of the
Board in Risk Oversight</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee
of our Board of Directors is primarily responsible for overseeing our financial risk management processes on behalf of the Board.
Going forward, we expect that the Audit Committee will receive reports from management at least quarterly regarding our assessment
of risks. In addition, the audit Committee reports regularly to the full Board, which also considers our risk profile. The Audit
Committee and the Board focus on the most significant risks we face and our general risk management strategies. While the Board
oversees our risk management, our management is responsible for day-to-day risk management processes. The Board expects management
to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and
processes for day-to-day activities and to effectively implement risk management strategies adopted by the Audit Committee and
the Board. We believe this division of responsibilities is the most effective approach for addressing the risks we face and that
our board of directors leadership structure, which also emphasizes the independence of our board of directors in its oversight
of its business and affairs, supports this approach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Meetings of
The Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors met eleven times
during the last fiscal year. Each Board member attended 75% or more of the total number of meetings of the Board and of the committees
on which he or she served, held during the portion of the last fiscal year for which he or she was a director or committee member.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As required under applicable NYSE MKT listing
standards, during 2016, the Company&rsquo;s independent directors met on a regular basis in executive session without the presence
of non-independent directors and management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Information Regarding Committees
of the Board of Directors&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors has an Audit
Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. The following table provides membership
and meeting information during 2016 for each of the Board committees:</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 60%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 10%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Audit</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 13%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Compensation</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 14%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nominating</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>and Corporate</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Governance</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis Drapeau<SUP>(2)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael S. Perry, Ph.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian P. Kirk<SUP>(3)</SUP></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay B. Samant</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. Scott Salka</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy S. Johnson</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-right: 1pt; padding-left: 2pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total meetings during 2016</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.7pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Committee Chairperson</TD>
</TR></TABLE>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Mr. Curnock Cook resigned from the Audit Committee
in January 2016.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Mr. Drapeau resigned from the Compensation Committee
in January 2016. He was reappointed to the Compensation Committee in June 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: justify">Mr. Kirk resigned from the Board in April 2016.</TD>
</TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Below is a description of each committee
of the Board of Directors. The Board of Directors has determined that each member of each committee meets the applicable NYSE MKT
rules and regulations regarding &ldquo;independence&rdquo; and each member is free of any relationship that would impair his or
her individual exercise of independent judgment with regard to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Audit Committee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee of the Board of Directors
was established by the Board in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended, or the
Exchange Act, to oversee the Company&rsquo;s corporate accounting and financial reporting processes and audits of its financial
statements. The functions of this Audit Committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">evaluating the performance, independence and qualifications
of our independent auditors and determining whether to retain our existing independent auditors or engage new independent auditors
and to present the committee&rsquo;s conclusion to our Board of Directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing and approving the engagement of our independent auditors to perform audit services and
any permissible non-audit services;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">monitoring the rotation of partners of our independent auditors on our audit engagement team as
required by law;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">prior to engagement of any independent auditor, and at least annually thereafter, reviewing relationships
that may reasonably be thought to bear on their independence, and assessing and otherwise taking the appropriate action to oversee
the independence of our independent auditor;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing our annual and quarterly financial statements and reports, including the disclosures
contained under the caption &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations,&rdquo;
and discussing the statements and reports with our independent auditors and management;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing with our independent auditors and management significant issues that arise regarding
accounting principles and financial statement presentation and matters concerning the scope, adequacy and effectiveness of our
internal control over financial reporting;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing with management and our auditors any earnings announcements and other public announcements
regarding material developments;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">establishing procedures for the receipt, retention and treatment of complaints received by us regarding
internal accounting controls, accounting or auditing matters and other matters;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">preparing the report that the SEC requires in our annual proxy statement;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing and providing oversight of any related-person transactions in accordance with our related-person
transactions policy and reviewing and monitoring compliance with legal and regulatory responsibilities, including our code of business
conduct and ethics;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing on a periodic basis our investment policy; and</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">reviewing and evaluating on an annual basis its own performance, including its compliance with
its charter.</TD></TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Audit Committee consists of Louis Drapeau,
Michael S. Perry and Vijay Samant. The Board of Directors reviews the NYSE MKT listing standards definition of independence for
Audit Committee members on an annual basis and has determined that each of the members of our Audit Committee satisfies the NYSE
MKT listing requirements and SEC independence requirements. Mr. Drapeau serves as the chair of our Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Board of Directors has determined that
Mr. Drapeau qualifies as an Audit Committee financial expert within the meaning of SEC regulations. In making this determination,
our Board of Directors has considered Mr. Drapeau&rsquo;s formal education and previous and current experience in financial roles.
Both our independent registered public accounting firm and management periodically meet privately with our Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee charter can be found
on our website at <I>www.ampliphibio.com/corporate-governance.htm</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Report of the Audit Committee of
the Board of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>The material in this report is not &ldquo;soliciting material,&rdquo;
is not deemed &ldquo;filed&rdquo; with the SEC and is not to be incorporated by reference in any filing of the Company under the
Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general
incorporation language in any such filing.</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee has reviewed and discussed the audited financial
statements for the fiscal year ended December 31, 2016 with management of the Company. The Audit
Committee has discussed with the independent registered public accounting firm the matters required to be discussed by Auditing
Standard No. 1301, <I>Communications with Audit Committees,</I> as adopted by the Public Company Accounting Oversight Board (&ldquo;PCAOB&rdquo;).
The Audit Committee has also received the written disclosures and the letter from the independent registered public accounting
firm required by applicable requirements of the PCAOB regarding the independent accountants&rsquo; communications with the Audit
Committee concerning independence, and has discussed with the independent registered public accounting firm the accounting firm&rsquo;s
independence. Based on the foregoing, the Audit Committee has recommended to the Board of Directors that the audited financial
statements be included in the Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Louis Drapeau<BR>
Dr. Michael S. Perry<BR>
Mr. Vijay Samant</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Compensation Committee </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Compensation Committee consists of Jeremy Curnock Cook,
Louis Drapeau and Michael S. Perry. Dr. Perry serves as the chair of our Compensation Committee. Our Board of Directors has determined
that each of the members of our Compensation Committee is a non-employee director, as defined in Rule 16b-3 promulgated under the
Exchange Act, as defined pursuant to Section 162(m) of the Code, and satisfies the NYSE MKT listing independence requirements.
The functions of this committee include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">reviewing, modifying and approving (or if it deems
appropriate, making recommendations to the full Board of Directors regarding) our overall compensation strategy and policies;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and approving (or if it deems appropriate, making recommendations to the full Board of Directors regarding) the compensation
and other terms of employment of our executive officers;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and approving (or if it deems appropriate, making recommendations to the full Board of Directors regarding) performance
goals and objectives relevant to the compensation of our executive officers and assessing their performance against these goals
and objectives;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and approving (or if it deems it appropriate, making recommendations to the full Board of Directors regarding) the
equity incentive plans, compensation plans and similar programs advisable for us, as well as modifying, amending or terminating
existing plans and programs;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>evaluating risks associated with our compensation policies and practices and assessing whether risks arising from our compensation
policies and practices for our employees are reasonably likely to have a material adverse effect on us;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing making recommendations to the full Board of Directors regarding the type and amount of compensation to be paid or
awarded to our non-employee board members;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>establishing policies with respect to votes by our shareholders to approve executive compensation as required by Section 14A
of the Exchange Act and determining our recommendations regarding the frequency of advisory votes on executive compensation, to
the extent required by law;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and assessing the independence of compensation consultants, legal counsel and other advisors as required by Section
10C of the Exchange Act;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>administering our equity incentive plans;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>establishing policies with respect to equity compensation arrangements;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing the competitiveness of our executive compensation programs and evaluating the effectiveness of our compensation policy
and strategy in achieving expected benefits to us;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and approving (or if it deems appropriate, making recommendations to the full Board of Directors regarding) the terms
of any employment agreements, severance arrangements, change-of-control protections and any other compensatory arrangements for
our executive officers;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing the adequacy of its charter on a periodic basis;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing with management and approving our disclosures, if any, under the caption &ldquo;Compensation Discussion and Analysis&rdquo;
and related tables in our periodic reports or proxy statements to be filed with the SEC;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>preparing the report that the SEC requires in our annual proxy statement; and</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>reviewing and assessing on an annual basis its own performance.</TD></TR></TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Compensation Committee Processes
and Procedures </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Typically, the Compensation Committee meets
quarterly and with greater frequency if necessary. The agenda for each meeting is usually developed by the Chair of the Compensation
Committee, in consultation with the Chief Executive Officer<B>. </B>The Compensation Committee meets regularly in executive session.
However, from time to time, various members of management and other employees as well as outside advisors or consultants may be
invited by the Compensation Committee to make presentations, to provide financial or other background information or advice or
to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present
during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance
objectives. The charter of the Compensation Committee grants the Compensation Committee full access to all books, records, facilities
and personnel of the Company. In addition, under the charter, the Compensation Committee has the authority to obtain, at the expense
of the Company, advice and assistance from compensation consultants and internal and external legal, accounting or other advisors
and other external resources that the Compensation Committee considers necessary or appropriate in the performance of its duties.
The Compensation Committee has direct responsibility for the oversight of the work of any consultants or advisers engaged for the
purpose of advising the Committee. In particular, the Compensation Committee has the sole authority to retain, in its sole discretion,
compensation consultants to assist in its evaluation of executive and director compensation, including the authority to approve
the consultant&rsquo;s reasonable fees and other retention terms. Under the charter, the Compensation Committee may select, or
receive advice from, a compensation consultant, legal counsel or other adviser to the compensation committee, other than in-house
legal counsel and certain other types of advisers, only after taking into consideration six factors, prescribed by the SEC and
NYSE MKT, that bear upon the adviser&rsquo;s independence; however, there is no requirement that any adviser be independent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, the Compensation Committee
has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance
objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers
matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues,
such as the efficacy of the Company&rsquo;s compensation strategy, potential modifications to that strategy and new trends, plans
or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&rsquo;s process comprises
two related elements: the determination of compensation levels and the establishment of performance objectives for the current
year. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and
recommendations submitted to the Committee by the Chief Executive Officer. In the case of the Chief Executive Officer, the evaluation
of his performance is conducted by the Compensation Committee, which determines any adjustments to his compensation as well as
awards to be granted. For all executives and directors as part of its deliberations, the Compensation Committee may review and
consider, as appropriate, materials such as financial reports and projections, operational data, tax and accounting information,
tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive
and director stock ownership information, company stock performance data, analyses of historical executive compensation levels
and current Company-wide compensation levels and recommendations of the Compensation Committee&rsquo;s compensation consultant,
if any, including analyses of executive and director compensation paid at other companies identified by the consultant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Compensation Committee charter can
be found on our website at <I>www.ampliphibio.com/corporate-governance.htm</I>.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Nominating and Corporate Governance Committee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Nominating and Corporate Governance Committee of the Board
of Directors is responsible for, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">identifying, reviewing and evaluating candidates to
serve on our Board of Directors consistent with criteria approved by our Board of Directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">evaluating director performance on management and
the board and applicable committees of the board and determining whether continued service on our Board of Directors is appropriate;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">evaluating, nominating and recommending individuals
for membership on our Board of Directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">evaluating nominations by shareholders of candidates
for election to our Board of Directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">considering and assessing the independence of members
of our Board of Directors;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">developing a set of corporate governance policies
and principles, periodically reviewing and assessing these policies and principles and their application and recommending to our
Board of Directors any changes to such policies and principles;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">reviewing the adequacy of its charter on an annual
basis; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">annually evaluating the performance of the Nominating
and Corporate Governance Committee.</TD>
</TR></TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Nominating and Corporate
Governance Committee consists of Jeremy Curnock Cook, Louis Drapeau and Michael S. Perry. Our Board of Directors has
determined that each of the members of this committee satisfies the NYSE MKT listing independence requirements. Mr. Curnock
Cook serves as the chair of our Nominating and Corporate Governance Committee. The Nominating and Corporate Governance
Committee believes that candidates for director should, both individually and collectively, have the integrity, experience,
judgment, commitment (including having sufficient time to devote to us and a sufficient level of participation), skills,
diversity and expertise appropriate for our company. In assessing the directors, both individually and collectively, the
Nominating and Corporate Governance Committee may consider our current needs and the needs of our Board of Directors, to
maintain a balance of knowledge, experience and capability in various areas. However, the Nominating and Corporate Governance
Committee retains the right to modify these qualifications from time to time. In the case of new director candidates, the
Nominating and Corporate Governance Committee also determines whether the nominee is independent for NYSE MKT purposes, which
determination is based upon applicable NYSE MKT listing standards, applicable SEC rules and regulations and the advice of
counsel, if necessary. The Nominating and Corporate Governance Committee then uses its network of contacts to compile a list
of potential candidates, but may also engage, if it deems appropriate, a professional search firm. The Nominating and
Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of
possible candidates after considering the function and needs of the Board of Directors. The Nominating and Corporate
Governance Committee meets to discuss and consider the candidates&rsquo; qualifications and then selects a nominee
for recommendation to the Board of Directors by majority vote.<BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><BR></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating and Corporate Governance
Committee will consider director candidates recommended by shareholders. The Nominating and Corporate Governance Committee does
not intend to alter the manner in which it evaluates candidates, including the criteria set forth above, based on whether or not
the candidate was recommended by a shareholder. Shareholders who wish to recommend individuals for consideration by the Nominating
and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation
to the Secretary of the Company at 3579 Valley Centre Drive, San Diego, California 92130, no later than the close of business on
the 90<SUP>th</SUP> day and no earlier than the 120<SUP>th</SUP> day prior to the one year anniversary of the preceding year&rsquo;s
annual meeting of shareholders. Submissions must include the full name of the proposed nominee, a description of the proposed nominee&rsquo;s
business experience for at least the previous five years, complete biographical information, a description of the proposed nominee&rsquo;s
qualifications as a director and the number of shares of the Company&rsquo;s stock that are owned beneficially by such nominating
shareholder as of the date the submission is made. Any such submission must be accompanied by the written consent of the proposed
nominee to be named as a nominee and to serve as a director if elected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Nominating and Corporate Governance
Committee charter can be found on our website at <I>www.ampliphibio.com/corporate-governance.html</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Shareholder Communications With
The Board Of Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s Board has adopted a formal process by which
shareholders may communicate with the Board or any of its directors. Shareholders who wish to communicate with the Board may do
so by sending written communications addressed to the Secretary of the Company at AmpliPhi Biosciences Corporation, 3579 Valley
Centre Drive, Suite 100, San Diego, California 92130. All communications will be compiled by the Secretary of the Company and submitted
to the Board of Directors or the individual directors on a periodic basis. These communications will be reviewed by the Company&rsquo;s
Secretary, who will determine whether the communication should be presented to the Board. The purpose of this screening is to allow
the Board to avoid having to consider irrelevant or inappropriate communications (such as advertisements, solicitations and hostile
communications). All communications directed to the Audit Committee in accordance with the Company&rsquo;s Open Door Policy for
Reporting Complaints Regarding Accounting and Auditing Matters, discussed below, will be treated in accordance with that policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any interested person may, however, communicate
directly with the presiding director or the independent directors as a group. Persons interested in communicating directly with
the independent directors regarding their concerns or issues may do so by addressing correspondence to a particular director, or
to the independent directors generally, in care of AmpliPhi Biosciences Corporation at 3579 Valley Centre Drive, Suite 100, San
Diego, California 92130. If no particular director is named, letters will be forwarded, depending upon the subject matter, to the
Chair of the Audit, Compensation, or Nominating and Corporate Governance Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Code of Ethics&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have adopted a code of ethics for
directors, officers (including our principal executive officer, principal financial officer and principal accounting officer) and
employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website
at <I>http://www.ampliphibio.com</I> under the Corporate Governance section of our Investor Relations page. We will promptly disclose
on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial
officer, principal accounting officer or controller, or persons performing similar functions and (ii) the nature of any waiver,
including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals that is required
to be disclosed pursuant to SEC rules and regulations, the name of such person who is granted the waiver and the date of the waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Open Door Policy for Reporting Complaints Regarding Accounting
and Auditing Matters&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted an Open Door Policy for
Reporting Complaints Regarding Accounting and Auditing Matters to facilitate the receipt, retention and treatment of complaints
regarding accounting, internal accounting controls or auditing matters, as well as the confidential, anonymous submission by our
employees of concerns regarding these matters. The Open Door Policy is available on our website at <I>http://www.ampliphibio.com/corporate-governance.html.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposal 2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>



<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Approval of
        the proposed issuance by the Company of 523,210 shares of common stock to certain former holders of the Company&rsquo;s Series
        B convertible preferred stock, pursuant to the terms of that certain First Amendment to Common Stock Issuance Agreement, dated
        June 27, 2017, by and among the Company and such holders</B></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Background </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 8, 2016, the Company&nbsp;entered
into a Common Stock Issuance Agreement (the &ldquo;CSIA&rdquo;) with certain former holders of the Company&rsquo;s Series B convertible
preferred stock (the &ldquo;Holders&rdquo;). Pursuant to Section 3 of the CSIA, the Company agreed to issue a formula-based number
of shares of its common stock to the Holders for no additional consideration upon completion of one or more bona fide equity financings
in which the Company sells shares of its common stock below a specified price (a &ldquo;Dilutive Issuance&rdquo;) in a transaction
that occurs prior to the earlier of June 30, 2018 or such time as the Company has raised, following the date of the CSIA, $10.0
million in the aggregate (the &ldquo;Price Protection Obligations&rdquo;). In each of June 2016, November 2016 and May 2017, the
Company completed offerings of its common stock that constituted Dilutive Issuances under the CSIA. Due in part to limitations
on the number of shares issuable to the Holders under the rules of the NYSE MKT, no additional shares of common stock were issued
to the Holders in connection with the November 2016 or May 2017 offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On June 27, 2017, the Company and the Holders entered into an
amendment to the CSIA (the &ldquo;Amendment&rdquo;) to, among other things, terminate the Price Protection Obligations. In consideration
for the termination of the Price Protection Obligations and a release of claims by the Holders, the Company agreed to (i) issue
to the Holders, within five business days of the Amendment, an aggregate of 28,684 shares of its common stock (the &ldquo;First
Issuance&rdquo;), which, under the rules of the NYSE MKT, is the maximum number of shares the Company was permitted to issue to
the Holders pursuant to the CSIA without further shareholder approval, and (ii) issue to the Holders in a subsequent closing an
aggregate of 523,210 shares of common stock (the &ldquo;Second Issuance&rdquo;), subject to obtaining shareholder approval of the
Second Issuance at the Company&rsquo;s 2017 Annual Meeting of Shareholders and the Company&rsquo;s receipt of a release of claims
from the Holders at the time of the Second Issuance. The First Issuance was completed on June 29, 2017. The Company agreed to use
its commercially reasonable efforts to obtain shareholder approval of the Second Issuance at the annual meeting, and accordingly
the Board is seeking your approval of this Proposal 2. If this Proposal 2 is not approved at the annual meeting, the Company will
not be obligated to issue the shares contemplated by the Second Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Section 713(a) of the NYSE MKT Company Guide </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to Section 713(a) of the NYSE MKT Company Guide, shareholder
approval is generally required prior to the issuance of securities in connection with a transaction other than a public offering
involving the sale, issuance, or potential issuance by the issuer of common stock (or securities convertible into common stock)
equal to 20% or more of presently outstanding stock for less than the greater of book or market value of the stock. The Company&rsquo;s
prior issuances of common stock to the Holders pursuant to the CSIA, including the Price Protection Obligations, are aggregated
for purposes of determining the number of shares issuable pursuant to the 20% cap referred to above. The Company sought and received
shareholder approval at the Company&rsquo;s 2016 Annual Meeting of Shareholders for the issuance of a number of shares in excess
of the NYSE MKT 20% cap. However, following the First Issuance in accordance with the terms of the Amendment, no further shares
of common stock may be issued to the Holders pursuant to the terms of the CSIA or the Amendment without shareholder approval of
such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain Consequences if the Proposal is Approved </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company&rsquo;s shareholders will incur dilution of their
percentage ownership interest in the Company to the extent the Company issues the 523,210 shares of common stock contemplated by
the Second Issuance to the Holders. Further, because such shares will be issued without cash payment from the Holders to the Company,
the issuance would reduce the net tangible book value per share of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The issuance of the shares subject to the Second Issuance will
result in an exercise price adjustment under the common stock warrants issued by the Company in November 2016 in its public offering
(the &ldquo;November 2016 Warrants&rdquo;). As of the date of this proxy statement, on a cash-exercise basis the November 2016
Warrants are currently exercisable for, in the aggregate, 533,497 shares of common stock at an exercise price of $0.9954 per share.
Based on the relevant exercise price adjustment provision under the November&nbsp;2016 Warrants, and assuming no other events that
would affect the exercise price of the November 2016 Warrants, if this Proposal&nbsp;2 is approved and the Second Issuance is completed,
the exercise price of the November 2016 Warrants will be reduced to $0.57 per share following the Second Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Interest of Certain Persons in the Proposal </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">One Fund Management Limited as Trustee for Asia Pacific Healthcare
Fund II (&ldquo;One Funds&rdquo;), an entity affiliated with Jeremy Curnock Cook, the Chairman of the Company&rsquo;s Board of
Directors, is a party to the CSIA and the Amendment as a Holder. The CSIA and the Amendment were approved by the Company&rsquo;s
Audit Committee and no special terms were given to Mr. Cook or One Funds. Pursuant to the First Issuance, on June 29, 2017 the
Company issued 5,757 shares of common stock to One Funds. If Proposal 2 is approved, the Company has agreed to issue One Funds
an additional 105,015 shares of common stock subject to our receipt of a release of claims from One Funds at the time of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote Required </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order for Proposal 2 to be approved, the number of shares
that vote &ldquo;For&rdquo; the proposal must exceed the number of shares that vote &ldquo;Against&rdquo; the proposal. Abstentions
will be counted towards the vote total for Proposal 2 and will have the same effect as &ldquo;Against&rdquo; votes. Broker non-votes
are counted towards a quorum, but are not counted for any purpose in determining whether Proposal 2 has been approved.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Board of Directors Recommends</B><BR>
<B>a Vote &ldquo;For&rdquo; Proposal 2.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>




<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposal 3<BR>
<BR>
</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Approval of an amendment to the AmpliPhi Biosciences Corporation 2016 Equity Incentive Plan </B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In April 2016, our Board of Directors originally approved our
AmpliPhi Biosciences Corporation 2016 Equity Incentive Plan, or the 2016 Plan, and the shareholders originally approved the 2016
Plan on June 20, 2016. In this Proposal 3, we are requesting shareholders to approve an amendment (the &ldquo;Plan Amendment&rdquo;)
to the 2016 Plan in order to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">increase the number of shares of common stock authorized for issuance
under the 2016 Plan by 800,000 shares, including a corresponding increase in the number of shares of common stock authorized for
issuance under the 2016 Plan pursuant to the grant of incentive stock options by  2,000,000 shares,</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">enable us to approve the grant of an option under 2016 Plan for 475,189
shares to our recently appointed Chief Executive Officer, Dr. Grint, pursuant to the terms of his employment offer letter dated
June 1, 2017, as without the Plan Amendment, an insufficient number of shares are available under the 2016 Plan for such grant,
and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">for purposes of Section 162(m) of the Internal Revenue Code:</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>increase to  1,000,000 shares of common stock the maximum number of shares that may be granted per calendar year to any
                                                               one participant pursuant to stock options, stock appreciation rights and other stock awards whose value is determined by
                                                               reference to an increase over an exercise price or strike price of at least 100% of the fair market value of the underlying
                                                               common stock on the date of grant, and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">o</TD><TD>increase to  1,000,000 shares of common stock the maximum number of shares that may be granted per calendar year to any
                                                               one participant as a &quot;performance stock award&quot;.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors believes the Plan Amendment is an integral
part of our long-term compensation philosophy and is necessary to continue providing the appropriate levels and types of equity
compensation for our employees.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We Intend to Recruit Additional Personnel
and Need to Retain Existing Personnel to Facilitate the Growth of Our Business and Equity Awards Are an Important Part of Our Compensation
Philosophy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of June 30, 2017, only 36,069 shares
remained available for future grant under the 2016 Plan. The Board of Directors believes that the future success of the Company
depends, in large part, upon the ability of the Company to implement our plans for future expansion and growth in light of our
anticipated recruiting and retention needs and is necessary to maintain a competitive position in recruiting, retaining and motivating
key personnel, consultants and advisors. The Board of Directors believes that the issuance of equity awards is a key element underlying
our ability to recruit, retain and motivate key personnel, consultants and advisors, better aligns the interests of such persons
with those of our shareholders, and is a substantial contributing factor to our success and the future growth of our business.
However, we believe that the shares currently available for grant under the 2016 Plan will be insufficient to meet our anticipated
recruiting and retention needs. Therefore, the Board of Directors believes that the approval of the Plan Amendment is in the best
interests of the Company and its shareholders and recommends a vote in favor of this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Proposal 3 is adopted by our shareholders,
the Plan Amendment will become effective upon the date of the annual meeting. In the event that our shareholders do not approve
this Proposal 3, the Plan Amendment will not become effective, the 2016 Plan will continue in its current form, and the option
grant to Dr. Grint contemplated by his employment offer letter for 475,189 shares will not be made until such time as there are
sufficient shares available for the grant pursuant to the scheduled automatic &ldquo;evergreen increase&rdquo; in the 2016 Plan
authorized share reserve on January 1, 2018 (see &ldquo;Description of 2016 Plan, as proposed to be amended&mdash;Share reserve&rdquo;
below) or otherwise. However, we believe that the shares currently available for grant under the 2016 Plan will be insufficient
to meet our anticipated recruiting and retention needs.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of June 30, 2017, stock awards (which
consist solely of stock options) covering an aggregate of 285,276 shares of common stock were outstanding under <FONT STYLE="background-color: white">the
2016 Plan and the 2009 Targeted Genetics Stock Incentive Plan (the &ldquo;2009 Plan&rdquo;), the AmpliPhi Biosciences Corporation
2012 Stock Incentive Plan (the &ldquo;2012 Plan&rdquo;), the AmpliPhi Biosciences Corporation 2013 Stock Incentive Plan (the &ldquo;2013
Plan&rdquo; and</FONT> collectively with the 2009 Plan and the 2012 Plan, the &ldquo;Prior Plans&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The Size of Our Share Reserve Increase Request Is Reasonable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If our request to increase the share reserve of the 2016 Plan
by 800,000 shares is approved, we will have approximately 836,069 shares available for grant after the annual meeting which, together
with the annual &ldquo;evergreen&rdquo; increases described below, the Board believes will provide sufficient equity for attracting,
retaining and motivating employees for at least the next two years. The Board believes the size of the request is also reasonable
in light of the equity granted to our employees and directors over the last three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We Manage Our Equity Award Use Carefully
and Our Dilution Is Reasonable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We manage our long-term shareholder dilution
by limiting the number of equity awards granted annually. The Compensation Committee monitors our annual burn rate, dilution, and
equity expense to ensure that we maximize shareholders&rsquo; value by granting only the appropriate number of equity awards necessary
to recruit, reward, and retain key personnel, consultants and advisors.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides certain additional information
regarding our equity incentive program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of June 30, 2017</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; font: 10pt Times New Roman, Times, Serif; text-align: left">Total shares subject to outstanding stock options</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">285,276</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Weighted-average exercise price per share of outstanding stock options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">9.83</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Weighted-average remaining term of outstanding stock options</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.20 yrs</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Total shares available for grant under the 2016 Plan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">36,069</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Total shares available for grant under other equity plans</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">21,016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(1)</SUP></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_____________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(1) Represents shares issuable pursuant to the Company&rsquo;s
2016 Employee Stock Purchase Plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">As of July 12, 2017<BR> (Record Date)</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; font: 10pt Times New Roman, Times, Serif; text-align: left">Total common stock outstanding</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">8,749,052</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Closing price of common stock as reported on The NYSE MKT</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">$1.00</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Common measures of an equity incentive
plan&rsquo;s cost include burn rate, dilution and overhang. The burn rate, or run rate, refers to how fast a company uses the supply
of shares authorized for issuance under its equity incentive plan. Over the last three years, the Company has maintained an average
equity run rate of 3.8% of shares of common stock outstanding per year, including shares of preferred stock on an as-converted
basis. Our run rates in 2015 was unusually high due primarily to an equity grant to our then-Chief Executive Officer in 2015 in
connection with his commencement of employment as our Chief Executive Officer which the Compensation Committee believed was consistent
with the level of options granted to chief executive officers in our industry. Dilution measures the degree to which our stockholders&rsquo;
ownership has been diluted by stock-based compensation awarded under our equity incentive plans and also includes shares that may
be awarded under our equity incentive plans in the future (&ldquo;overhang&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows how our key equity metrics have changed
over the past three years:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Key Equity Metrics</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2014</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2015<SUP>(4)</SUP></B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2016</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 61%; padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity Run Rate <SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.3</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.6</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overhang <SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.6</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.9</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution <SUP>(3)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Equity run rate is calculated by dividing the number of shares subject to equity awards granted
during the year by the weighted-average number of shares outstanding during the year.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Overhang is calculated by dividing (a) the sum of (x) the number of shares subject to equity awards
outstanding at the end of the year and (y) the number of shares available for future grants, by (b) the number of shares outstanding
at the end of the year.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Dilution is calculated by dividing the number of shares subject to equity awards outstanding at
the end of the fiscal year by the number of shares outstanding at the end of the fiscal year.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In evaluating whether to approve the Plan
Amendment our Board of Directors and Compensation Committee reviewed our historical issuances under our 2016 Plan and our 2013
Plan and considered our future needs for equity awards under the 2016 Plan, based on our plans for future expansion and growth
in light of our anticipated recruiting and retention needs and potential changes in company capitalization and dilution. We intend
to grant future equity awards under the 2016 Plan in amounts that are reasonable and based on market data prepared by the independent
compensation consultant to the Compensation Committee. If this Proposal 3 is approved by our shareholders, we expect the adjusted
share reserve to last for approximately two years of awards. While we believe this is a reasonable estimate of how long the share
reserve could last, because there are a number of uncertain factors that could impact our future share usage, we are not able to
presently forecast the share amounts and rate at which we will utilize equity as a tool for attracting and retaining talent.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Vote Required</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order for Proposal 3 to be approved, the number of shares
that vote &ldquo;For&rdquo; the proposal must exceed the number of shares that vote &ldquo;Against&rdquo; the proposal. Abstentions
will be counted towards the vote total for Proposal 3 and will have the same effect as &ldquo;Against&rdquo; votes. Broker non-votes
are counted towards a quorum, but are not counted for any purpose in determining whether this matter has been approved.</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Board of Directors Recommends</B><BR>
<B>a Vote &ldquo;For&rdquo; Proposal 3.</B>&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Description of 2016 Plan, as proposed
to be amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The material features of the 2016 Plan,
as proposed to be amended pursuant to Proposal 3, are outlined below. This summary is qualified in its entirety by reference to
the complete text of the 2016 Plan. Shareholders are encouraged to read the actual text of the 2016 Plan, as amended, which is
appended to this proxy statement as Appendix A and may be accessed from the SEC&rsquo;s website at <U>www.sec.gov</U>. Except as
modified by the Plan Amendment as described above, the terms of the 2016 Plan as proposed to be amended are materially the same
as the terms of the 2016 Plan prior to implementation of the Plan Amendment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Purpose</I>. The 2016 Plan is critical
to our ongoing effort to build shareholder value through recruiting, retaining and motivating employees, directors and consultants.
We are seeking to approval of the 2016 Plan to provide for the shares necessary so that we can ensure that we have the most qualified,
motivated employees possible to help us move the Company&rsquo;s programs forward and implement our recruiting plans to facilitate
the future growth of our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Awards</I>. The 2016 Plan provides for
the grant of incentive stock options, or ISOs, nonstatutory stock options, or NSOs, stock appreciation rights, restricted stock
awards, restricted stock unit awards, performance-based stock awards, and other forms of equity compensation, or collectively,
stock awards, all of which may be granted to employees, including officers, non-employee directors and consultants of us and our
affiliates. Additionally, the 2016 Plan provides for the grant of performance cash awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Eligibility.</I> As of July 12, 2017,
all of our approximately 32 employees and five non-employee directors were eligible to participate in the 2016 Plan and may receive
all types of awards other than ISOs. ISOs may be granted only to our employees (including officers) and employees of our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Share Reserve</I>. If Proposal 3 is
approved, <FONT STYLE="background-color: white">the total number of shares of our common stock reserved for issuance under the
2016 Plan will not exceed 1,119,740 shares, consisting of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">237,300 shares, which is the total maximum reserve that
was approved in connection with the initial adoption of the 2016 Plan, including, but not limited to, the Prior Plans&rsquo; Returning
Shares;</FONT> plus</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">82,440 shares added to the 2016 Plan pursuant to the January 1, 2017 evergreen increase, plus</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify"><FONT STYLE="background-color: white">the 800,000 shares to be added pursuant this Proposal 3.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">The
&ldquo;Prior Plans&rsquo; Returning Shares&rdquo; are the number of shares that are subject to stock awards outstanding under the
Prior Plans that subsequently terminate prior to exercise or would otherwise be returned to the share reserves of our Prior Plans.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, the number of shares of our
common stock reserved for issuance under the 2016 Plan automatically increases on January 1 of each year, beginning on January
1, 2017 and continuing through and including January 1, 2026, by 5% of the total number of shares of our capital stock outstanding
on December 31 of the preceding calendar year, or a lesser number of shares determined by our Board of Directors. The maximum number
of shares that may be issued upon the exercise of ISOs under our 2016 Plan is  2,474,600 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a stock award granted under the 2016
Plan expires or otherwise terminates without being exercised in full, or is settled in cash, the shares of our common stock not
acquired pursuant to the stock award again will become available for subsequent issuance under the 2016 Plan. In addition, the
following types of shares under the 2016 Plan may become available for the grant of new stock awards under the 2016 Plan: (1) shares
that are forfeited to or repurchased by us prior to becoming fully vested; (2) shares withheld to satisfy income or employment
withholding taxes; or (3) shares used to pay the exercise or purchase price of a stock award. Shares issued under the 2016 Plan
may be previously unissued shares or reacquired shares bought by us on the open market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Section 162(m) Limits</I>. No person
may be granted stock awards for purposes of Section 162(m) of the Code covering more than 1,000,000 shares of our common stock
under our 2016 Plan during any calendar year pursuant to stock options, stock appreciation rights and other stock awards whose
value is determined by reference to an increase over an exercise or strike price of at least 100% of the fair market value on the
date the stock award is granted. Additionally, no person may be granted in a calendar year a performance stock award for purposes
of Section 162(m) of the Code covering more than 1,000,000 shares or a performance cash award for purposes of Section 162(m) of
the Code having a maximum value in excess of $2,000,000. Such limitations are designed to help assure that any deductions to which
we would otherwise be entitled with respect to such awards will not be subject to the $1,000,000 limitation on the income tax deductibility
of compensation paid to any covered executive officer imposed by Section 162(m) of the Code.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Non-Employee Director Compensation Limit.
</I>The aggregate value of all compensation paid or granted, as applicable, to any individual for service as a non-employee director
of our Board of Directors with respect to any calendar year commencing with the 2016 calendar year, including awards granted under
the 2016 Plan and cash fees paid by us to such non-employee director, will not exceed (i) $375,000 in total value or (ii) in the
event such non-employee director is first appointed or elected to our Board of Directors during such calendar year, $783,000 in
total value, in each case calculating the value of any awards granted under the 2016 Plan based on the grant date fair value of
such awards for financial reporting purposes. However, the Board of Directors may make exceptions to the applicable limit for individual
non-employee directors in extraordinary circumstances (for example, to compensate such individual for interim service in the capacity
of an officer of the Company), as the Board of Directors may determine in its discretion, provided that the non-employee director
receiving such additional compensation may not participate in the decision to award such compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Administration.</I> Our Board of Directors,
or a duly authorized committee thereof, has the authority to administer the 2016 Plan. Our Board of Directors has delegated authority
to administer the 2016 Plan to our Compensation Committee. Subject to the terms of the 2016 Plan, the Compensation Committee, referred
to herein as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted
and the terms and conditions of the stock awards, including the period of their exercisability and vesting schedule applicable
to a stock award. Subject to the limitations set forth below, the plan administrator will also determine the exercise price, strike
price or purchase price of awards granted and the types of consideration to be paid for the award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator has the authority
to modify outstanding awards under our 2016 Plan. Subject to the terms of our 2016 Plan, the plan administrator has the authority
to reduce the exercise, purchase or strike price of any outstanding stock award, cancel any outstanding stock award in exchange
for new stock awards, cash or other consideration, or take any other action that is treated as a repricing under generally accepted
accounting principles, with the consent of any adversely affected participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Options</I>. ISOs and NSOs are
granted pursuant to stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price
for a stock option, within the terms and conditions of the 2016 Plan, provided that the exercise price of a stock option generally
cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2016 Plan
vest at the rate specified by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator determines the term
of stock options granted under the 2016 Plan, up to a maximum of 10 years. Unless the terms of an option holder&rsquo;s stock option
agreement provide otherwise, if an option holder&rsquo;s service relationship with us, or any of our affiliates, ceases for any
reason other than disability, death or cause, the option holder may generally exercise any vested options for a period of three
months following the cessation of service. The option term may be extended in the event that exercise of the option following such
a termination of service is prohibited by applicable securities laws or our insider trading policy. If an optionholder&rsquo;s
service relationship with us or any of our affiliates ceases due to disability or death, or an optionholder dies within a certain
period following cessation of service, the optionholder or a beneficiary may generally exercise any vested options for a period
of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, options generally
terminate immediately upon the termination of the individual for cause. In no event may an option be exercised beyond the expiration
of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Acceptable consideration for the purchase
of common stock issued upon the exercise of a stock option will be determined by the plan administrator and may include (1) cash,
check, bank draft or money order, (2) a broker-assisted cashless exercise, (3) the tender of shares of our common stock previously
owned by the optionholder, (4) a net exercise of the option if it is an NSO, and (5) other legal consideration approved by the
plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Unless the plan administrator provides
otherwise, options generally are not transferable except by will, the laws of descent and distribution, or pursuant to a domestic
relations order. An optionholder may designate a beneficiary, however, who may exercise the option following the optionholder&rsquo;s
death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Tax Limitations on Incentive Stock Options</I>.
The aggregate fair market value, determined at the time of grant, of our common stock with respect to ISOs that are exercisable
for the first time by an optionholder during any calendar year under all of our stock plans may not exceed $100,000. Options or
portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time
of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our
affiliates unless (1) the option exercise price is at least 110% of the fair market value of the stock subject to the option on
the date of grant, and (2) the term of the ISO does not exceed five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Awards</I>. Restricted
stock awards are granted pursuant to restricted stock award agreements adopted by the plan administrator. Restricted stock awards
may be granted in consideration for (1) cash, check, bank draft or money order, (2) services rendered to us or our affiliates,
or (3) any other form of legal consideration. Common stock acquired under a restricted stock award may, but need not, be subject
to a share repurchase option in our favor in accordance with a vesting schedule to be determined by the plan administrator. Rights
to acquire shares under a restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator.
Except as otherwise provided in the applicable award agreement, restricted stock unit awards that have not vested will be forfeited
upon the participant&rsquo;s cessation of continuous service for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Unit Awards</I>. Restricted
stock unit awards are granted pursuant to restricted stock unit award agreements adopted by the plan administrator. Restricted
stock unit awards may be granted in consideration for any form of legal consideration. A restricted stock unit award may be settled
by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form
of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in
respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted
stock units that have not vested will be forfeited upon the participant&rsquo;s cessation of continuous service for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Appreciation Rights</I>. Stock
appreciation rights are granted pursuant to stock appreciation grant agreements adopted by the plan administrator. The plan administrator
determines the strike price for a stock appreciation unit, which generally cannot be less than 100% of the fair market value of
our common stock on the date of grant. Upon the exercise of a stock appreciation unit, we will pay the participant an amount equal
to the product of (1) the excess of the per share fair market value of our common stock on the date of exercise over the strike
price, multiplied by (2) the number of shares of common stock with respect to which the stock appreciation unit is exercised. A
stock appreciation unit granted under the 2016 Plan vests at the rate specified in the stock appreciation grant agreement as determined
by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The plan administrator determines the term
of stock appreciation rights granted under the 2016 Plan, up to a maximum of ten years. Unless the terms of a participant&rsquo;s
stock appreciation right agreement provides otherwise, if a participant&rsquo;s service relationship with us or any of our affiliates
ceases for any reason other than cause, disability or death, the participant may generally exercise any vested stock appreciation
right for a period of three months following the cessation of service. The stock appreciation right term may be further extended
in the event that exercise of the stock appreciation right following such a termination of service is prohibited by applicable
securities laws. If a participant&rsquo;s service relationship with us, or any of our affiliates, ceases due to disability or death,
or a participant dies within a certain period following cessation of service, the participant or a beneficiary may generally exercise
any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In
the event of a termination for cause, stock appreciation rights generally terminate immediately upon the occurrence of the event
giving rise to the termination of the individual for cause. In no event may a stock appreciation right be exercised beyond the
expiration of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Performance Awards</I>. The 2016 Plan
permits the grant of performance-based stock and cash awards that may qualify as performance-based compensation that is not subject
to the $1,000,000 limitation on the income tax deductibility of compensation paid to a covered executive officer imposed by Section
162(m) of the Code. To help assure that the compensation attributable to performance-based awards will so qualify, our Compensation
Committee can structure such awards so that stock or cash will be issued or paid pursuant to such award only after the achievement
of certain pre-established performance goals during a designated performance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance stock award is a stock award
that is payable (including that may be granted, may vest, or may be exercised) contingent upon the achievement of pre-determined
performance goals during a performance period. A performance stock award may require the completion of a specified period of continuous
service. The length of any performance period, the performance goals to be achieved during the performance period, and the measure
of whether and to what degree such performance goals have been attained will generally be determined by our Compensation Committee,
except that the plan administrator also may make any such determinations to the extent that the award is not intended to comply
with Section 162(m) of the Code. In addition, to the extent permitted by applicable law and the performance stock award agreement,
the plan administrator may determine that cash may be used in payment of performance stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A performance cash award is a cash award
that is payable contingent upon the achievement of pre-determined performance goals during a performance period. A performance
cash award may require the completion of a specified period of continuous service. The length of any performance period, the performance
goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been
attained will generally be determined by our Compensation Committee, except that the plan administrator also may make any such
determinations to the extent that the award is not intended to comply with Section 162(m) of the Code. The plan administrator may
specify the form of payment of performance cash awards, which may be cash or other property, or may provide for a participant to
have the option for his or her performance cash award, or such portion thereof as the plan administrator may specify, to be paid
in whole or in part in cash or other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In granting a performance award intended
to qualify as &ldquo;performance-based compensation&rdquo; under Section 162(m) of the Code, our Compensation Committee will set
a period of time, or a performance period, over which the attainment of one or more goals, or performance goals, will be measured.
Within the time period prescribed by Section 162(m) of the Code (no later than the earlier of the 90th day of a performance period
and the date on which 25% of the performance period has elapsed, and in any event at a time when the achievement of the performance
goals remains substantially uncertain), our Compensation Committee will establish the performance goals, based upon one or more
criteria, or performance criteria, enumerated in the 2016 Plan and described below. As soon as administratively practicable following
the end of the performance period, our Compensation Committee will certify in writing whether the performance goals have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Performance goals under the 2016 Plan will
be based on any one or more of the following performance criteria: (1) earnings (including earnings per share and net earnings);
(2) earnings before interest, taxes and depreciation; (3) earnings before interest, taxes, depreciation and amortization; (4) earnings
before interest, taxes, depreciation, amortization and legal settlements; (5) earnings before interest, taxes, depreciation, amortization,
legal settlements and other income (expense); (6) earnings before interest, taxes, depreciation, amortization, legal settlements,
other income (expense) and stock-based compensation; (7) earnings before interest, taxes, depreciation, amortization, legal settlements,
other income (expense), stock-based compensation and changes in deferred revenue; (8) earnings before interest, taxes, depreciation,
amortization, legal settlements, other income (expense), stock-based compensation, other non-cash expenses and changes in deferred
revenue; (9) total shareholder return; (10) return on equity or average shareholder&rsquo;s equity; (11) return on assets, investment,
or capital employed; (12) stock price; (13) margin (including gross margin); (14) income (before or after taxes); (15) operating
income; (16) operating income after taxes; (17) pre-tax profit; (18) operating cash flow; (19) sales or revenue targets; (20) increases
in revenue or product revenue; (21) expenses and cost reduction goals; (22) improvement in or attainment of working capital levels;
(23) economic value added (or an equivalent metric); (24) market share; (25) cash flow; (26) cash flow per share; (27) cash balance;
(28) cash burn; (29) cash collections; (30) share price performance; (31) debt reduction; (32) implementation or completion of
projects or processes (including, without limitation, clinical trial initiation, clinical trial enrollment and dates, clinical
trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or advisory committee interactions, regulatory
approvals, and product supply); (33) shareholders&rsquo; equity; (34) capital expenditures; (35) debt levels; (36) operating profit
or net operating profit; (37) workforce diversity; (38) growth of net income or operating income; (39) billings; (40) bookings;
(41) employee retention; (42) initiation of studies by specific dates; (43) budget management; (44) submission to, or approval
by, a regulatory body (including, but not limited to the U.S. Food and Drug Administration) of an applicable filing or a product;
(45) regulatory milestones; (46) progress of internal research or development programs; (47) acquisition of new customers; (48)
customer retention and/or repeat order rate; (49) improvements in sample and test processing times; (50) progress of partnered
programs; (51) partner satisfaction; (52) timely completion of clinical trials; (53) submission of 510(k)s or pre-market approvals
and other regulatory achievements; (54) milestones related to research development (including, but not limited to, preclinical
and clinical studies), product development and manufacturing; (55) expansion of sales in additional geographies or markets; (56)
research progress, including the development of programs; (57) strategic partnerships or transactions (including in-licensing and
out-licensing of intellectual property; and (58) and to the extent that an award is not intended to comply with Section 162(m)
of the Code, other measures of performance selected by the plan administrator.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Performance goals may be based on a company-wide
basis, with respect to one or more business units, divisions, affiliates or business segments, and in either absolute terms or
relative to the performance of one or more comparable companies or the performance of one or more relevant indices. Under the 2016
Plan, unless specified otherwise by our Compensation Committee (or, if not required for compliance with Section 162(m) of the Code,
the plan administrator) (i) in the award agreement at the time the award is granted or (ii) in such other document setting forth
the performance goals at the time the performance goals are established, our compensation committee (or, if not required for compliance
with Section 162(m) of the Code, the plan administrator) will appropriately make adjustments in the method of calculating the attainment
of performance goals for a performance period: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange
rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of
any statutory adjustments to corporate tax rates; (5) to exclude the effects of any items that are &ldquo;unusual&rdquo; in nature
or occur &ldquo;infrequently&rdquo; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects
of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted
levels during the balance of a performance period following such divestiture; (8) to exclude the effect of any change in the outstanding
shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,
merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common
shareholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses
under the Company&rsquo;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures
that are required to be expensed under generally accepted accounting principles; (11) to exclude the goodwill and intangible asset
impairment charges that are required to be recorded under generally accepted accounting principles; and (12) to exclude the effects
of the timing of acceptance for review and/or approval of submissions to the U.S. Food and Drug Administration or any other regulatory
body. In addition, our Compensation Committee (or, if not required for compliance with Section 162(m) of the Code, the plan administrator)
retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any performance goals
and to define the manner of calculating the performance criteria it selects to use for a performance period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Other Stock Awards</I>. The plan administrator
may grant other awards based in whole or in part by reference to our common stock. The plan administrator will set the number of
shares under the stock award and all other terms and conditions of such awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Changes to Capital Structure</I>. In
the event that there is a specified type of change in our capital structure, such as a stock split or recapitalization, appropriate
adjustments will be made to (a) the class and maximum number of shares reserved for issuance under the 2016 Plan, (b) the class
and maximum number of shares by which the share reserve may increase automatically each year, (c) the class and maximum number
of shares that may be issued upon the exercise of ISOs, (d) the class and maximum number of shares subject to stock awards that
can be granted in a calendar year (as established under the 2016 Plan pursuant to Section 162(m) of the Code) and (e) the class
and number of shares and exercise price, strike price, or purchase price, if applicable, of all outstanding stock awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Corporate Transactions</I>. In the event
of certain specified significant corporate transactions, the plan administrator has the discretion to take any of the following
actions with respect to stock awards:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">arrange for the assumption, continuation or substitution of a stock award by a surviving or acquiring
entity or parent company;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">arrange for the assignment of any reacquisition or repurchase rights held by us to the surviving
or acquiring entity or parent company;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">accelerate the vesting of the stock award and provide for its termination prior to the effective
time of the corporate transaction;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">arrange for the lapse of any reacquisition or repurchase right held by us;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">cancel or arrange for the cancellation of the stock award in exchange for such cash consideration,
if any, as our plan administrator may deem appropriate; or</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD STYLE="text-align: justify">make a payment equal to the excess of (a) the value of the property the participant would have
received upon exercise of the stock award over (b) the exercise price otherwise payable in connection with the stock award.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our plan administrator is not obligated
to treat all stock awards, even those that are of the same type, in the same manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the 2016 Plan, a corporate transaction
is generally the consummation of (i) a sale or other disposition of all or substantially all of our consolidated assets, (ii) a
sale or other disposition of at least 50% of our outstanding securities, (iii) a merger, consolidation or similar transaction following
which we are not the surviving corporation, or (iv) a merger, consolidation or similar transaction following which we are the surviving
corporation but the shares of our common stock outstanding immediately prior to such transaction are converted or exchanged into
other property by virtue of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Change of Control</I>. The plan administrator
may provide, in an individual award agreement or in any other written agreement between a participant and us that the stock award
will be subject to additional acceleration of vesting and exercisability in the event of a change of control. Under the 2016 Plan,
a change of control is generally (i) the acquisition by a person or entity of more than 50% of our combined voting power other
than by merger, consolidation or similar transaction; (ii) a consummated merger, consolidation or similar transaction immediately
after which our shareholders cease to own more than 50% of the combined voting power of the surviving entity; (iii) a consummated
sale, lease or exclusive license or other disposition of all or substantially of our consolidated assets; (iv) a complete dissolution
or liquidation; or (v) when a majority of the Board of Directors becomes comprised of individuals whose nomination, appointment,
or election was not approved by a majority of the Board of Directors members or their approved successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Amendment and Termination</I>. Our Board
of Directors has the authority to amend, suspend, or terminate our 2016 Plan, provided that such action does not materially impair
the existing rights of any participant without such participant&rsquo;s written consent. No ISOs may be granted after the tenth
anniversary of the date our Board of Directors adopted our 2016 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>U.S. Federal Income Tax Consequences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following is a summary of the principal
United States federal income tax consequences to participants and us with respect to participation in the 2016 Plan. This summary
is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign jurisdiction in which
a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when
those rules change. Because the tax consequences to any participant may depend on his or her particular situation, each participant
should consult the participant&rsquo;s tax adviser regarding the federal, state, local and other tax consequences of the grant
or exercise of an award or the disposition of stock acquired the 2016 Plan. The 2016 Plan is not qualified under the provisions
of Section 401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974.
Our ability to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as
the requirement of reasonableness, the provisions of Section 162(m) of the Code and the satisfaction of our tax reporting obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Nonstatutory Stock Options </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, there is no taxation upon the
grant of an NSO if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on
the grant date. Upon exercise, a participant will recognize ordinary income equal to the excess, if any, of the fair market value
of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by
us or one of our affiliates, that income will be subject to withholding taxes. The participant&rsquo;s tax basis in those shares
will be equal to their fair market value on the date of exercise of the stock option, and the participant&rsquo;s capital gain
holding period for those shares will begin on that date. Subject to the requirement of reasonableness, the provisions of Section
162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to a tax deduction equal to
the taxable ordinary income realized by the participant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Incentive Stock Options </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The 2016 Plan provides for the grant of
stock options that are intended to qualify as &ldquo;incentive stock options,&rdquo; as defined in Section 422 of the Code. Under
the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant
holds a share received upon exercise of an ISO for more than two years from the date the stock option was granted and more than
one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if
any, between the amount realized on a sale or other taxable disposition of that share and the participant&rsquo;s tax basis in
that share will be long-term capital gain or loss. If, however, a participant disposes of a share acquired upon exercise of an
ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally
will recognize ordinary income in the year of the disqualifying disposition equal to the excess, if any, of the fair market value
of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than
the fair market value of the share on the date of exercise of the stock option, the amount of ordinary income recognized by the
participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds
the fair market value of the share on the date of exercise of the stock option, that excess will be short-term or long-term capital
gain, depending on whether the holding period for the share exceeds one year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For purposes of the alternative minimum
tax, the amount by which the fair market value of a share of stock acquired upon exercise of an ISO exceeds the exercise price
of the stock option generally will be an adjustment included in the participant&rsquo;s alternative minimum taxable income for
the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in
which the stock option is exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share.
In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the
amount of the adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock
option is exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not allowed an income tax deduction
with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required
holding period. If there is a disqualifying disposition of a share, however, we will generally be entitled to a tax deduction equal
to the taxable ordinary income realized by the participant, subject to the requirement of reasonableness and the provisions of
Section 162(m) of the Code, and provided that either the employee includes that amount in income or we timely satisfy our reporting
requirements with respect to that amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Awards </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, the recipient of a restricted
stock award will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value
of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the stock is not vested when
it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock),
the recipient generally will not recognize income until the stock becomes vested, at which time the recipient will recognize ordinary
income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by
the recipient in exchange for the stock. A recipient may, however, file an election with the Internal Revenue Service, within 30
days following his or her receipt of the stock award, to recognize ordinary income, as of the date the recipient receives the award,
equal to the excess, if any, of the fair market value of the stock on the date the award is granted over any amount paid by the
recipient for the stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recipient&rsquo;s basis for the determination
of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such
shares plus any ordinary income recognized either when the stock is received or when the stock becomes vested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirement of reasonableness,
the provisions of Section 162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled
to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Unit Awards </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, the recipient of a restricted
stock unit award structured to conform to the requirements of Section 409A of the Code or an exception to Section 409A of the Code
will recognize ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market value of the
stock received over any amount paid by the recipient in exchange for the stock. To conform to the requirements of Section 409A
of the Code, the stock subject to a restricted stock unit award may generally only be delivered upon one of the following events:
a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on another
date, unless the restricted stock unit award otherwise complies with or qualifies for an exception to the requirements of Section
409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest
on any taxes owed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The recipient&rsquo;s basis for the determination
of gain or loss upon the subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid for
such shares plus any ordinary income recognized when the stock is delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subject to the requirement of reasonableness,
the provisions of Section 162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled
to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock unit award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Stock Appreciation Rights </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Generally, if a stock appreciation right
is granted with an exercise price equal to the fair market value of the underlying stock on the grant date, the recipient will
recognize ordinary income equal to the fair market value of the stock or cash received upon such exercise. Subject to the requirement
of reasonableness, the provisions of Section 162(m) of the Code, and the satisfaction of a tax reporting obligation, we will generally
be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the stock appreciation right.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>New Plan Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 81%; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    and position<SUP>(1)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 17%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of shares</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D., Chief Executive Officer</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">475,189 <SUP>(2)</SUP></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Igor P. Bilinsky, Chief Operating Officer</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve R. Martin, Chief Financial Officer</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All current executive officers as a group</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All current directors who are not executive officers as a group</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 1pt; padding-left: 2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All employees, including all current officers who are not executive officers, as a group</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt">___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.3pt">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Except as listed in the table, no other awards that may be made under the 2016 Plan are currently determinable, as there are
no guaranteed or contractually required awards. Future grants are subject to approval of our Board or the applicable committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Pursuant to his employment offer letter agreement with the Company, Dr. Grint is entitled to receive, subject to approval by
our Board or the Compensation Committee, an initial stock option grant under the 2016 Plan exercisable for up to 475,189 shares
of our common stock at an exercise price per share equal to the fair market value on the date of grant, 40% of which shares will
be subject to time-based vesting over a four-year period (25% of such time-based shares to vest after one year, and the balance
to vest monthly over the following 36 months), and 60% of which shares will be subject to vesting upon achievement of corporate
performance criteria to be established by the Board or the Compensation Committee. The Board expects this grant to be completed
if Proposal 3 is approved at the annual meeting.</TD></TR></TABLE>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2016 Plan Benefits </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth, for each of the individuals
and groups indicated, the total number of shares of our common stock subject to awards that have been granted (even if not currently
outstanding) under the 2016 Plan through June 30, 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2016 Plan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name and position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of shares</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Paul. C. Grint, M.D., Chief Executive Officer</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;&nbsp;<SUP>(1)</SUP></TD><TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;Igor P. Bilinsky, Chief Operating Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">129,534</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Steve R. Martin, Chief Financial Officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">16,128</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">All current executive officers as a group</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">145,662</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">All current directors who are not executive officers as a group</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Director nominees</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Wendy S. Johnson</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Vijay B. Samant</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Each associate of any director or executive officer</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -12pt; padding-left: 12pt">Each other person who received or is to receive 5% of rights under the 2016 Plan</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&mdash;</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -11.5pt; padding-left: 11.5pt">All employees, including all current officers who are not executive officers, as a group</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">3,650</TD><TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<DIV STYLE="padding: 0in 0in 0in 0; border: white 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">___________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">See footnote 2 under the New Plan Benefits table above.</TD>
</TR></TABLE>

</DIV>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides information as of December 31,
2016 with respect to our equity compensation plans, retrospectively adjusted to give effect to our 1-for-10 reverse split of our
common stock effected in April 2017:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">securities remaining</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Weighted-</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">available for</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Number of securities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">average</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">future issuance</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">to be issued upon</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">exercise</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">under equity</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">exercise</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">price of</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">compensation plans</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">of outstanding options,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">outstanding</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(excluding securities</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">options, warrants</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">reflected in</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Plan Category</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">and rights</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">and rights</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">column (a))</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(b)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">(c)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 43%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders <SUP>(1)</SUP></FONT></TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,680</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">62.40</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 15%; font: 10pt Times New Roman, Times, Serif; text-align: right">164,016</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 3pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders <SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,210</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">100.00</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 3pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">74,890</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">64.50</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">164,016</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.9pt">(1)</TD><TD>The 2009 Plan, 2013 Plan and 2016 Plan.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 17.9pt">(2)</TD><TD>The 2012 Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>
<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proposal 4<BR>
<BR>
<FONT STYLE="font-size: 10pt">Ratification of Selection of Independent Registered Public Accounting Firm</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><FONT STYLE="font-size: 10pt">&nbsp;</FONT></B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Audit Committee of the Board of Directors
has selected Ernst &amp; Young LLP as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending
December 31, 2017 and has further directed that management submit the selection of its independent registered public accounting
firm for ratification by the shareholders at the annual meeting. Ernst &amp; Young LLP was selected as our independent accountant
as of January 20, 2015. Prior to selecting Ernst &amp; Young LLP, PBMares, LLP served as our independent registered public accounting
firm. Representatives of Ernst &amp; Young LLP are expected to be present at the annual meeting. They will have an opportunity
to make a statement if they so desire and will be available to respond to appropriate questions. Representatives of PBMares, LLP
are not expected to be present at the annual meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Neither the Company&rsquo;s Bylaws nor
other governing documents or law require shareholder ratification of the selection of Ernst &amp; Young LLP as the Company&rsquo;s
independent registered public accounting firm. However, the Audit Committee of the Board is submitting the selection of Ernst &amp;
Young LLP to the shareholders for ratification as a matter of good corporate practice. If the shareholders fail to ratify the selection,
the Audit Committee of the Board will reconsider whether or not to retain that firm. Even if the selection is ratified, the Audit
Committee of the Board in its discretion may direct the appointment of different independent auditors at any time during the year
if they determine that such a change would be in the best interests of the Company and its shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In order for Proposal 4 to be approved,
the number of shares that vote &ldquo;For&rdquo; the proposal must exceed the number of shares that vote &ldquo;Against&rdquo;
the proposal. Abstentions will be counted towards the vote total for Proposal 4 and will have the same effect as &ldquo;Against&rdquo;
votes. Broker non-votes, if any, are counted towards a quorum, but are not counted for any purpose in determining whether this
matter has been approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Principal Accountant
Fees and Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following
table represents aggregate fees billed to us for the fiscal years ended December 31, 2016 and December 31, 2015 by Ernst &amp;
Young LLP, our current principal accountant.</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fiscal Year<BR> Ended<BR> December 31,<BR> 2016</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fiscal Year<BR> Ended<BR> December 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Audit Fees</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">493,195</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">510,988</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Audit Related Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">165,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,600</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Tax Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2pt">All Other Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 2pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">658,195</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">533,588</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following
table represents aggregate fees billed to us for the fiscal year ended December 31, 2015 by PBMares, LLP, our former principal
accountant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Fiscal Year<BR> Ended<BR> December 31,<BR> 2015</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Audit Fees</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">51,551</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Audit Related Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 2pt">Tax Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; padding-left: 2pt">All Other Fees</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 2pt">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">51,551</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Representatives
of Ernst &amp; Young LLP attended all of the meetings of the Audit Committee occurring between and including the dates of January
20, 2015 and December 31, 2016. Representatives of PBMares, LLP attended all of the meetings of the Audit Committee during the
period commencing on January 1, 2015 and ending on January 20, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pre-Approval Policies and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Audit Committee approves in advance the engagement and fees
of the independent registered public accounting firm for all audit services and non-audit services, based upon independence, qualifications
and, if applicable, performance. The Audit Committee may form and delegate to subcommittees of one or more members of the Audit
Committee the authority to grant pre-approvals for audit and permitted non-audit services, up to specific amounts. All audit services
provided by Ernst &amp; Young LLP and PBMares, LLP for the periods presented were pre-approved by the Audit Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Ability to Continue as a Going Concern&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The report of Ernst &amp; Young LLP on
the consolidated financial statements of the Company for the fiscal year ended December&nbsp;31, 2016, included in the Form 10-K
filed with the Securities and Exchange Commission on March 27, 2017 states that the Company has incurred net losses since its inception
and has negative operating cash flows, which raise substantial doubts about the Company&rsquo;s ability to continue as a going
concern. Other than the foregoing, Ernst &amp; Young LLP&rsquo;s report on the financial statements for the past two years contained
no adverse opinion or disclaimer of opinion and was not qualified as to audit scope or accounting principles.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Board Of Directors Recommends</B><BR>
<B>A Vote &ldquo;For&rdquo; Proposal 4.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>




<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Executive Officers&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table sets forth information
regarding our executive officers as of the date of this proxy statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 35%; padding-right: 3pt; padding-left: 25.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="width: 22%; padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="width: 43%; padding-right: 3pt; padding-left: 32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position(s)</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 3pt; padding-left: 25.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">59</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 3pt; padding-left: 25.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Igor P. Bilinsky </FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">44</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-right: 3pt; padding-left: 25.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve R. Martin </FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 3pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</FONT></TD>
    <TD STYLE="padding-right: 3pt; padding-left: 32.85pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following
is biographical information for Igor P. Bilinsky, our Chief Operating Officer, and Steve R. Martin, our Chief Financial Officer.
The biographical information for Dr. Grint is included under Proposal 1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Igor P. Bilinsky, Ph.D</I>. </B>has served as our Senior
Vice President, Chief Operating Officer, since January 30, 2017. Dr. Bilinsky previously served as Senior Vice President, Research
Operations and General Manager, Immuno-Oncology of Ignyta, Inc. from February 2016 to January 2017, and before that served as Ignyta&rsquo;s
General Manager, Immuno-Oncology and Senior Vice President, Special Operations since September 2015. Prior to joining Ignyta, Dr.
Bilinsky was Senior Vice President, Corporate Development at Vical Incorporated, a position he held since 2010. Dr. Bilinsky was
previously Vice President, Business Development and Special Operations at Halozyme Therapeutics from 2008 to 2010, after joining
Halozyme in 2007 as Executive Director, Corporate Development and Special Operations. From 2005 to 2007, Dr. Bilinsky was Chief
Executive Officer of Androclus Therapeutics, a privately-held biotechnology company developing novel therapeutics for autoimmune
and inflammatory diseases. He joined Androclus in 2004 as Chief Operating Officer. From 1999 to 2004, Dr. Bilinsky served in positions
of increasing responsibility as a management consultant, project leader and ultimately as principal in the healthcare practice
of the Boston Consulting Group, where he advised companies in the biotechnology, pharmaceutical and life science industries on
business strategy, operational performance and mergers and acquisitions. Prior to joining the Boston Consulting Group, Dr. Bilinsky
worked in research positions at Symyx Technologies and the Massachusetts Institute of Technology (&ldquo;MIT&rdquo;) Lincoln Laboratory.
Dr. Bilinsky received his B.S. degree in physics from the Moscow Institute of Physics and Technology and his Ph.D. degree in physics
from MIT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Steve R. Martin</I></B> has served as our Chief Financial
Officer since January 2016. Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc.,
a molecular diagnostics company, from December 2014 to August 2015. From June 2011 to December 2014, Mr. Martin served as Senior
Vice President and Chief Financial Officer of Apricus Biosciences, Inc., a publicly traded pharmaceutical company, and served as
the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From 2008 to January 2011, Mr. Martin served
as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly traded software company. During his final
10 months with BakBone until the company&rsquo;s acquisition in January 2011, Mr. Martin also served as BakBone&rsquo;s Interim
Chief Executive Officer. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly
traded research products and clinical diagnostics company. Mr. Martin&rsquo;s previous experience also includes serving as Controller
with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years with Deloitte &amp; Touche LLP,
a public accounting firm. Mr. Martin holds a B.S. degree from San Diego State University and is a certified public accountant (inactive).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Security Ownership
of Certain Beneficial Owners and Management&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth information regarding beneficial
ownership of our capital stock by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>each of our directors;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>each of our named executive officers; and</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>all of our current executive officers and directors as a group.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The percentage ownership information in the table below is based
on 8,549,152 shares of common stock outstanding as of June 30, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Information with respect to beneficial ownership provided in
the table below is based upon information supplied by officers and directors and based upon Schedules 13D and 13G and Form 4 filed
with the SEC. We have determined beneficial ownership in accordance with the rules of the SEC. These rules generally attribute
beneficial ownership of securities to persons who possess sole or shared voting power or investment power with respect to those
securities. In addition, the rules include shares of common stock issuable pursuant to the exercise of stock options or warrants
that are either immediately exercisable or exercisable on or before August 29, 2017, which is 60 days after June 30, 2017. These
shares are deemed to be outstanding and beneficially owned by the person holding those options or warrants for the purpose of computing
the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership
of any other person. Unless otherwise indicated, the persons or entities identified in this table have sole voting and investment
power with respect to all shares shown as beneficially owned by them, subject to applicable community property laws.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as otherwise noted below, the address for each person
or entity listed in the table is c/o AmpliPhi Biosciences Corporation, 3579 Valley Centre Drive, Suite 100, San Diego, California
92130.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Beneficial Ownership</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Beneficial Owner</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Percent of Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Greater than 5% Shareholders</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">None <BR></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Directors and Named Executive Officers</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">M. Scott Salka<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">22,541</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">183,095</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis Drapeau<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,576</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael S. Perry, Ph.D.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,026</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay B. Samant<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(5)</SUP></FONT></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">712</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint, M.D.<SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">712</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy Johnson<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(7)</SUP></FONT></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,432</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Martin<SUP>(8)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,335</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Igor P. Bilinsky, Ph.D.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>All current executive officers and directors as a group (8 persons)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(9)</SUP></FONT></B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">196,908</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2.3</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 2in">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.35in; text-align: left">*</TD><TD STYLE="text-align: left">Represents beneficial ownership of less than 1%.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(1)</TD><TD STYLE="text-align: left">Consists of 1,120 shares of common stock and 21,421 shares
of common stock that Mr. Salka has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of stock
options. Mr. Salka resigned from our Board of Directors in May 2017.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(2)</TD><TD STYLE="text-align: left">Consists of (a) 330 shares of common stock, (b) 124,251
shares referenced held by One Fund Management Limited as Trustee for Asia Pacific Healthcare Fund II (&ldquo;One Funds&rdquo;),
an entity with which Mr. Cook is affiliated, and warrant exercisable for 55,365 shares of common stock, and (c) 3,149 shares of
common stock that Mr. Cook has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of stock
options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(3)</TD><TD STYLE="text-align: left">Consists of 1,000 shares of common stock and 576 shares
of common stock that Mr. Drapeau has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of
stock options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(4)</TD><TD STYLE="text-align: left">Consists of 230 shares of common stock and 796 shares
of common stock that Dr. Perry has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of stock
options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(5)</TD><TD STYLE="text-align: left">Consists of 712 shares of common stock that Mr. Samant
has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of stock options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(6)</TD><TD STYLE="text-align: left">Consists of 712 shares of common stock that Dr. Grint
has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of stock options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(7)</TD><TD STYLE="text-align: left">Consists of 100 shares of common stock and 5,332 shares
of common stock that Ms. Johnson has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of
stock options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(8)</TD><TD STYLE="text-align: left">Consists of 376 shares of common stock and 3,959 shares
of common stock that Mr. Martin has the right to acquire from us within 60 days of June 30, 2017, pursuant to the exercise of
stock options.</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in; text-align: left"></TD><TD STYLE="width: 0.35in; text-align: left">(9)</TD><TD STYLE="text-align: left">Consists of (a) 126,307 shares of common stock, (b) 55,365
shares of common stock issuable upon exercise of warrants, and (c) 15,236 shares of common stock exercisable within 60 days of
June 30, 2017.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Section 16(a) Beneficial Ownership Reporting
Compliance&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 16(a) of the Exchange Act requires
the Company&rsquo;s directors and executive officers, and persons who own more than ten percent of a registered class of the Company&rsquo;s
equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and other
equity securities of the Company. Officers, directors and greater than ten percent shareholders are required by SEC regulation
to furnish the Company with copies of all Section 16(a) forms they file.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Company&rsquo;s knowledge, based
solely on a review of the copies of such reports furnished to the Company and written representations that no other reports were
required, during the fiscal year ended December 31, 2016, all Section 16(a) filing requirements applicable to its officers, directors
and greater than ten percent beneficial owners were complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>






<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Executive Compensation&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our named executive officers for the year ended December 31,
2016, which consist of all individuals who served as our principal executive officer during 2016 and our two most highly compensated
executive officers other than our principal executive officer who were serving as executive officers as of December 31, 2016 are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>M. Scott Salka, our former Chief Executive Officer;</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Steve Martin, our Chief Financial Officer; and</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&bull;</TD><TD>Wendy S. Johnson, our former Interim Chief Operating Officer.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Summary Compensation Table</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table provides information regarding the compensation
paid during the last two fiscal years to our named executive officers for the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name and Principal Position</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Year</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Salary</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Bonus</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Option </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Awards <SUP>(1)</SUP></B></P></TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Non-Equity Incentive Plan Compensation</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">All Other Compensation</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 23%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael Scott Salka, Chief Executive Officer <SUP>(2)</SUP>&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">2016</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">425,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">102,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">988</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 8%; font: 10pt Times New Roman, Times, Serif; text-align: right">527,988</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">264,263</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,469,919</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">85,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">364</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,819,546</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steve Martin, Senior VP and Chief Financial Officer <SUP>(3)</SUP>&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">306,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">239,801</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">67,200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,341</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">615,009</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left"><SUP>&nbsp;</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wendy S. Johnson, Interim Chief Operating Officer and Director <SUP>(4)</SUP>&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2016</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">300,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">40,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">590,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2015</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">270,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">25,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">289,373</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">0</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">30,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><SUP>(5)</SUP></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">614,373</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: left">In accordance with SEC rules, this column represents
the aggregate grant date fair value of the option awards granted during 2016 and 2015 (if any) computed in accordance with Financial
Accounting Standard Board Accounting Standards Codification Topic 718 for stock-based compensation transactions (ASC 718). Assumptions
used in the calculation of these amounts are included in the notes to our audited financial statements of our Annual Report on
Form 10-K for the year ended December 31, 2016, filed with the SEC on March 27, 2017. These amounts do not reflect the actual
economic value that will be realized by the named executive officer upon the vesting of the stock options, the exercise of the
stock options, or the sale of the common stock underlying such stock options.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: left">Mr. Salka commenced employment with us as Chief Executive
Officer in May 2015. Mr. Salka resigned as our Chief Executive Officer in May 2017.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">(3)</TD><TD STYLE="text-align: left">Mr. Martin commenced employment with us as Chief Financial
Officer in January 2016.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">(4)</TD><TD STYLE="text-align: left">Ms. Johnson served as our Interim Chief Operating
Officer until Dr. Bilinsky&rsquo;s appointment in January 2017.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.3pt; text-indent: 0pt; text-align: left">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"></TD><TD STYLE="width: 0.25in; text-align: left">(5)</TD><TD STYLE="text-align: left">Represents board of directors service retainers paid
to Ms. Johnson.</TD>
</TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Base Salary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The base salary or consulting compensation of our named executive
officers, as applicable, is generally determined and approved by our Board of Directors, based on the recommendation of the Compensation
Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Salka&rsquo;s annual base salary for 2015 and 2016 was $425,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Martin&rsquo;s annual base salary for 2016 was $320,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ms. Johnson was paid monthly consulting fees for her service
as our Interim Chief Operating Officer during 2015 and 2016. Ms. Johnson was compensated at a rate of $20,000 per month for her
consulting services as Interim Chief Operating Officer from January 1, 2015 until June 30, 2015, which rate was increased to $25,000
per month effective on July 1, 2015 and remained as such during 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Bonus Opportunity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to base salaries, certain of our named executive
officers are eligible to receive annual performance-based cash bonuses, which are designed to provide appropriate incentives to
our executives to achieve defined annual corporate goals and to reward our executives for individual achievement towards these
goals. The performance-based bonus a named executive officer may be eligible to receive is generally based on the extent to which
we achieve the specified corporate goals that our Board of Directors or Compensation Committee establishes. After the end of the
year, typically in February or March, the Board of Directors and/or Compensation Committee reviews our performance against the
established corporate goals and approves the extent to which we achieved such goals. In addition, we may award a named executive
officer a discretionary cash or equity bonus, if our Board of Directors or Compensation Committee determines appropriate based
on the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Board of Directors and/or Compensation Committee generally
will consider each executive officer&rsquo;s individual contributions towards reaching our corporate goals and may also establish
specific individual goals for our executive officers as it determines appropriate. There is no minimum bonus percentage or amount
established for the named executive officers and, as a result, the bonus amounts vary based on corporate and individual performance,
as applicable. Under the terms of his offer letter agreement described below, Mr. Salka was eligible to receive an annual performance-based
bonus for 2016 equal to, at target, 40% of his annual salary based on our achievement of certain performance goals. Under the terms
of her consulting agreement described below, Ms. Johnson was eligible to receive up to $250,000 in cash bonus payments for 2016
upon achievement of specific goals relating to dosing of the first patient in the first clinical trial utilizing our drug product,
the successful regulatory filing in the United States related to one of our clinical trials and the issuance of a final report
related to on-going clinical trials utilizing our drug product. Mr. Martin is eligible to receive an annual performance-based bonus
for 2016 equal to, at target, 35% of his annual salary based on our achievement of certain performance goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mr. Salka&rsquo;s and Mr. Martin&rsquo;s 2016 bonuses were based
entirely on corporate goals relating to capital raising, management of operating costs, our clinical trial and manufacturing progress,
and certain organizational achievements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In February 2017, the Compensation Committee reviewed the corporate
performance goals for Mr. Salka and Mr. Martin and determined that on an overall basis, we had achieved 60% of such goals for 2016,
based on the evaluation of the results by the Compensation Committee and considering the importance of each goal to our company.
The Compensation Committee assessed the goals established for Ms. Johnson&rsquo;s bonus throughout the fiscal year and determined
that she had met the goals established for 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity-Based Awards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our equity-based incentive awards are designed to align our
interests with those of our employees and consultants, including our named executive officers. Our Board of Directors or our Compensation
Committee approves equity grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional
retention measure. Our executives may be awarded an initial new hire grant upon commencement of service and may receive additional
grants, as the Board of Directors or Compensation Committee determines appropriate, in order to incentivize and/or reward such
executives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have traditionally granted stock options to our named executive
officers under our equity incentive plans, the terms of which are described below under &ldquo;&mdash;Equity Benefit Plans.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On January 18, 2016, in accordance with Mr. Martin&rsquo;s offer
letter agreement, we granted Mr. Martin an option to purchase 9,991 shares of our common stock with an exercise price of $28.50
per share (as adjusted to give effect to the 1-for-10 reverse split of our common stock effected in April 2017). Twenty-five percent
of the shares underlying this option vested on January 18, 2017, with the balance vesting in equal monthly installments thereafter
over the next three years, subject to Mr. Martin&rsquo;s continued service with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Agreements with our Named Executive Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Below are descriptions of our employment and consulting agreements
with our named executive officers governing the terms of their service with us. For a discussion of the severance pay and other
benefits that may be provided in connection with a termination of service and/or a change in control under the arrangements with
our named executive officers, please see &ldquo;&mdash;Potential Payments and Benefits upon Termination or Change in Control&rdquo;
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Salka. </I>In April 2015, we entered into an offer letter
agreement with Mr. Salka, our Chief Executive Officer until his resignation in May 2017. Mr. Salka&rsquo;s employment under the
agreement was at will and terminable at any time by us or Mr. Salka. Under the terms of the agreement, Mr. Salka was entitled to
receive an initial annual base salary of $425,000, an annual target performance bonus of 40% of his annual salary based on our
achievement of certain performance objectives and an option to purchase a number of shares of our common stock under our 2013 Plan
equal to 4% of the number of shares of common stock outstanding on a fully-diluted basis. Mr. Salka resigned from the Company in
May 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Ms. Johnson. </I>We entered into an agreement with Ms. Johnson
in September 2014 which provided for Ms. Johnson&rsquo;s services as an independent contractor on an interim basis as our Chief
Operating Officer. In September 2015, we entered into a consulting agreement with Ms. Johnson, which superseded her prior agreement,
effective July 1, 2015. Under the terms of her consulting agreement, including amendments, Ms. Johnson was entitled to receive
monthly compensation of $25,000 for consulting services of at least 120 hours per month, cash bonus payments up to an aggregate
of $300,000 upon the achievement of certain Company milestones and an option to purchase a number of shares of our common stock
under our 2013 Plan equal to 0.5% of the number of shares of common stock outstanding on a fully-diluted basis, which was granted
in September 2015. In February 2017, upon termination of her prior September 2015 consulting agreement, we entered into a new consulting
agreement with Ms. Johnson, pursuant to which Ms. Johnson has agreed to provide consulting services to us in the areas of clinical,
regulatory, manufacturing and other operating activities as deemed necessary by the Company&rsquo;s Chief Executive Officer and
Chief Operating Officer. Ms. Johnson was entitled to receive cash compensation in the amount of $25,000 for services performed
over an initial service period that extends for 60 days following the date of the consulting agreement. Ms. Johnson may provide
additional services to us on a project-by-project basis in exchange for compensation at a rate of $400 per hour.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Martin</I>. In January 2016, we entered into an offer
letter agreement with Mr. Martin, our Senior Vice President and Chief Financial Officer. Mr. Martin&rsquo;s employment under the
agreement is at will and may be terminated by us or Mr. Martin at any time. Under the terms of the agreement, Mr. Martin is entitled
to receive an initial annual base salary of $320,000, an annual target performance bonus of 35% of his annual salary based on our
achievement of certain performance objectives and an option to purchase a number of shares of our common stock equal to 1% of the
number of shares of common stock outstanding on a fully-diluted basis, which was granted in January 2016 and is described above
under &ldquo;&mdash;Equity-Based Awards&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Potential Payments and Benefits upon Termination or Change
in Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Salka</I>. Under the terms of his offer letter agreement,
as amended, Mr. Salka was entitled to receive 12 months of continued base salary if his employment with us was terminated without
cause or if he resigned for good reason, and additionally, if such termination or resignation occurs in connection with a change
in control, full acceleration of his equity awards, provided that in either case Mr. Salka were to execute an effective release
of claims against us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Mr. Martin</I>. Under the terms of his offer letter agreement,
Mr. Martin is entitled to receive 12 months of continued base salary if his employment with us is terminated without cause or
if he resigns for good reason, and additionally, if such termination or resignation occurs in connection with a change in control,
full acceleration of his equity awards, provided that in either case Mr. Martin executes an effective release of claims against
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the named executive officers hold stock options under
our equity incentive plans that were granted subject to the general terms of our equity incentive plans and form of stock option
agreements. A description of the termination and change in control provisions in such equity incentive plans and stock options
granted thereunder is provided below under &ldquo;&mdash;Equity Benefit Plans&rdquo; and the specific vesting terms of each named
executive officer&rsquo;s stock options are described below under &ldquo;&mdash;Outstanding Equity Awards at Fiscal Year End.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Outstanding Equity Awards at Fiscal Year End</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth certain information regarding
all outstanding equity awards held by our named executive officers as of December 31, 2016, which information has been retrospectively
adjusted to give effect to the 1-for-10 reverse split of our common stock effected in April 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Equity Incentive</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center">&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan Awards:</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underlying</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercised</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exercise</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(#)</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unearned</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Price</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Option</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(#) Exercisable</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unexercisable</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Options (#)</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>($)</B></FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD NOWRAP STYLE="border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration Date</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Salka</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,601</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,045</FONT></TD>
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(1)</SUP></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">94.50</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/5/2025</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Martin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9,991</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(2)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28.50</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1/17/2026</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ms. Johnson</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,996</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">74.60</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/8/2025</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #FEFEFE">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">224</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">426</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(3)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/21/2025</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD>
    <TD NOWRAP>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">970</FONT></TD>
    <TD NOWRAP><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>(4)</SUP></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.80</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/21/2025</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>13,323 of the shares underlying the option were subject to vesting over a four year period commencing on May 18, 2015 (with
25% vesting on the one-year anniversary of the commencement of Mr. Salka&rsquo;s employment and the balance vesting in monthly
installments thereafter), subject to Mr. Salka&rsquo;s continued service with us, and 13,323 of the shares underlying this option
were subject to vesting upon satisfaction of certain business goals relating to human clinical trial milestones for our phage products.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>Twenty-five percent of the shares underlying this option vested on January 18, 2017, with the balance vesting in equal monthly
installments thereafter over the next three years, subject to Mr. Martin&rsquo;s continued service with us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>The shares underlying this option vest on an equal monthly basis over a four-year period commencing on August 3, 2015. This
option was granted to Ms. Johnson for her services as a non-employee director.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>The shares underlying this option will vest on the date that the market price of our common stock reaches $250.00 per share
before the option expires. This option was granted to Ms. Johnson for her services as a non-employee director.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All of the stock options held by our named executive officers
listed in the table above were granted under and subject to the terms of our 2013 Stock Incentive Plan, the terms of which are
described below under &ldquo;&mdash;Equity Benefit Plans&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Option Exercises and Stock Vested</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our named executive officers did not exercise any stock option
awards during the year ended December 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Pension Benefits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of our named executive officers participate in or have
account balances in qualified or non-qualified defined benefit plans sponsored by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Qualified Deferred Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of our named executive officers participate in or have
account balances in qualified or non-qualified defined contribution plans or other non-qualified compensation plans sponsored by
us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Equity Benefit Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The historical share numbers described under this &ldquo;Equity
Benefit Plans&rdquo; heading have been retrospectively adjusted to give effect to the 1-for-10 reverse split of our common stock
effected in April 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2016 Equity Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2016 Equity Incentive Plan, or the 2016 Plan, was approved
by our Board of Directors in April 2016 and subsequently approved by our stockholders in June 2016. The plan provides for the issuance
of incentive awards in the form of non-qualified and incentive stock options, stock appreciation rights, restricted stock awards,
restricted stock unit awards and performance-based stock awards. The awards may be granted by the Company&rsquo;s Board of Directors
to its employees, including officers, non-employee directors and consultants who provide services to the Company or to a subsidiary
of the Company. The exercise price for stock options must not be less than the fair market value of the underlying shares on the
date of grant. Stock options expire no later than ten years from the date of grant and generally vest and typically become exercisable
over a four-year period following the date of grant. Upon the exercise of stock options, the Company issues the resulting shares
from shares reserved for issuance under the 2016 Plan. With the approval of the 2016 Plan, the remaining unallocated shares under
the Company&rsquo;s 2013 Stock Incentive Plan were allocated to the 2016 Plan and an additional 100,000 new shares were added to
the authorized share reserve under the 2016 Plan. On January 1, 2017, pursuant to the terms of the 2016 Plan, the number of shares
available for issuance under the 2016 Plan automatically increased by 82,440 shares. If Proposal 3 described herein is approved
at the annual meeting, the number of shares authorized for issuance under the 2016 Plan will be increased by 800,000 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>2013 Stock Incentive Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our 2013 Stock Incentive Plan, or the 2013 Plan, was first approved
by our Board of Directors in December 2013 and approved by our stockholders in February 2014, and subsequently amended by our Board
of Directors and stockholders effective in August 2015. With the approval of the 2016 Plan, we will not issue any further awards
under the 2013 Plan. We have included this description of the 2013 Plan in order to provide information regarding the material
terms of the awards we granted to our named executive officers during the years ended December 31, 2015 and December 31, 2016.
As of December&nbsp;31, 2016, there were outstanding stock options to purchase 66,380 shares of our common stock under the 2013
Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The 2013 Plan permitted the granting of stock options (both
options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that
do not so qualify), stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, and cash-based
awards. The exercise price of each stock option was determined by our plan administrator to be at no less than 100% of the fair
market value of our common stock on the date of grant or, in the case of an incentive stock option granted to a 10% owner, no less
than 110% of the fair market value of our common stock on the date of grant. The term of each stock option was fixed by the plan
administrator and may not exceed 10 years from the date of grant. The plan administrator determines at what time or times each
option may be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the 2013 Plan, an option may be exercised
following the cessation of a participant&rsquo;s service with us only to the extent provided in the applicable option agreement.
If a participant&rsquo;s service relationship with us or any of our affiliates ceases for any reason other than disability or death,
the participant may generally exercise any vested options for a period of three months following the cessation of service. If a
participant&rsquo;s service relationship with us or any of our affiliates ceases due to disability or death, or a participant dies
within a certain period following cessation of service, the participant or a beneficiary may generally exercise any vested options
for a period of 12 months. In no event may an option be exercised beyond the expiration of its term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the 2013 Plan, upon the effectiveness of
a corporate transaction (as such term is defined in the 2013 Plan) in the event that all awards are not affirmed by us or assumed
by the successor entity, all awards granted under the 2013 Plan shall terminate. In addition, in connection with a corporate transaction
or change in control (as such term is defined in the 2013 Plan) the plan administrator may provide the full or partial automatic
vesting and exercisability of one or more outstanding unvested awards under the 2013 Plan and the release from restrictions on
transfer or forfeiture rights of such awards in connection with such transaction, on such terms and conditions as the plan administrator
may specify.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Board of Directors may amend the 2013 Plan at any time;
no further grants will be made under the 2013 Plan as of the effectiveness of our 2016 Plan, but outstanding awards granted under
the 2013 Plan continue to be governed by its terms. The plan administrator may amend the terms of any outstanding award granted
under the 2013 Plan, but no such action may adversely affect the holder&rsquo;s rights under an outstanding award without the holder&rsquo;s
consent. Certain amendments to the 2013 Plan require the approval of our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Employee Stock Purchase Plan</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additional long-term equity incentives are provided through
our 2016 Employee Stock Purchase Plan (the &ldquo;ESPP&rdquo;), which became effective in connection with our 2016 Annual Meeting
of Shareholders in May 2016. The ESPP is intended to qualify as an &ldquo;employee stock purchase plan&rdquo; within the meaning
of section 423 of the Code. Our Board of Directors has delegated its authority to administer the ESPP to our Compensation Committee.
Under the ESPP, all of our regular employees (including our named executive officers) may participate and may contribute, normally
through payroll deductions, up to 15% of their earnings for the purchase of our common stock. The ESPP is implemented through a
series of offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with a duration of not more
than 27 months, and may specify shorter purchase periods within each offering. Each offering will have one or more purchase dates
on which our common stock will be purchased for employees participating in the offering. Unless otherwise determined by our Compensation
Committee, shares are purchased for accounts of employees participating in the ESPP at a price per share equal to the lower of
(a) 85% of the fair market value of our common stock on the first date of an offering or (b) 85% of the fair market value of our
common stock on the date of purchase. As of December 31, 2016, there were 8,727 shares available for future issuance under the
ESPP. On January 1, 2017, pursuant to the terms of the ESPP, the number of shares available for issuance under the ESPP automatically
increased by 16,488 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Non-Employee Director Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table and related footnotes show the compensation
paid during the year ended December 31, 2016 to our non-employee directors, other than Ms. Johnson whose 2016 compensation is set
forth above under &ldquo;Executive Compensation&rdquo; above. We did not grant any equity awards to our non-employee directors
during the year ended December 31, 2016. The stock option share numbers set forth in the footnotes below the following table have
been retrospectively adjusted to give effect to the 1-for-10 reverse split of our common stock effected in April 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Fees Earned <BR>
or Paid in</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Name</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Cash</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Total</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">70,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Louis Drapeau<SUP>(2)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">58,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael S. Perry, Ph.D.<SUP>(3)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">59,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay Samant <SUP>(4)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">46,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul C. Grint <SUP>(5)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Julian Kirk <SUP>(6)</SUP></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">11,667</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">_______________&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>As of December 31, 2016, Mr. Cook held stock options for an aggregate of 4,910 shares, of which 2,517 shares were vested and
exercisable.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>As of December 31, 2016, Mr. Drapeau held stock options for an aggregate of 1,620 shares, of which 464 shares were vested and
exercisable.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>As of December 31, 2016, Mr. Perry held stock options for an aggregate of 1,740 shares, of which 6,784 shares were vested and
exercisable.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>As of December 31, 2016, Mr. Samant held stock options for an aggregate of 1,620 shares, of which 440 shares were vested and
exercisable.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD>As of December 31, 2016, Dr. Grint held stock options for an aggregate of 1,620 shares, of which 440 shares were vested and
exercisable.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(6)</TD><TD>Mr. Kirk resigned from our Board of Directors in April 2016. As of December 31, 2016, Mr. Kirk did not have any outstanding
or vested stock options.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2015, the Board of Directors approved a revised
compensation structure for our non-employee directors. In 2016, the chairman of the Board received an annual cash retainer of $60,000
and each other non-employee director received an annual cash retainer of $40,000. For the Audit Committee, the committee chair
received an additional annual cash retainer of $15,000 and each member received an additional annual cash retainer of $6,000. For
the Compensation Committee, the committee chair received an additional annual cash retainer of $10,000 and each member received
an additional annual cash retainer of $5,000. For the Nominating and Corporate Governance Committee, the committee chair received
an additional annual cash retainer of $5,000 and each member received an additional annual cash retainer of $3,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During 2016, Mr. Salka and Ms. Johnson served on our Board of
Directors. As an employee, Mr. Salka did not receive cash or equity compensation for his services as a director during 2016. Ms.
Johnson received a retainer of $40,000 for her services as a director during 2016. As named executive officers, the compensation
of each of Mr. Salka and Ms. Johnson is reflected in the Summary Compensation Table above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>




<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Transactions With Related Persons&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Related-Person Transactions policy and
Procedures&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have adopted a written related-person
transactions policy that sets forth our policies and procedures regarding the identification, review, consideration and oversight
of &ldquo;related-person transactions.&rdquo; For purposes of our policy only, a &ldquo;related-person transaction&rdquo; is a
transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and
any &ldquo;related person&rdquo; are participants involving an amount that exceeds $120,000 (or such lower threshold as may be
applicable to us from time to time pursuant to the rules and regulations of the SEC or the NYSE MKT).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Transactions involving compensation for
services provided to us by an employee, consultant or director are not considered related-person transactions under this policy.
A related person is any executive officer, director or a holder of more than five percent of our common stock, including any of
their immediate family members and any entity owned or controlled by such persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the policy, where a transaction has
been identified as a related-person transaction, management must present information regarding the proposed related-person transaction
to our Audit Committee (or, where review by our Audit Committee would be inappropriate, to another independent body of our Board
of Directors) for approval. The presentation must include a description of, among other things, the material facts, the direct
and indirect interests of the related persons, the benefits of the transaction to us and whether any alternative transactions are
available. To identify related-person transactions in advance, we rely on information supplied by our executive officers, directors
and certain significant shareholders. In considering related-person transactions, our Audit Committee or other independent body
of our Board of Directors takes into account the relevant available facts and circumstances including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the risks, costs and benefits to us;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the impact on a director&rsquo;s independence in the
event the related person is a director, immediate family member of a director or an entity with which a director is affiliated;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the terms of the transaction;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the availability of other sources for comparable services
or products; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&bull;</TD><TD STYLE="text-align: justify">the terms available to or from, as the case may be,
unrelated third parties.</TD>
</TR></TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the event a director has an interest
in the proposed transaction, the director must recuse himself or herself from the deliberations and approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Certain Related-Person Transactions&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following includes a summary of transactions since January
1, 2015 to which we have been a party, in which the amount involved in the transaction exceeded the lesser of $120,000 or one percent
of the average of our total assets at year end for the last two completed fiscal years, and in which any of our directors, executive
officers or, to our knowledge, beneficial owners of more than 5% of our capital stock or any member of the immediate family of
any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation,
termination, change in control and other arrangements, which are described in the sections above entitled &ldquo;Executive Compensation&rdquo;
and &ldquo;Non-Employee Director Compensation.&rdquo; The historical share and share-based numbers for the transactions summarized
below have been retrospectively adjusted to give effect to the 1-for-10 reverse split of our common stock effected in April 2017
and, where applicable, the 1-for-50 reverse split of our common stock effected in August 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sale of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2015, in connection with a private placement of our
common stock, we sold an aggregate of 6,845 shares and 1,711 shares underlying warrants to One Fund Management Limited as Trustee
for Asia Pacific Healthcare Fund II, which is also known as Phillip Asset Management Limited as Trustee for Asia Pacific Healthcare
Fund II, or Phillip Asset Management. Jeremy Curnock Cook, our then-interim Chief Executive Officer and the current chairman of
the Board, is a Managing Director and holds an ownership interest in Bioscience Managers Pty Ltd. Phillip Asset Management Limited
is 100% owned by Phillip Capital Holdings Ltd., an Australian stockbroker. Phillip Asset Management holds all shares in its capacity
as trustee for Bioscience Managers Pty Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, in connection with the March 2015 private placement,
we sold an aggregate of 27,878 shares and 6,969 shares underlying warrants to Intrexon Corporation. Intrexon was affiliated with
Randal J. Kirk, one of our principal stockholders and also the father of a former member of our board of directors, Julian P. Kirk.
In connection with the March 2015 private placement, we entered into a registration rights agreement with Intrexon and certain
other purchasers in the private placement, pursuant to which we registered for resale on Form S-1 (File No. 333-203454) 82,484
shares of common stock held or issuable upon exercise of warrants by Intrexon. We also granted Intrexon certain piggyback registration
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exclusive Channel Collaboration</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to that certain Exclusive Channel Collaboration Agreement,
dated as of March 29, 2013, with Intrexon Corporation, which we refer to as the ECC Agreement, we agreed to pay Intrexon Corporation
royalties as a percentage in the upper-single digits of the net product sales of a product developed under the collaboration, and
up to $7.5 million in aggregate milestone payments for each product developed. Intrexon Corporation owned more than 5% of our common
stock at the time of the transaction. On April 13, 2016, we provided written notice to Intrexon Corporation of our election to
voluntarily terminate the ECC Agreement. The effective date of termination was July 12, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock Issuance Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 8, 2016, we entered into the CSIA with certain former
holders of our Series&nbsp;B convertible preferred stock, including Pendinas Limited (which owned more than 5% of our common stock
on the date of the CSIA) and One Funds. Pursuant to the CSIA, we issued shares of our common stock to such holders, and amended
certain warrants to purchase common stock issued to such holders in the private placement of Series B convertible preferred stock
in June 2013 and/or July 2013, in order to reduce the exercise price of such warrants from $70.00 per share to $40.50 per share
and extend the expiration date thereof from June 26, 2018 to March 31, 2021. As consideration for the transactions described above,
such holders waived their right to receive approximately $2.2 million in aggregate cash payments to which they were entitled upon
the conversion of all outstanding shares of Series B convertible preferred stock into shares of common stock on April 8, 2016,
in respect of accrued dividends on their former shares of Series B convertible preferred stock. Such holders also waived their
registration rights with respect to certain future registration statements that may be filed, and certain future public offerings
that may be conducted, by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The table below summarizes the shares issued to Pendinas Limited
and One Funds and the accrued dividends waived by such parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid">Related Person</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Shares<BR> Issued</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">Accrued<BR> Dividends<BR> Waived</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font: 10pt Times New Roman, Times, Serif; text-align: left">Pendinas Limited</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">58,455</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,504,433</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">One Funds</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,129</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">440,859</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the CSIA and in connection with the
registered direct public offering that we completed in June 2016, on June 21, 2016 we issued 51,383 and 15,057 shares of common
stock to Pendinas Limited and One Funds, respectively, for no additional consideration. Pendinas Limited ceased to be a &ldquo;related
person&rdquo; following the completion of our May 2017 public offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 27, 2017, we entered into an amendment
to the CSIA (the &ldquo;Amendment&rdquo;), as described in further detail under Proposal&nbsp;2 above. Pursuant to the Amendment,
on June 29, 2017 we issued an aggregate of 28,684 shares of common stock to the stockholders party to the Amendment, including
<FONT STYLE="background-color: white">5,757 shares to One Funds. If Proposal 2 is approved, we have agreed to issue One Funds an
additional 105,015 shares of common stock subject to </FONT>our receipt of a release of claims from One Funds at the time of issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Settlement Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On November 12, 2016, we entered into a settlement agreement
with NRM VII Holdings I, LLC (&ldquo;NRM&rdquo;) to settle a complaint filed by NRM in April 2016 against us and the members of
our board of directors in the Superior Court of California, County of San Diego, alleging that we breached the implied covenant
of good faith and fair dealing by entering into an alleged scheme to force NRM to convert its shares of Series B convertible preferred
stock into shares of our common stock. The complaint further alleged that the members of our Board of Directors who were named
as defendants breached their fiduciary duty of good faith and loyalty owed to NRM, as one of our stockholders, by participating
in this alleged scheme. Pursuant to the settlement agreement, NRM dismissed the allegation with prejudice upon receipt of a cash
payment of $2.0 million, which was paid to NRM by our insurance carrier in 2016. The settlement agreement contains mutual releases
covering all claims that we or our affiliates, or NRM or its affiliates, have or may have against the other party or such other
party's affiliates in connection with the allegation or otherwise as of the date of the settlement agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Upon the automatic conversion of NRM's shares of our Series
B convertible preferred stock into shares of our common stock on April 8, 2016, we became obligated to pay NRM accrued dividends
in the amount of approximately $914,000. Upon NRM's receipt of the $2.0 million settlement payment described above, our accrued
dividends payment obligation to NRM was extinguished.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Employment Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered into compensatory arrangements with our executive
officers, as more fully described in the section above entitled &ldquo;Executive Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Stock Options Granted to Executive Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have granted stock options to our executive officers and
directors, as more fully described in the sections above entitled &ldquo;Executive Compensation&rdquo; and &ldquo;Non-Employee
Director Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Indemnification Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have entered, and intend to continue to enter, into separate
indemnification agreements with each of our directors and executive officers, as described in the sections above entitled &ldquo;Executive
Compensation&rdquo; and &ldquo;Non-Employee Director Compensation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Householding of Proxy Materials</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC has adopted rules that permit companies
and intermediaries (e.g., brokers) to satisfy the delivery requirements for annual meeting materials with respect to two or more
shareholders sharing the same address by delivering a single set of annual meeting materials addressed to those shareholders. This
process, which is commonly referred to as &ldquo;householding,&rdquo; potentially means extra convenience for shareholders and
cost savings for companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This year, a number of brokers with account
holders who are AmpliPhi shareholders will be &ldquo;householding&rdquo; the Company&rsquo;s proxy materials. A single set of annual
meeting materials will be delivered to multiple shareholders sharing an address unless contrary instructions have been received
from the affected shareholders. Once you have received notice from your broker that they will be &ldquo;householding&rdquo; communications
to your address, &ldquo;householding&rdquo; will continue until you are notified otherwise or until you revoke your consent. If,
at any time, you no longer wish to participate in &ldquo;householding&rdquo; and would prefer to receive a separate set of annual
meeting materials, please notify your broker or AmpliPhi. Direct your written request to AmpliPhi Biosciences Corporation, Attn:
Investor Relations, 3579 Valley Centre Drive, Suite 100, San Diego, California 92130 or contact Matt Dansey at (858) 800-4869.
Shareholders who currently receive multiple copies of the annual meeting materials at their addresses and would like to request
&ldquo;householding&rdquo; of their communications should contact their brokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Other Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors knows of no other
matters that will be presented for consideration at the annual meeting. If any other matters are properly brought before the meeting,
it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-top: white 1pt solid; border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 50%; border-top: white 1pt solid; border-right: white 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By Order of the Board of Directors, </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jeremy Curnock Cook</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chairman of the Board of Directors</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego, California</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: white 1pt solid; border-left: white 1pt solid; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-right: white 1pt solid; border-bottom: white 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;&nbsp;&nbsp;, 2017</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>A copy of the
Company&rsquo;s Annual Report to the Securities and Exchange Commission on Form 10-K for the fiscal year ended December 31, 2016
is available without charge upon written request to: Secretary, AmpliPhi Biosciences Corporation, 3579 Valley Centre Drive, Suite
100, San Diego, California 92130. We will furnish a copy of any exhibit to such report upon written request and payment of reasonable
expenses in furnishing such exhibit.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>



<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Appendix A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>AmpliPhi
Biosciences Corporation </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>2016
Equity Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Adopted
by the Board of Directors: April 21, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Approved
by the Shareholders: June 20, 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Amended
by the Board of Directors:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Approved
by the Shareholders: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">General.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT><B>Successor
to and Continuation of Prior Plan.</B> The Plan is intended as the successor to and continuation of the <FONT STYLE="color: windowtext">AmpliPhi
Biosciences Corporation 2013 Stock Incentive Plan</FONT> (the &ldquo;<B><I>2013 Plan</I></B>&rdquo;). From and after 12:01 a.m.
Pacific Time on the Effective Date, no additional stock awards will be granted under the 2013 Plan. All Awards granted on or after
12:01 a.m. Pacific Time on the Effective Date will be granted under this Plan. All stock awards granted under the 2013 Plan or
under the 2009 Targeted Genetics Stock Incentive Plan or the AmpliPhi Biosciences Corporation 2012 Stock Incentive Plan (collectively,
with the 2013 Plan, the &ldquo;<B><I>Prior Plans</I></B>&rdquo;), will remain subject to the terms of the Prior Plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
shares that would otherwise remain available for future grants under the 2013 Plan as of 12:01 a.m. Pacific Time on the Effective
Date (the &ldquo;<B><I>2013 Plan&rsquo;s Available Reserve</I></B>&rdquo;) will cease to be available under the 2013 Plan at such
time. Instead, that number of shares of Common Stock equal to the 2013 Plan&rsquo;s Available Reserve will be added to the Share
Reserve (as further described in Section 3(a) below) and will be immediately available for grants and issuance pursuant to Stock
Awards hereunder, up to the maximum number set forth in Section 3(a) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, from and after 12:01 a.m. Pacific Time on the Effective Date, any shares subject, at such time, to outstanding stock
awards granted under the Prior Plans that <FONT STYLE="color: windowtext">(i) expire or terminate for any reason prior to exercise
or settlement; (ii) are forfeited because of the failure to meet a contingency or condition required to vest such shares or otherwise
return to the Company; or (iii) are reacquired, withheld (or not issued) to satisfy a tax withholding obligation in connection
with an award or to satisfy the purchase price or exercise price of a stock award</FONT> (such shares the &ldquo;<B><I>Returning
Shares</I></B>&rdquo;) will immediately be added to the Share Reserve (as further described in Section 3(a) below) as and when
such shares become Returning Shares, up to the maximum number set forth in Section 3(a) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligible
Award Recipients.</B> Employees, Directors and Consultants are eligible to receive Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Available
Awards.</B> The Plan provides for the grant of the following Awards: (i)&nbsp;Incentive Stock Options, (ii) Nonstatutory Stock
Options, (iii) Stock Appreciation Rights, (iv)&nbsp;Restricted Stock Awards, (v) Restricted Stock Unit Awards, (vi) Performance
Stock Awards, (vii) Performance Cash Awards, and (viii) Other Stock Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purpose.</B>
The Plan, through the grant of Awards, is intended to help the Company secure and retain the services of eligible award recipients,
provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate, and provide a means
by which the eligible recipients may benefit from increases in value of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 45; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Administration.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Administration
by Board.</B> The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees,
as provided in Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Powers
of Board.</B> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
determine: (A) who will be granted Awards; (B) when and how each Award will be granted; (C) what type of Award will be granted;
(D) the provisions of each Award (which need not be identical), including when a person will be permitted to exercise or otherwise
receive cash or Common Stock under the Award; (E) the number of shares of Common Stock subject to, or the cash value of, an Award;
and (F) the Fair Market Value applicable to a Stock Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
construe and interpret the Plan and Awards granted under it, and to establish, amend and revoke rules and regulations for administration
of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan
or in any Award Agreement or in the written terms of a Performance Cash Award, in a manner and to the extent it will deem necessary
or expedient to make the Plan or Award fully effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
settle all controversies regarding the Plan and Awards granted under it.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
accelerate, in whole or in part, the time at which an Award may be exercised or vest (or the time at which cash or shares of Common
Stock may be issued in settlement thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
suspend or terminate the Plan at any time. Except as otherwise provided in the Plan or an Award Agreement, suspension or termination
of the Plan will not materially impair a Participant&rsquo;s rights under the Participant&rsquo;s then-outstanding Award without
the Participant&rsquo;s written consent, except as provided in subsection (viii) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting amendments relating
to Incentive Stock Options and certain nonqualified deferred compensation under Section 409A of the Code and/or bringing the Plan
or Awards granted under the Plan <FONT STYLE="color: Black">into compliance with the requirements for Incentive Stock Options or
ensuring that they are exempt from, or compliant with, the requirements for nonqualified deferred compensation under Section 409A
of the Code</FONT>, subject to the limitations, if any, of applicable law. If required by applicable law or listing requirements,
and except as provided in Section 9(a) relating to Capitalization Adjustments, the Company will seek shareholder approval of any
amendment of the Plan that (A) materially increases the number of shares of Common Stock available for issuance under the Plan,
(B) materially expands the class of individuals eligible to receive Awards under the Plan, (C) materially increases the benefits
accruing to Participants under the Plan, (D) materially reduces the price at which shares of Common Stock may be issued or purchased
under the Plan, (E) materially extends the term of the Plan, or (F) materially expands the types of Awards available for issuance
under the Plan. Except as otherwise provided in the Plan or an Award Agreement, no amendment of the Plan will materially impair
a Participant&rsquo;s rights under an outstanding Award without the Participant&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
submit any amendment to the Plan for shareholder approval, including, but not limited to, amendments to the Plan intended to satisfy
the requirements of (A) Section 162(m) of the Code regarding the exclusion of performance-based compensation from the limit on
corporate deductibility of compensation paid to Covered Employees, (B) Section 422 of the Code regarding &ldquo;incentive stock
options&rdquo; or (C) Rule 16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more Awards, including, but not limited
to, amendments to provide terms more favorable to the Participant than previously provided in the Award Agreement, subject to any
specified limits in the Plan that are not subject to Board discretion; <I>provided, however,</I> that a Participant&rsquo;s rights
under any Award will not be impaired by any such amendment unless (A) the Company requests the consent of the affected Participant,
and (B) such Participant consents in writing. Notwithstanding the foregoing, (1) a Participant&rsquo;s rights will not be deemed
to have been impaired by any such amendment if the Board, in its sole discretion, determines that the amendment, taken as a whole,
does not materially impair the Participant&rsquo;s rights, and (2) subject to the limitations of applicable law, if any, the Board
may amend the terms of any one or more Awards without the affected Participant&rsquo;s consent (A) to maintain the qualified status
of the Award as an Incentive Stock Option under Section 422 of the Code; (B) to change the terms of an Incentive Stock Option,
if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock
Option under Section 422 of the Code; (C) to clarify the manner of exemption from, or to bring the Award into compliance with,
Section 409A of the Code; or (D) to comply with other applicable laws or listing requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the
Company and that are not in conflict with the provisions of the Plan or Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
adopt such procedures and sub-plans as are necessary or appropriate to permit participation in the Plan by Employees, Directors
or Consultants who are foreign nationals or employed outside the United States (provided that Board approval will not be necessary
for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant
foreign jurisdiction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>To
effect, with the consent of any adversely affected Participant, (A) the reduction of the exercise, purchase or strike price of
any outstanding Stock Award; (B) the cancellation of any outstanding Stock Award and the grant in substitution therefor of a new
(1) Option or SAR, (2) Restricted Stock Award, (3) Restricted Stock Unit Award, (4) Other Stock Award, (5) cash and/or (6) other
valuable consideration determined by the Board, in its sole discretion, with any such substituted award (x) covering the same or
a different number of shares of Common Stock as the cancelled Stock Award and (y) granted under the Plan or another equity or compensatory
plan of the Company; or (C) any other action that is treated as a repricing under generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delegation
to Committee.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</B>
The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan
is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore
possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee
any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter
be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions,
not inconsistent with the provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Board
may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some
or all of the powers previously delegated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
162(m) and Rule 16b-3 Compliance.</B> The Committee may consist solely of two or more Outside Directors, in accordance with Section
162(m) of the Code, or solely of two or more Non-Employee Directors, in accordance with Rule 16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delegation
to an Officer.</B> To the extent permissible under applicable law, the Board may delegate to one (1) or more Officers the authority
to do one or both of the following (i) designate Employees who are not Officers to be recipients of Options and SARs (and, to the
extent permitted by applicable law, other Stock Awards) and, to the extent permitted by applicable law, the terms of such Awards,
and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Stock Awards granted to such Employees; <I>provided,
however</I>, that the Board resolutions regarding such delegation will specify the total number of shares of Common Stock that
may be subject to the Stock Awards granted by such Officer and that such Officer may not grant a Stock Award to himself or herself.
Any such Stock Awards will be granted on the form of Stock Award Agreement most recently approved for use by the Committee or the
Board, unless otherwise provided in the resolutions approving the delegation authority. The Board may not delegate authority to
an Officer who is acting solely in the capacity of an Officer (and not also as a Director) to determine the Fair Market Value pursuant
to Section 13(y)(iii) below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect
of Board&rsquo;s Decision.</B> All determinations, interpretations and constructions made by the Board in good faith will not be
subject to review by any person and will be final, binding and conclusive on all persons.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Shares
Subject to the Plan.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Share
Reserve. </B>Subject to Section 9(a) relating to Capitalization Adjustments, and the following sentence regarding the annual
increase, the aggregate number of shares of Common Stock that may be issued pursuant to Stock Awards will not exceed
1,119,740 shares (the &ldquo;<B><I>Share Reserve</I></B>&rdquo;), which number is the sum of (i) an additional 100,000 new
shares approved by the Board of Directors in April 2016 and subsequently approved by the Company&rsquo;s shareholders in June
2016, (iii) an additional 800,000 new shares approved by the Board of Directors in June 2017 and subsequently approved by the
Company&rsquo;s shareholders in September 2017 <I>plus</I> (iii) the number of shares subject to the 2013 Plan&rsquo;s
Available Reserve, <I>plus</I> (iii) the number of shares that are Returning Shares, as such shares become available from
time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition, the Share
Reserve will automatically increase on January 1<SUP>st</SUP> of each year, for a period of not more than ten years, commencing
on January 1<SUP>st</SUP> of the year following the year in which the Effective Date occurs and ending on (and including) January
1, 2026, in an amount equal to 5% of the total number of shares of Capital Stock outstanding on December 31<SUP>st</SUP> of the
preceding calendar year. Notwithstanding the foregoing, the Board may act prior to January 1<SUP>st</SUP> of a given year to provide
that there will be no January 1<SUP>st</SUP> increase in the Share Reserve for such year or that the increase in the Share Reserve
for such year will be a lesser number of shares of Common Stock than would otherwise occur pursuant to the preceding sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">For clarity, the Share
Reserve in this Section 3(a) is a limitation on the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly,
this Section 3(a) does not limit the granting of Stock Awards except as provided in Section 7(a). Shares may be issued in connection
with a merger or acquisition as permitted by NASDAQ Listing Rule 5635(c), NYSE Listed Company Manual Section 303A.08, AMEX Company
Guide Section 711 or other applicable rule, and such issuance will not reduce the number of shares available for issuance under
the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reversion
of Shares to the Share Reserve. </B>If a Stock Award or any portion thereof (i) expires or otherwise terminates without all of
the shares covered by such Stock Award having been issued or (ii) is settled in cash (<I>i.e.</I>, the Participant receives cash
rather than stock), such expiration, termination or settlement will not reduce (or otherwise offset) the number of shares of Common
Stock that may be available for issuance under the Plan. If any shares of Common Stock issued pursuant to a Stock Award are forfeited
back to or repurchased by the Company because of the failure to meet a contingency or condition required to vest such shares in
the Participant, then the shares that are forfeited or repurchased will revert to and again become available for issuance under
the Plan. Any shares reacquired by the Company in satisfaction of tax withholding obligations on a Stock Award or as consideration
for the exercise or purchase price of a Stock Award will again become available for issuance under the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive
Stock Option Limit. </B>Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, the aggregate maximum
number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 2,474,600 shares
of Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
162(m) Limitations</B>. Subject to the provisions of Section 9(a) relating to Capitalization Adjustments, at such time as the Company
may be subject to the applicable provisions of Section 162(m) of the Code, the following limitations shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>A
maximum of 1,000,000 shares of Common Stock subject to Options, SARs and Other Stock Awards whose value is determined by reference
to an increase over an exercise or strike price of at least 100% of the Fair Market Value on the date the Stock Award is granted
may be granted to any one Participant during any one calendar year. Notwithstanding the foregoing, if any additional Options, SARs
or Other Stock Awards whose value is determined by reference to an increase over an exercise or strike price of at least 100% of
the Fair Market Value on the date the Stock Award are granted to any Participant during any calendar year, compensation attributable
to the exercise of such additional Stock Awards will not satisfy the requirements to be considered &ldquo;qualified performance-based
compensation&rdquo; under Section 162(m) of the Code unless such additional Stock Award is approved by the Company&rsquo;s shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>A
maximum of 1,000,000 shares of Common Stock subject to Performance Stock Awards may be granted to any one Participant during any
one calendar year (whether the grant, vesting or exercise is contingent upon the attainment during the Performance Period of the
Performance Goals).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>
A maximum of $2,000,000 may be granted as a Performance Cash Award to any one Participant during any one calendar year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitation
on Grants to Non-Employee Directors. </B><FONT STYLE="background-color: white">The (i) maximum number of shares of Common Stock
subject to Stock Awards granted under the Plan or otherwise during any one calendar year (beginning with the 2016 calendar year)
to any Non-Employee Director, taken together with the (ii) cash fees paid by the Company to such Non-Employee Director during such
calendar year, and in both cases for service on the Board, will not exceed $375,000 in total value (calculating the value of any
such Stock Awards based on the grant date fair value of such Stock Awards for financial reporting purposes), or, with respect to
the calendar year in which a Non-Employee Director is first appointed or elected to the Board, $783,000. The Board</FONT> may make
exceptions to the applicable limit in this Section 3(e) for individual Non-Employee Directors in extraordinary circumstances (for
example, to compensate such individual for interim service in the capacity of an officer of the Company), as the Board may determine
in its discretion, provided that the Non-Employee Director receiving such additional compensation may not participate in the decision
to award such compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Source
of Shares.</B> The stock issuable under the Plan will be shares of authorized but unissued or reacquired Common Stock, including
shares repurchased by the Company on the open market or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Eligibility.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility
for Specific Stock Awards</B>. Incentive Stock Options may be granted only to employees of the Company or a &ldquo;parent corporation&rdquo;
or &ldquo;subsidiary corporation&rdquo; thereof (as such terms are defined in Sections 424(e) and 424(f) of the Code). Stock Awards
other than Incentive Stock Options may be granted to Employees, Directors and Consultants; <I>provided, however</I>, that Stock
Awards may not be granted to Employees, Directors and Consultants who are providing Continuous Service only to any &ldquo;parent&rdquo;
of the Company, as such term is defined in Rule 405 of the Securities Act, unless (i) the stock underlying such Stock Awards is
treated as &ldquo;service recipient stock&rdquo; under Section 409A of the Code (for example, because the Stock Awards are granted
pursuant to a corporate transaction such as a spin off transaction), (ii) the Company, in consultation with its legal counsel,
has determined that such Stock Awards are otherwise exempt from Section 409A of the Code, or (iii) the Company, in consultation
with its legal counsel, has determined that such Stock Awards comply with the distribution requirements of Section 409A of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ten
Percent Shareholders.</B> A Ten Percent Shareholder will not be granted an Incentive Stock Option unless the exercise price of
such Option is at least 110% of the Fair Market Value on the date of grant and the Option is not exercisable after the expiration
of five years from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Provisions
Relating to Options and Stock Appreciation Rights.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Option or SAR
will be in such form and will contain such terms and conditions as the Board deems appropriate. All Options will be separately
designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate
certificate or certificates will be issued for shares of Common Stock purchased on exercise of each type of Option. If an Option
is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some
portion or all of the Option fails to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion
thereof) will be a Nonstatutory Stock Option. The provisions of separate Options or SARs need not be identical; <I>provided, however</I>,
that each Award Agreement will conform to (through incorporation of provisions hereof by reference in the applicable Award Agreement
or otherwise) the substance of each of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term.</B>
Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders, no Option or SAR will be exercisable after the expiration
of ten years from the date of its grant or such shorter period specified in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
Price.</B> Subject to the provisions of Section 4(b) regarding Ten Percent Shareholders, the exercise or strike price of each Option
or SAR will be not less than 100% of the Fair Market Value of the Common Stock subject to the Option or SAR on the date the Award
is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price lower than 100% of
the Fair Market Value of the Common Stock subject to the Award if such Award is granted pursuant to an assumption of or substitution
for another option or stock appreciation right pursuant to a Corporate Transaction and in a manner consistent with the provisions
of Section 409A of the Code and, if applicable, Section 424(a) of the Code. Each SAR will be denominated in shares of Common Stock
equivalents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchase
Price for Options.</B> The purchase price of Common Stock acquired pursuant to the exercise of an Option may be paid, to the extent
permitted by applicable law and as determined by the Board in its sole discretion, by any combination of the methods of payment
set forth below. The Board will have the authority to grant Options that do not permit all of the following methods of payment
(or otherwise restrict the ability to use certain methods) and to grant Options that require the consent of the Company to use
a particular method of payment. The permitted methods of payment are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>by
cash, check, bank draft or money order payable to the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>pursuant
to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of the stock
subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions
to pay the aggregate exercise price to the Company from the sales proceeds;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>by
delivery to the Company (either by actual delivery or attestation) of shares of Common Stock;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>if
an Option is a Nonstatutory Stock Option, by a &ldquo;net exercise&rdquo; arrangement pursuant to which the Company will reduce
the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that
does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company will accept a cash or other payment from
the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number
of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and will not be exercisable thereafter
to the extent that (A) shares issuable upon exercise are used to pay the exercise price pursuant to the &ldquo;net exercise,&rdquo;
(B) shares are delivered to the Participant as a result of such exercise, and (C) shares are withheld to satisfy tax withholding
obligations; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>in
any other form of legal consideration that may be acceptable to the Board and specified in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exercise
and Payment of a SAR.</B> To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company
in compliance with the provisions of the Stock Appreciation Right Agreement evidencing such SAR. The appreciation distribution
payable on the exercise of a SAR will be not greater than an amount equal to the excess of (A) the aggregate Fair Market Value
(on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents
in which the Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date,
over (B) the aggregate strike price of the number of Common Stock equivalents
with respect to which the Participant is exercising the SAR on such date. The appreciation distribution may be paid in Common
Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in
the Award Agreement evidencing such SAR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability
of Options and SARs.</B> The Board may, in its sole discretion, impose such limitations on the transferability of Options and SARs
as the Board will determine. In the absence of such a determination by the Board to the contrary, the following restrictions on
the transferability of Options and SARs will apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restrictions
on Transfer.</B> An Option or SAR will not be transferable except by will or by the laws of descent and distribution (or pursuant
to subsections (ii) and (iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. The
Board may permit transfer of the Option or SAR in a manner that is not prohibited by applicable tax and securities laws. Except
as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Domestic
Relations Orders.</B> Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be transferred pursuant
to the terms of a domestic relations order, official marital settlement agreement <FONT STYLE="color: Black">or other divorce or
separation instrument as permitted by Treasury Regulations Section 1.421-1(b)(2)</FONT>. If an Option is an Incentive Stock Option,
such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficiary
Designation.</B> Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice
to the Company, in a form approved by the Company (or the designated broker), designate a third party who, on the death of the
Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting
from such exercise. In the absence of such a designation, upon the death of the Participant, the executor or administrator of the
Participant&rsquo;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting
from such exercise. However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion
by the Company that such designation would be inconsistent with the provisions of applicable laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting
Generally.</B> The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic
installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times
when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria) as the Board
may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section 5(f) are subject
to any Option or SAR provisions governing the minimum number of shares of Common Stock as to which an Option or SAR may be exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
of Continuous Service.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant
and the Company, if a Participant&rsquo;s Continuous Service terminates (other than for Cause and other than upon the Participant&rsquo;s
death or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to
exercise such Award as of the date of termination of Continuous Service) within the period of time ending on the earlier of (i)
the date three months following the termination of the Participant&rsquo;s Continuous Service <FONT STYLE="color: Black">(or such
longer or shorter period specified in the applicable Award Agreement),</FONT> and (ii) the expiration of the term of the Option
or SAR as set forth in the Award Agreement. If, after termination of Continuous Service, the Participant does not exercise his
or her Option or SAR (as applicable) within the applicable time frame, the Option or SAR will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Extension
of Termination Date.</B> If the exercise of an Option or SAR following the termination of the Participant&rsquo;s Continuous Service
(other than for Cause and other than upon the Participant&rsquo;s death or Disability) would be prohibited at any time solely because
the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or
SAR will terminate on the earlier of (i) the expiration of a total period of time (that need not be consecutive) equal to the applicable
post termination exercise period after the termination of the Participant&rsquo;s Continuous Service during which the exercise
of the Option or SAR would not be in violation of such registration requirements, and (ii) the expiration of the term of the Option
or SAR as set forth in the applicable Award Agreement. In addition, unless otherwise provided in a Participant&rsquo;s Award Agreement,
if the sale of any Common Stock received on exercise of an Option or SAR following the termination of the Participant&rsquo;s Continuous
Service (other than for Cause) would violate the Company&rsquo;s insider trading policy, then the Option or SAR will terminate
on the earlier of (i) the expiration of a period of months (that need not be consecutive) equal to the applicable post-termination
exercise period after the termination of the Participant&rsquo;s Continuous Service during which the sale of the Common Stock received
upon exercise of the Option or SAR would not be in violation of the Company&rsquo;s insider trading policy, or (ii) the expiration
of the term of the Option or SAR as set forth in the applicable Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disability
of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and
the Company, if a Participant&rsquo;s Continuous Service terminates as a result of the Participant&rsquo;s Disability, the Participant
may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the
date of termination of Continuous Service), but only within such period of time ending on the earlier of (i) the date 12 months
following such termination of Continuous Service <FONT STYLE="color: Black">(or such longer or shorter period specified in the Award
Agreement),</FONT> and (ii) the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after termination
of Continuous Service, the Participant does not exercise his or her Option or SAR within the applicable time frame, the Option
or SAR (as applicable) will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Death
of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other agreement between the Participant and
the Company, if (i) a Participant&rsquo;s Continuous Service terminates as a result of the Participant&rsquo;s death, or (ii) the
Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&rsquo;s
Continuous Service for a reason other than death, then the Option or SAR may be exercised (to the extent the Participant was entitled
to exercise such Option or SAR as of the date of death) by the Participant&rsquo;s estate, by a person who acquired the right to
exercise the Option or SAR by bequest or inheritance or by a person designated to exercise the Option or SAR upon the Participant&rsquo;s
death, but only within the period ending on the earlier of (i) the date 18 months following the date of death <FONT STYLE="color: Black">(or
such longer or shorter period specified in the Award Agreement),</FONT> and (ii) the expiration of the term of such Option or SAR
as set forth in the Award Agreement. If, after the Participant&rsquo;s death, the Option or SAR is not exercised within the applicable
time frame, the Option or SAR (as applicable) will terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
for Cause.</B> Except as explicitly provided otherwise in a Participant&rsquo;s Award Agreement <FONT STYLE="color: Black">or other
individual written agreement between the Company or any Affiliate and the Participant</FONT>, if a Participant&rsquo;s Continuous
Service is terminated for Cause, the Option or SAR will terminate immediately upon such Participant&rsquo;s termination of Continuous
Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination
of Continuous Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Exempt
Employees</B>. If an Option or SAR is granted to an Employee who is a non-exempt employee for purposes of the Fair Labor Standards
Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months
following the date of grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions
of the Worker Economic Opportunity Act, (i) if such non-exempt Employee dies or suffers a Disability, (ii) upon a Corporate Transaction
in which such Option or SAR is not assumed, continued, or substituted, (iii) upon a Change in Control, or (iv) upon the Participant&rsquo;s
retirement (as such term may be defined in the Participant&rsquo;s Award Agreement in another agreement between the Participant
and the Company, or, if no such definition, in accordance with the Company&rsquo;s then current employment policies and guidelines),
the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing
provision is intended to operate so that any income derived by a non-exempt employee in connection with the exercise or vesting
of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for compliance
with the Worker Economic Opportunity Act to ensure that any income derived by a non-exempt employee in connection with the exercise,
vesting or issuance of any shares under any other Stock Award will be exempt from the employee&rsquo;s regular rate of pay, the
provisions of this Section 5(l) will apply to all Stock Awards and are hereby incorporated by reference into such Stock Award Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Provisions
of Stock Awards other than Options and SARs.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
Stock Awards.</B> Each Restricted Stock Award Agreement will be in such form and will contain such terms and conditions as the
Board will deem appropriate. To the extent consistent with the Company&rsquo;s bylaws, at the Board&rsquo;s election, shares of
Common Stock may be (x) held in book entry form subject to the Company&rsquo;s instructions until any restrictions relating to
the Restricted Stock Award lapse; or (y) evidenced by a certificate, which certificate will be held in such form and manner as
determined by the Board. The terms and conditions of Restricted Stock Award Agreements may change from time to time, and the terms
and conditions of separate Restricted Stock Award Agreements need not be identical. Each Restricted Stock Award Agreement will
conform to (through incorporation of the provisions hereof by reference in the agreement or otherwise) the substance of each of
the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration.</B>
A Restricted Stock Award may be awarded in consideration for (A) cash, check, bank draft or money order payable to the Company,
(B) past services to the Company or an Affiliate, or (C) any other form of legal consideration that may be acceptable to the Board,
in its sole discretion, and permissible under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting.
</B>Shares of Common Stock awarded under the Restricted Stock Award Agreement may be subject to forfeiture to the Company in accordance
with a vesting schedule to be determined by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
of Participant&rsquo;s Continuous Service.</B> If a Participant&rsquo;s Continuous Service terminates, the Company may receive
through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have
not vested as of the date of termination of Continuous Service under the terms of the Restricted Stock Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</B>
Rights to acquire shares of Common Stock under the Restricted Stock Award Agreement will be transferable by the Participant only
upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole
discretion, so long as Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted
Stock Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends.
</B>A Restricted Stock Award Agreement may provide that any dividends paid on Restricted Stock will be subject to the same vesting
and forfeiture restrictions as apply to the shares subject to the Restricted Stock Award to which they relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted
Stock Unit Awards. </B>Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions
as the Board will deem appropriate. The terms and conditions of Restricted Stock Unit Award Agreements may change from time to
time, and the terms and conditions of separate Restricted Stock Unit Award Agreements need not be identical. Each Restricted Stock
Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the Agreement or otherwise)
the substance of each of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consideration.</B>
At the time of grant of a Restricted Stock Unit Award, the Board will determine the consideration, if any, to be paid by the Participant
upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by
the Participant for each share of Common Stock subject to a Restricted Stock Unit Award may be paid in any form of legal consideration
that may be acceptable to the Board, in its sole discretion, and permissible under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Vesting.
</B>At the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting
of the Restricted Stock Unit Award as it, in its sole discretion, deems appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment</B>.
A Restricted Stock Unit Award may be settled by the delivery of shares of Common Stock, their cash equivalent, any combination
thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
Restrictions. </B>At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may impose such
restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to a Restricted
Stock Unit Award to a time after the vesting of such Restricted Stock Unit Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend
Equivalents. </B>Dividend equivalents may be credited in respect of shares of Common Stock covered by a Restricted Stock Unit Award,
as determined by the Board and contained in the Restricted Stock Unit Award Agreement. At the sole discretion of the Board, such
dividend equivalents may be converted into additional shares of Common Stock covered by the Restricted Stock Unit Award in such
manner as determined by the Board. Any additional shares covered by the Restricted Stock Unit Award credited by reason of such
dividend equivalents will be subject to all of the same terms and conditions of the underlying Restricted Stock Unit Award Agreement
to which they relate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination
of Participant&rsquo;s Continuous Service. </B>Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement,
such portion of the Restricted Stock Unit Award that has not vested will be forfeited upon the Participant&rsquo;s termination
of Continuous Service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
Awards</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
Stock Awards</B>. A Performance Stock Award is a Stock Award (covering a number of shares not in excess of that set forth in Section
3(d) above) that is payable (including that may be granted, may vest or may be exercised) contingent upon the attainment during
a Performance Period of certain Performance Goals. A Performance Stock Award may, but need not, require the Participant&rsquo;s
completion of a specified period of Continuous Service. The length of any Performance Period, the Performance Goals to be achieved
during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be
conclusively determined by the Committee (or, if not required for compliance with Section 162(m) of the Code, the Board), in its
sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine
that cash may be used in payment of Performance Stock Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance
Cash Awards</B>. A Performance Cash Award is a cash award (for a dollar value not in excess of that set forth in Section 3(d) above)
that is payable contingent upon the attainment during a Performance Period of certain Performance Goals. A Performance Cash Award
may also require the completion of a specified period of Continuous Service. At the time of grant of a Performance Cash Award,
the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether
and to what degree such Performance Goals have been attained will be conclusively determined by the Committee (or, if not required
for compliance with Section 162(m) of the Code, the Board), in its sole discretion. The Board may specify the form of payment of
Performance Cash Awards, which may be cash or other property, or may provide for a Participant to have the option for his or her
Performance Cash Award, or such portion thereof as the Board may specify, to be paid in whole or in part in cash or other property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Board
Discretion</B>. The Board retains the discretion to reduce or eliminate the compensation or economic benefit due upon attainment
of Performance Goals and to define the manner of calculating the Performance Criteria it selects to use for a Performance Period.
Partial achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as
specified in the Stock Award Agreement or the written terms of a Performance Cash Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section
162(m) Compliance</B>. Unless otherwise permitted in compliance with the requirements of Section 162(m) of the Code with respect
to an Award intended to qualify as &ldquo;performance-based compensation&rdquo; thereunder, the Committee will establish the Performance
Goals applicable to, and the formula for calculating the amount payable under, the Award no later than the earlier of (a) the date
90 days after the commencement of the applicable Performance Period, and (b) the date on which 25% of the Performance Period has
elapsed, and in any event at a time when the achievement of the applicable Performance Goals remains substantially uncertain. Prior
to the payment of any compensation under an Award intended to qualify as &ldquo;performance-based compensation&rdquo; under Section
162(m) of the Code, the Committee will certify the extent to which any Performance Goals and any other material terms under such
Award have been satisfied (other than in cases where such Performance Goals relate solely to the increase in the value of the Common
Stock). Notwithstanding satisfaction of, or completion of any Performance Goals, the number of shares of Common Stock, Options,
cash or other benefits granted, issued, retainable and/or vested under an Award on account of satisfaction of such Performance
Goals may be reduced by the Committee on the basis of such further considerations as the Committee, in its sole discretion, will
determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
Stock Awards</B>. Other forms of Stock Awards valued in whole or in part by reference to, or otherwise based on, Common Stock,
including the appreciation in value thereof (e.g., options or stock rights with an exercise price or strike price less than 100%
of the Fair Market Value of the Common Stock at the time of grant) may be granted either alone or in addition to Stock Awards provided
for under Section 5 and the preceding provisions of this Section 6. Subject to the provisions of the Plan, the Board will have
sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted,
the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other Stock Awards and all
other terms and conditions of such Other Stock Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Covenants
of the Company.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Availability
of Shares.</B> The Company will keep available at all times the number of shares of Common Stock reasonably required to satisfy
then-outstanding Awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
Law Compliance.</B> The Company will seek to obtain from each regulatory commission or agency having jurisdiction over the Plan
such authority as may be required to grant Stock Awards and to issue and sell shares of Common Stock upon exercise of the Stock
Awards; <I>provided, however</I>, that this undertaking will not require the Company to register under the Securities Act the Plan,
any Stock Award or any Common Stock issued or issuable pursuant to any such Stock Award. If, after reasonable efforts and at a
reasonable cost, the Company is unable to obtain from any such regulatory commission or agency the authority that counsel for the
Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any
liability for failure to issue and sell Common Stock upon exercise of such Stock Awards unless and until such authority is obtained.
A Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the
Award if such grant or issuance would be in violation of any applicable securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Obligation to Notify or Minimize Taxes. </B>The Company will have no duty or obligation to any Participant to advise such holder
as to the time or manner of exercising such Stock Award. Furthermore, the Company will have no duty or obligation to warn or otherwise
advise such holder of a pending termination or expiration of an Award or a possible period in which the Award may not be exercised.
The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Miscellaneous.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use
of Proceeds from Sales of Common Stock. </B>Proceeds from the sale of shares of Common Stock pursuant to Awards will constitute
general funds of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Corporate
Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any Participant will
be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument,
certificate, or letter evidencing the Award is communicated to, or actually received or accepted by, the Participant. In the event
that the corporate records (e.g., Board consents, resolutions or minutes) documenting the corporate action constituting the grant
contain terms (e.g., exercise price, vesting schedule or number of shares) that are inconsistent with those in the Award Agreement
or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the
corporate records will control and the Participant will have no legally binding right to the incorrect term in the Award Agreement
or related grant documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shareholder
Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares
of Common Stock subject to an Award unless and until (i) such Participant has satisfied all requirements for exercise of, or the
issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii) the issuance of the Common Stock subject to
such Award has been entered into the books and records of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
Employment or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or
in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the Company
or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate
to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant
pursuant to the terms of such Consultant&rsquo;s agreement with the Company or an Affiliate, or (iii) the service of a Director
pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which
the Company or the Affiliate is incorporated, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change
in Time Commitment.</B> In the event a Participant&rsquo;s regular level of time commitment in the performance of his or her services
for the Company and any Affiliates is reduced (for example, and without limitation, if the Participant is an Employee of the Company
and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an extended leave of absence)
after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (x) make a corresponding
reduction in the number of shares or cash amount subject to any portion of such Award that is scheduled to vest or become payable
after the date of such change in time commitment, and (y) in lieu of or in combination with such a reduction, extend the vesting
or payment schedule applicable to such Award. In the event of any such reduction, the Participant will have no right with respect
to any portion of the Award that is so reduced or extended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive
Stock Option Limitations.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant) of Common Stock
with respect to which Incentive Stock Options are exercisable for the first time by any Optionholder during any calendar year (under
all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the Code) or otherwise does not
comply with the rules governing Incentive Stock Options, the Options or portions thereof that exceed such limit (according to the
order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory Stock Options, notwithstanding
any contrary provision of the applicable Option Agreement(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment
Assurances.</B> The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award,
(i) to give written assurances satisfactory to the Company as to the Participant&rsquo;s knowledge and experience in financial
and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and
experienced in financial and business matters and that such Participant is capable of evaluating, alone or together with the purchaser
representative, the merits and risks of exercising the Award; and (ii) to give written assurances satisfactory to the Company stating
that the Participant is acquiring Common Stock subject to the Award for the Participant&rsquo;s own account and not with any present
intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant
to such requirements, will be inoperative if (A) the issuance of the shares upon the exercise or acquisition of Common Stock under
the Award has been registered under a then currently effective registration statement under the Securities Act, or (B) as to any
particular requirement, a determination is made by counsel for the Company that such requirement need not be met in the circumstances
under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates
issued under the Plan as such counsel deems necessary or appropriate in order to comply with applicable securities laws, including,
but not limited to, legends restricting the transfer of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Withholding
Obligations.</B> Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion, satisfy any federal,
state or local tax withholding obligation relating to an Award by any of the following means or by a combination of such means:
(i) causing the Participant to tender a cash payment; (ii) withholding shares of Common Stock from the shares of Common Stock issued
or otherwise issuable to the Participant in connection with the Award; <I>provided, however, </I>that no shares of Common Stock
are withheld with a value exceeding the minimum amount of tax required to be withheld by law (or such lesser amount as may be necessary
to avoid classification of the Stock Award as a liability for financial accounting purposes); (iii) withholding cash from an Award
settled in cash; (iv) withholding payment from any amounts otherwise payable to the Participant; or (v) by such other method as
may be set forth in the Award Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Electronic
Delivery</B>. Any reference herein to a &ldquo;written&rdquo; agreement or document will include any agreement or document delivered
electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&rsquo;s intranet <FONT STYLE="color: Black">(or
other shared electronic medium controlled by the Company to which the Participant has access)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferrals.</B>
To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or
the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be deferred and may establish
programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance
with Section 409A of the Code. Consistent with Section 409A of the Code, the Board may provide for distributions while a Participant
is still an employee or otherwise providing services to the Company. The Board is authorized to make deferrals of Awards and determine
when, and in what annual percentages, Participants may receive payments, including lump sum payments, following the Participant&rsquo;s
termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and
in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with Section 409A of the Code. </B>Unless otherwise expressly provided for in an Award Agreement, the Plan and Award Agreements
will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from
Section 409A of the Code, and, to the extent not so exempt, in compliance with Section 409A of the Code. If the Board determines
that any Award granted hereunder is not exempt from and is therefore subject to Section 409A of the Code, the Award Agreement evidencing
such Award will incorporate the terms and conditions necessary to avoid the consequences specified in Section 409A(a)(1) of the
Code, and to the extent an Award Agreement is silent on terms necessary for compliance, such terms are hereby incorporated by reference
into the Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides
otherwise), if the shares of Common Stock are publicly traded, and if a Participant holding an Award that constitutes &ldquo;deferred
compensation&rdquo; under Section 409A of the Code is a &ldquo;specified employee&rdquo; for purposes of Section 409A of the Code,
no distribution or payment of any amount that is due because of a &ldquo;separation from service&rdquo; (as defined in Section
409A of the Code without regard to alternative definitions thereunder) will be issued or paid before the date that is six months
following the date of such Participant&rsquo;s &ldquo;separation from service&rdquo; (as defined in Section 409A of the Code without
regard to alternative definitions thereunder) or, if earlier, the date of the Participant&rsquo;s death, unless such distribution
or payment can be made in a manner that complies with Section 409A of the Code, and any amounts so deferred will be paid in a lump
sum on the day after such six month period elapses, with the balance paid thereafter on the original schedule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clawback/Recovery</B>.
All Awards granted under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required
to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&rsquo;s securities
are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.
In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines
necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares of Common
Stock or other cash or property upon the occurrence of an event constituting Cause. No recovery of compensation under such a clawback
policy will be an event giving rise to a right to resign for &ldquo;good reason&rdquo; or &ldquo;constructive termination&rdquo;
(or similar term) under any agreement with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-variant: small-caps">Adjustments
upon Changes in Common Stock; Other Corporate Events.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capitalization
Adjustments</B>. In the event of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i) the
class(es) and maximum number of securities subject to the Plan pursuant to Section 3(a), (ii) the class(es) and maximum number
of securities that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section 3(c), (iii) the class(es)
and maximum number of securities that may be awarded to any person pursuant to Sections 3(d), and (iv) the class(es) and number
of securities and price per share of stock subject to outstanding Stock Awards. The Board will make such adjustments, and its determination
will be final, binding and conclusive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dissolution</B>.
Except as otherwise provided in the Stock Award Agreement, in the event of a Dissolution of the Company, all outstanding Stock
Awards (other than Stock Awards consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition
or the Company&rsquo;s right of repurchase) will terminate immediately prior to the completion of such Dissolution, and the shares
of Common Stock subject to the Company&rsquo;s repurchase rights or subject to a forfeiture condition may be repurchased or reacquired
by the Company notwithstanding the fact that the holder of such Stock Award is providing Continuous Service; <I>provided, however</I>,
that the Board may, in its sole discretion, cause some or all Stock Awards to become fully vested, exercisable and/or no longer
subject to repurchase or forfeiture (to the extent such Stock Awards have not previously expired or terminated) before the Dissolution
is completed but contingent on its completion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transactions.</B>
The following provisions shall apply to Stock Awards in the event of a Transaction unless otherwise provided in the instrument
evidencing the Stock Award or any other written agreement between the Company or any Affiliate and the Participant or unless otherwise
expressly provided by the Board at the time of grant of a Stock Award. In the event of a Transaction, then, notwithstanding any
other provision of the Plan, the Board shall take one or more of the following actions with respect to Stock Awards, contingent
upon the closing or completion of the Transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>arrange
for the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&rsquo;s parent company) to assume
or continue the Stock Award or to substitute a similar stock award for the Stock Award (including, but not limited to, an award
to acquire the same consideration paid to the shareholders of the Company pursuant to the Transaction);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>arrange
for the assignment of any reacquisition or repurchase rights held by the Company in respect of Common Stock issued pursuant to
the Stock Award to the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&rsquo;s parent
company);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>accelerate
the vesting, in whole or in part, of the Stock Award (and, if applicable, the time at which the Stock Award may be exercised) to
a date prior to the effective time of such Transaction as the Board shall determine (or, if the Board shall not determine such
a date, to the date that is five days prior to the effective date of the Transaction), with such Stock Award terminating if not
exercised (if applicable) at or prior to the effective time of the Transaction;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>arrange
for the lapse, in whole or in part, of any reacquisition or repurchase rights held by the Company with respect to the Stock Award;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>cancel
or arrange for the cancellation of the Stock Award, to the extent not vested or not exercised prior to the effective time of the
Transaction, in exchange for such cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>make
a payment, in such form as may be determined by the Board equal to the excess, if any, of (A) the value of the property the Participant
would have received upon the exercise of the Stock Award immediately prior to the effective time of the Transaction, over (B) any
exercise price payable by such holder in connection with such exercise. For clarity, this payment may be zero ($0) if the value
of the property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that
payment of consideration to the holders of Common Stock in connection with the Transaction is delayed as a result of escrows, earn
outs, holdbacks or other contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board need not
take the same action or actions with respect to all Stock Awards or portions thereof or with respect to all Participants. <FONT STYLE="color: Black">The
Board may take different actions with respect to the vested and unvested portions of a Stock Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change
in Control.</B> A Stock Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in
Control as may be provided in the Stock Award Agreement for such Stock Award or as may be provided in any other written agreement
between the Company or any Affiliate and the Participant, but in the absence of such provision, no such acceleration will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>10.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Plan Term;
Earlier Termination or Suspension of the Plan.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Board may suspend
or terminate the Plan at any time. No Incentive Stock Options may be granted after the tenth anniversary of the earlier of (i)
the date the Plan is adopted by the Board (the &ldquo;<B><I>Adoption Date</I></B>&rdquo;), or (ii) the date the Plan is approved
by the shareholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated.
Suspension or termination of the Plan will not impair rights and obligations under any Award granted while the Plan is in effect
except with the written consent of the affected Participant or as otherwise permitted in the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>11.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Existence of
the Plan.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Plan will become
effective on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>12.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Choice of Law.</B></FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The law of the State
of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to
that state&rsquo;s conflict of laws rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"><B>13.</B></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B>Definitions.
</B></FONT>As used in the Plan, the following definitions will apply to the capitalized terms indicated below:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Affiliate</I></B>&rdquo;
means, at the time of determination, any &ldquo;parent&rdquo; or &ldquo;subsidiary&rdquo; of the Company as such terms are defined
in Rule 405 of the Securities Act. The Board will have the authority to determine the time or times at which &ldquo;parent&rdquo;
or &ldquo;subsidiary&rdquo; status is determined within the foregoing definition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Award</I></B>&rdquo;
means a Stock Award or a Performance Cash Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Award
Agreement</I></B>&rdquo; means a written agreement between the Company and a Participant evidencing the terms and conditions of
an Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Board</I></B>&rdquo;
means the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Capital
Stock</I></B>&rdquo; means each and every class of common stock of the Company, regardless of the number of votes per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Capitalization
Adjustment</I></B>&rdquo; means any change that is made in, or other events that occur with respect to, the Common Stock subject
to the Plan or subject to any Stock Award after the Adoption Date without the receipt of consideration by the Company through merger,
consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large nonrecurring
cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate
structure or any similar equity restructuring transaction, as that term is used in Statement of Financial Accounting Standards
Board Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of
any convertible securities of the Company will not be treated as a Capitalization Adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Cause</I></B>&rdquo;
shall have the meaning ascribed to such term in any written agreement between the Participant and the Company defining such term
and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of any of the following events:
(i)&nbsp;such Participant&rsquo;s commission of any felony or any crime involving fraud, dishonesty or moral turpitude under the
laws of the United States or any state thereof; (ii) such Participant&rsquo;s attempted commission of, or participation in, a fraud
or act of dishonesty against the Company; (iii)&nbsp;such Participant&rsquo;s intentional, material violation of any contract or
agreement between the Participant and the Company or of any statutory duty owed to the Company; (iv)&nbsp;such Participant&rsquo;s
unauthorized use or disclosure of the Company&rsquo;s confidential information or trade secrets; or (v)&nbsp;such Participant&rsquo;s
gross misconduct. The determination that a termination of the Participant&rsquo;s Continuous Service is either for Cause or without
Cause shall be made by the Company, in its sole discretion. Any determination by the Company that the Continuous Service of a Participant
was terminated with or without Cause for the purposes of outstanding Awards held by such Participant shall have no effect upon
any determination of the rights or obligations of the Company or such Participant for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Change
in Control</I></B>&rdquo; means the occurrence, in a single transaction or in a series of related transactions, of any one or more
of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined
voting power of the Company&rsquo;s then outstanding securities other than by virtue of a merger, consolidation or similar transaction.
Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A) on account of the acquisition of securities
of the Company directly from the Company, (B)&nbsp;on account of the acquisition of securities of the Company by an investor, any
affiliate thereof or any other Exchange Act Person that acquires the Company&rsquo;s securities in a transaction or series of related
transactions the primary purpose of which is to obtain financing for the Company through the issuance of equity securities, (C)
on account of the acquisition of securities of the Company by any individual who is, on the Adoption Date, either an executive
officer or a Director (either, a &ldquo;<B><I>Legacy Investor</I></B>&rdquo;) and/or any entity in which a Legacy Investor has
a direct or indirect interest (whether in the form of voting rights or participation in profits or capital contributions) of more
than 50% (collectively, the &ldquo;<B><I>Legacy Entities</I></B>&rdquo;) or on account of the Legacy Entities continuing to hold
shares that come to represent more than 50% of the combined voting power of the Company&rsquo;s then outstanding securities as
a result of the conversion of any class of the Company&rsquo;s securities into another class of the Company&rsquo;s securities
having a different number of votes per share pursuant to the conversion provisions set forth in the Company&rsquo;s Amended and
Restated Certificate of Incorporation; or (D) solely because the level of Ownership held by any Exchange Act Person (the &ldquo;<B><I>Subject
Person</I></B>&rdquo;) exceeds the designated percentage threshold of the outstanding voting securities as a result of a repurchase
or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in
Control would occur (but for the operation of this sentence) as a result of the acquisition of voting securities by the Company,
and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase
or other acquisition had not occurred, increases the percentage of the then outstanding voting securities Owned by the Subject
Person over the designated percentage threshold, then a Change in Control will be deemed to occur;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>there
is consummated a merger, consolidation or similar transaction involving (directly or indirectly) the Company and, immediately after
the consummation of such merger, consolidation or similar transaction, the shareholders of the Company immediately prior thereto
do not Own, directly or indirectly, either (A) outstanding voting securities representing more than 50% of the combined outstanding
voting power of the surviving Entity in such merger, consolidation or similar transaction or (B) more than 50% of the combined
outstanding voting power of the parent of the surviving Entity in such merger, consolidation or similar transaction, in each case
in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior
to such transaction; <I>provided, however</I>, that a merger, consolidation or similar transaction will not constitute a Change
in Control under this prong of the definition if the outstanding voting securities representing more than 50% of the combined voting
power of the surviving Entity or its parent are owned by the Legacy Entities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>there
is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of
the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated
assets of the Company and its Subsidiaries to an Entity, more than 50% of the combined voting power of the voting securities of
which are Owned by shareholders of the Company in substantially the same proportions as their Ownership of the outstanding voting
securities of the Company immediately prior to such sale, lease, license or other disposition; <I>provided, however</I>, that a
sale, lease, exclusive license or other disposition of all or substantially all of the consolidated assets of the Company and its
Subsidiaries will not constitute a Change in Control under this prong of the definition if the outstanding voting securities representing
more than 50% of the combined voting power of the acquiring Entity or its parent are owned by the Legacy Entities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>the
shareholders of the Company approve or the Board approves a plan of complete dissolution or liquidation of the Company, or a complete
dissolution or liquidation of the Company will otherwise occur, except for a liquidation into a parent corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>individuals
who, on the date the Plan is adopted by the Board, are members of the Board (the &ldquo;<B><I>Incumbent&nbsp;Board</I></B>&rdquo;)
cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however,</I> that if the appointment
or election (or nomination for election) of any new Board member was approved or recommended by a majority vote of the members
of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the
Incumbent Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing definition or any other provision of the Plan, the term Change in Control will not include a sale of assets, merger or
other transaction effected exclusively for the purpose of changing the domicile of the Company and the definition of Change in
Control (or any analogous term) in an individual written agreement between the Company or any Affiliate and the Participant will
supersede the foregoing definition with respect to Awards subject to such agreement; <I>provided, however</I>, that if no definition
of Change in Control or any analogous term is set forth in such an individual written agreement, the foregoing definition will
apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Code</I></B>&rdquo;
means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Committee</I></B>&rdquo;
means a committee of one or more Directors to whom authority has been delegated by the Board in accordance with Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Common
Stock</I></B>&rdquo; means the common stock of the Company, having one vote per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext"><B>(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT>&ldquo;<B><I>Company</I></B>&rdquo;
means <FONT STYLE="color: windowtext">AmpliPhi Biosciences Corporation</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Consultant</I></B>&rdquo;
means any person, including an advisor, who is (i) engaged by the Company or an Affiliate to render consulting or advisory services
and is compensated for such services, or (ii) serving as a member of the board of directors of an Affiliate and is compensated
for such services. However, service solely as a Director, or payment of a fee for such service, will not cause a Director to be
considered a &ldquo;Consultant&rdquo; for purposes of the Plan. Notwithstanding the foregoing, a person is treated as a Consultant
under this Plan only if a Form S-8 Registration Statement under the Securities Act is available to register either the offer or
the sale of the Company&rsquo;s securities to such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Continuous
Service</I></B>&rdquo; means that the Participant&rsquo;s service with the Company or an Affiliate, whether as an Employee, Director
or Consultant, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company
or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service,
provided that there is no interruption or termination of the Participant&rsquo;s service with the Company or an Affiliate, will
not terminate a Participant&rsquo;s Continuous Service; <I>provided, however</I>, that if the Entity for which a Participant is
rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&rsquo;s
Continuous Service will be considered to have terminated on the date such Entity ceases to qualify as an Affiliate. To the extent
permitted by law, the Board or the chief executive officer of the Company, in that party&rsquo;s sole discretion, may determine
whether Continuous Service will be considered interrupted in the case of (i) any leave of absence approved by the Board or chief
executive officer, including sick leave, military leave or any other personal leave, or (ii) transfers between the Company, an
Affiliate, or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes
of vesting in an Award only to such extent as may be provided in the Company&rsquo;s leave of absence policy, in the written terms
of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Corporate
Transaction</I></B>&rdquo; means the consummation, in a single transaction or in a series of related transactions, of any one or
more of the following events:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
sale or other disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated
assets of the Company and its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
sale or other disposition of more than 50% of the outstanding securities of the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
merger, consolidation or similar transaction following which the Company is not the surviving corporation; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>a
merger, consolidation or similar transaction following which the Company is the surviving corporation but the shares of Common
Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of
the merger, consolidation or similar transaction into other property, whether in the form of securities, cash or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Covered
Employee</I></B>&rdquo; will have the meaning provided in Section 162(m)(3) of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Director</I></B>&rdquo;
means a member of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Disability</I></B>&rdquo;
means, with respect to a Participant, the inability of such Participant to engage in any substantial gainful activity by reason
of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be
expected to last for a continuous period of not less than 12 months, as provided in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the
Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Dissolution</I></B>&rdquo;
means when the Company, after having executed a certificate of dissolution with the State of Delaware (or other applicable state),
has completely wound up its affairs. Conversion of the Company into a Limited Liability Company (or any other pass-through entity)
will not be considered a &ldquo;Dissolution&rdquo; for purposes of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Effective
Date</I></B>&rdquo; means June 20, 2016, which is the date the Company&rsquo;s shareholders first approved the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Employee</I></B>&rdquo;
means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services,
will not cause a Director to be considered an &ldquo;Employee&rdquo; for purposes of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Entity</I></B>&rdquo;
means a corporation, partnership, limited liability company or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Exchange
Act</I></B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Exchange
Act Person</I></B>&rdquo; means any natural person, Entity or &ldquo;group&rdquo; (within the meaning of Section 13(d) or 14(d)
of the Exchange Act), except that &ldquo;Exchange Act Person&rdquo; will not include (i) the Company or any Subsidiary of the Company,
(ii) any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any Subsidiary of the Company, (iii) an underwriter temporarily holding securities
pursuant to a registered public offering of such securities, (iv) an Entity Owned, directly or indirectly, by the shareholders
of the Company in substantially the same proportions as their Ownership of stock of the Company; or (v) any natural person, Entity
or &ldquo;group&rdquo; (within the meaning of Section 13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the
Owner, directly or indirectly, of securities of the Company representing more than 50% of the combined voting power of the Company&rsquo;s
then outstanding securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Fair
Market Value</I></B>&rdquo; means, as of any date, the value of the Common Stock determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>If
the Common Stock is listed on any established stock exchange or traded on any established market, the Fair Market Value of a share
of Common Stock will be, unless otherwise determined by the Board, the closing sales price for such stock as quoted on such exchange
or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as
reported in a source the Board deems reliable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>Unless
otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the
Fair Market Value will be the closing selling price on the last preceding date for which such quotation exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>In
the absence of such markets for the Common Stock, the Fair Market Value will be determined by the Board in good faith and in a
manner that complies with Sections 409A and 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Incentive
Stock Option</I></B>&rdquo; means an option granted pursuant to Section 5 of the Plan that is intended to be, and qualifies as,
an &ldquo;incentive stock option&rdquo; within the meaning of Section 422 of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(aa)&#9;</B>&ldquo;<B><I>Non-Employee
Director</I></B>&rdquo; means a Director who either (i) is not a current employee or officer of the Company or an Affiliate, does
not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant
or in any capacity other than as a Director (except for an amount as to which disclosure would not be required under Item 404(a)
of Regulation S-K promulgated pursuant to the Securities Act (&ldquo;<B><I>Regulation S-K</I></B>&rdquo;)), does not possess an
interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation S-K, and is not engaged
in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation S-K; or (ii) is otherwise
considered a &ldquo;non-employee director&rdquo; for purposes of Rule 16b-3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(bb)&#9;</B>&ldquo;<B><I>Nonstatutory
Stock Option</I></B>&rdquo; means any Option granted pursuant to Section 5 of the Plan that does not qualify as an Incentive Stock
Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(cc)&#9;</B>&ldquo;<B><I>Officer</I></B>&rdquo;
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(dd)&#9;</B>&ldquo;<B><I>Option</I></B>&rdquo;
means an Incentive Stock Option or a Nonstatutory Stock Option to purchase shares of Common Stock granted pursuant to the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ee)&#9;</B>&ldquo;<B><I>Option
Agreement</I></B>&rdquo; means a written agreement between the Company and an Optionholder evidencing the terms and conditions
of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ff)&#9;</B>&ldquo;<B><I>Optionholder</I></B>&rdquo;
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding
Option.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(gg)&#9;</B>&ldquo;<B><I>Other
Stock Award</I></B>&rdquo; means an award based in whole or in part by reference to the Common Stock which is granted pursuant
to the terms and conditions of Section 6(d).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(hh)&#9;</B>&ldquo;<B><I>Other
Stock Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of an Other Stock Award evidencing
the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms and conditions
of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Outside
Director</I></B>&rdquo; means a Director who either (i) is not a current employee of the Company or an &ldquo;affiliated corporation&rdquo;
(within the meaning of Treasury Regulations promulgated under Section 162(m) of the Code), is not a former employee of the Company
or an &ldquo;affiliated corporation&rdquo; who receives compensation for prior services (other than benefits under a tax-qualified
retirement plan) during the taxable year, has not been an officer of the Company or an &ldquo;affiliated corporation,&rdquo; and
does not receive remuneration from the Company or an &ldquo;affiliated corporation,&rdquo; either directly or indirectly, in any
capacity other than as a Director, or (ii) is otherwise considered an &ldquo;outside director&rdquo; for purposes of Section 162(m)
of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(jj)&#9;</B>&ldquo;<B><I>Own,</I></B>&rdquo;
&ldquo;<B><I>Owned,</I></B>&rdquo; &ldquo;<B><I>Owner,</I></B>&rdquo; &ldquo;<B><I>Ownership</I></B>&rdquo; means a person or Entity
will be deemed to &ldquo;Own,&rdquo; to have &ldquo;Owned,&rdquo; to be the &ldquo;Owner&rdquo; of, or to have acquired &ldquo;Ownership&rdquo;
of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship
or otherwise, has or shares voting power, which includes the power to vote or to direct the voting, with respect to such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(kk)&#9;</B>&ldquo;<B><I>Participant</I></B>&rdquo;
means a person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Stock
Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ll)&#9;</B>&ldquo;<B><I>Performance
Cash Award</I></B>&rdquo; means an award of cash granted pursuant to the terms and conditions of Section 6(c)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext"><B>(mm)&#9;</B></FONT>&ldquo;<B><I>Performance
Criteria</I></B>&rdquo; means the one or more criteria that the Board will select for purposes of establishing the Performance
Goals for a Performance Period. The Performance Criteria that will be used to establish such Performance Goals may be based on
any one of, or combination of, the following as determined by the Board: (i) earnings (including earnings per share and net earnings);
(ii) earnings before interest, taxes and depreciation; (iii) earnings before interest, taxes, depreciation and amortization; (iv)
earnings before interest, taxes, depreciation, amortization and legal settlements; (v) earnings before interest, taxes, depreciation,
amortization, legal settlements and other income (expense); (vi) earnings before interest, taxes, depreciation, amortization, legal
settlements, other income (expense) and stock-based compensation; (vii) earnings before interest, taxes, depreciation, amortization,
legal settlements, other income (expense), stock-based compensation and changes in deferred revenue; <FONT STYLE="color: windowtext">(viii)
earnings before interest, taxes, depreciation, amortization, legal settlements, other income (expense), stock-based compensation,
other non-cash expenses and changes in deferred revenue; </FONT>(ix) total shareholder return; (x) return on equity or average
shareholder&rsquo;s equity; (xi) return on assets, investment, or capital employed; (xii) stock price; (xiii) margin (including
gross margin); (xiv) income (before or after taxes); (xv) operating income; (xvi) operating income after taxes; (xvii) pre-tax
profit; (xviii) operating cash flow; (xix) sales or revenue targets; (xx) increases in revenue or product revenue; (xxi) expenses
and cost reduction goals; (xxii) improvement in or attainment of working capital levels; (xxiii) economic value added (or an equivalent
metric); (xxiv) market share; (xxv) cash flow; (xxvi) cash flow per share; (xxvii) cash balance; (xxviii) cash burn; (xxix) cash
collections; (xxx) share price performance; (xxxi) debt reduction; (xxxii) implementation or completion of projects or processes
(including, without limitation, clinical trial initiation, clinical
trial enrollment and dates, clinical trial results, regulatory filing submissions, regulatory filing acceptances, regulatory or
advisory committee interactions, regulatory approvals, and product supply); (xxxiii) shareholders&rsquo; equity; (xxxiv)
capital expenditures; (xxxv) debt levels; (xxxvi) operating profit or net operating profit; (xxxvii) workforce diversity; (xxxviii)
growth of net income or operating income; (xxxix) billings; (xl) bookings; (xli) employee retention; (xlii) initiation of studies
by specific dates; (xliii) budget management; (xliv) submission to, or approval by, a regulatory body (including, but not limited
to the U.S. Food and Drug Administration)&nbsp;of an applicable filing or a product; (xlv) regulatory milestones; (xlvi) progress
of internal research or development programs; (xlvii) acquisition of new customers; (xlviii) customer retention and/or repeat order
rate; (xlix) improvements in sample and test processing times; (l) progress of partnered programs; (li) partner satisfaction; (lii)
timely completion of clinical trials; (liii) submission of 510(k)s or pre-market approvals and other regulatory achievements; (liv)
milestones related to research development (including, but not limited to, preclinical and clinical studies), product development
and manufacturing; (lv) expansion of sales in additional geographies or markets; (lvi) research progress, including the development
of programs; (lvii) strategic partnerships or transactions (including in-licensing and out-licensing of intellectual property;
and (lviii) and to the extent that an Award is not intended to comply with Section 162(m) of the Code, other measures of performance
selected by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(nn)&#9;</B>&ldquo;<B><I>Performance
Goals</I></B>&rdquo; means, for a Performance Period, the one or more goals established by the Board for the Performance Period
based upon the Performance Criteria. Performance Goals may be based on a Company-wide basis, with respect to one or more business
units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more
comparable companies or the performance of one or more relevant indices. Unless specified otherwise by the Board (i) in the Award
Agreement at the time the Award is granted or (ii) in such other document setting forth the Performance Goals at the time the Performance
Goals are established, the Board will appropriately make adjustments in the method of calculating the attainment of Performance
Goals for a Performance Period as follows: (1) to exclude restructuring and/or other nonrecurring charges; (2) to exclude exchange
rate effects; (3) to exclude the effects of changes to generally accepted accounting principles; (4) to exclude the effects of
any statutory adjustments to corporate tax rates; (5) to exclude the effects of any items that are &ldquo;unusual&rdquo; in nature
or occur &ldquo;infrequently&rdquo; as determined under generally accepted accounting principles; (6) to exclude the dilutive effects
of acquisitions or joint ventures; (7) to assume that any business divested by the Company achieved performance objectives at targeted
levels during the balance of a Performance Period following such divestiture; (8) to exclude the effect of any change in the outstanding
shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,
merger, consolidation, spin-off, combination or exchange of shares or other similar corporate change, or any distributions to common
shareholders other than regular cash dividends; (9) to exclude the effects of stock based compensation and the award of bonuses
under the Company&rsquo;s bonus plans; (10) to exclude costs incurred in connection with potential acquisitions or divestitures
that are required to be expensed under generally accepted accounting principles; (11) to exclude the goodwill and intangible asset
impairment charges that are required to be recorded under generally accepted accounting principles; and (12) to exclude the effects
of the timing of acceptance for review and/or approval of submissions to the U.S. Food and Drug Administration or any other regulatory
body. <FONT STYLE="color: Black">In addition, the</FONT> <FONT STYLE="color: Black">Board retains the discretion to reduce or eliminate
the compensation or economic benefit due upon attainment of Performance Goals and to define the manner of calculating the Performance
Criteria it selects to use for </FONT><FONT STYLE="color: Black">such Performance Period. </FONT><FONT STYLE="color: Black">Partial
achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified
in the Stock Award Agreement or the written terms of a Performance Cash Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Performance
Period</I></B>&rdquo; means the period of time selected by the Board over which the attainment of one or more Performance Goals
will be measured for the purpose of determining a Participant&rsquo;s right to and the payment of a Stock Award or a Performance
Cash Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(pp)&#9;</B>&ldquo;<B><I>Performance
Stock Award</I></B>&rdquo; means a Stock Award granted under the terms and conditions of Section 6(c)(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: windowtext"><B>(qq)&#9;</B></FONT>&ldquo;<B><I>Plan</I></B>&rdquo;
means this <FONT STYLE="color: windowtext">AmpliPhi Biosciences Corporation</FONT> 2016 Equity Incentive Plan, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(rr)&#9;</B>&ldquo;<B><I>Restricted
Stock Award</I></B>&rdquo; means an award of shares of Common Stock which is granted pursuant to the terms and conditions of Section
6(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ss)&#9;</B>&ldquo;<B><I>Restricted
Stock Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing
the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms
and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(tt)&#9;</B>&ldquo;<B><I>Restricted
Stock Unit Award</I></B>&rdquo; means a right to receive shares of Common Stock which is granted pursuant to the terms and conditions
of Section 6(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(uu)&#9;</B>&ldquo;<B><I>Restricted
Stock Unit Award Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a Restricted Stock Unit
Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will
be subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(vv)&#9;</B>&ldquo;<B><I>Rule
16b-3</I></B>&rdquo; means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ww)&#9;</B>&ldquo;<B><I>Securities
Act</I></B>&rdquo; means the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B>&ldquo;<B><I>Stock
Appreciation Right</I></B>&rdquo; or &ldquo;<B><I>SAR</I></B>&rdquo; means a right to receive the appreciation on Common Stock
that is granted pursuant to the terms and conditions of Section 5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(yy)&#9;</B>&ldquo;<B><I>Stock
Appreciation Right Agreement</I></B>&rdquo; means a written agreement between the Company and a holder of a Stock Appreciation
Right evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be
subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(zz)&#9;</B>&ldquo;<B><I>Stock
Award</I></B>&rdquo; means any right to receive Common Stock granted under the Plan, including an Incentive Stock Option, a Nonstatutory
Stock Option, a Restricted Stock Award, a Restricted Stock Unit Award, a Stock Appreciation Right, a Performance Stock Award or
any Other Stock Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(aaa)&#9;</B>&ldquo;<B><I>Stock
Award Agreement</I></B>&rdquo; means a written agreement between the Company and a Participant evidencing the terms and conditions
of a Stock Award grant. Each Stock Award Agreement will be subject to the terms and conditions of the Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(bbb)&#9;</B>&ldquo;<B><I>Subsidiary</I></B>&rdquo;
means, with respect to the Company, (i) any corporation of which more than 50% of the outstanding capital stock having ordinary
voting power to elect a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of
any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency)
is at the time, directly or indirectly, Owned by the Company, and (ii) any partnership, limited liability company or other entity
in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital contribution)
of more than 50%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ccc)&#9;</B>&ldquo;<B><I>Ten
Percent Shareholder</I></B>&rdquo; means a person who Owns (or is deemed to Own pursuant to Section 424(d) of the Code) stock possessing
more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>(ddd)&#9;</B>&ldquo;<B><I>Transaction</I></B>&rdquo;
means a Corporate Transaction or a Change in Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="card1.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 74 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="card2.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<IMG SRC="card3.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 76 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;<IMG SRC="card4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 77; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>card1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0, R # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)*RM(S0J2Y7[I)QR1V]*4:B3O_6]R:690IRYG%[6Z=[G*6G_ "'5_P"NL?\
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MK>*%0H4"- H &<#CL,G\Z3G[O*17Q\:E#V2C_5V_U)J***S/,"BBB@ HHHH
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M2;:^\KRO.3=LW9V_C@?RH NT5SEMXJ^T>+9="^QA=F[]\)LG@9Y7'&?K71T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <3XJ\<RZ/<R6-E9.9U0$SS*0BY'4#J<9'/3/%>:7VH7NHW9G
MO;AYY03SN)#$=@!CC/8=/;M[KJ.E6.K0>3?6L4Z#[N]<E?<'J/PKSGQ!\/+J
MT+7.EE[J$ YBS^\7CJ/[Q'Y^QH X8 X4YSWR6ZCZ]N3G@UR?Q$_Y'S5,#'S1
M\8QC]VM=A)%)%<2>9&\<BL >/F5L\\GGOWZ<<\&N/^(O_(^ZI_O1]/\ KFM
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MDG/R#GVZ8_+OFO1*X>QTS4(_B3/>/:RBS;?B<J0IRO3T[?\ UQT/<4 %%%%
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M-R2&*E?D/*D_SH;QOIR7:*UK>K9/<_9$U$QK]G:7<5V@[MWW@5SMQD=:BMO
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M&TC?>(8KN4$\D ]:JZ5X).CZ7?V-KJ\RI=#"O]D@W1_,2<_)\X.XC#YX/&*
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MMAJM"WM%:Y/1114G.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]YH$D=MN6T@NDF/F*-A=,+WYR?2E=7^_\BW7I>WOS*WO=?[ID:7_ ,@/2?\
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M5(=*TZ"2UVR0PHKCS%."(IU/?U=?S^M%UR)?UU+]O2]C%<RZ]?.?^9B>*O\
MD,7W_8MC_P!&"M9O]?'_ -<F_E:4:_X;U:]U*[FM[3>DFB"T4^8@S+O!V\GT
M[]*OG1-1,J-]GX$9!^=>N+?W_P"F;_E[BFY*RU_K4F5>E[&"YEMW\CF-=_Y&
M/Q'_ -?^G?RKH;3_ )#J_P#76/\ ]'W-4]6\-:O<ZUK=Q#:;HKF[LI(F\Q!N
M6,?.>3QCW_"MJWTB^35EG:#$8D1L[UZ"6=CW]'7\_K2;5EZ+\D*O7I.E%*2^
M'O\ W8G&V/\ R&4_[&2Z_P#0*]-T?_D!V'_7M'_Z"*XFT\,ZQ%J:3/9XC&MW
M%V3YJ?ZIEPK=>Y[=:[G389+?2K.&5=LD<"(PSG!"@&E4::T_K1'-FM6$U'DD
MGZ?(EN+F&T@::>01QKU8_D*BCU&SF2)TN$(F<QH#P2PSD8/.>#Q46K0S200R
M01&9X)EE\H$ N!U S@9YR,D=*JBUENY+6\DT]()4N2X!"^8J%<$L03R2!T/I
MZ5DCS84X.%V^_;\BW_;&G[96^UQD1$!L<\DD#'KR"./0T^74[*&!)I+J,1R1
MF1&SD,H&21[8K'B6]8W4\VCW,<F1'&J21#9$"<&/#GYN<G.WKQTJA+H&J>5:
M-)''.D<(B:%&V2(@3!4/G&2>X'7'.!FG9=3H6&HWM*5OFNQTBZQI[+"WVE )
MCB/((R<X[].2!^-,77M,?S=MVN8L;P5((R<#C'.2#6&-+U(7,,P2\.<+$'N=
MQB42$_O<M\_RD_WOSP:NWEA=20SS&*5I)+P.PA=1((DX7820!TSU_B;O19"=
M"@FES?BNYJIJ=E)/'"EU&TDJAD .=P(R,'W )^@JW7*V6DWT-W81F*2.*,QR
M2G<A0E4*\]]W08''?/:NJI-+H85Z<(-*#N%%%%(P"BBB@ HHHH **** "BBB
M@ HHHH Y72K75-7M[F[?Q+J=O_IUW"L4,5KL1([B2-0-T)/W5'4FKW]A:C_T
M-FL_]^K/_P",4>$_^0/<?]A._P#_ $KFKS/6;7Q.[V^I6>FZA),FJ3ZB8?)<
M;@)DBBC/' V M].?>A;V'TN>F?V%J/\ T-FL_P#?JS_^,4?V%J/_ $-FL_\
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M<EV!SR,%L?A2^$_^0/<?]A.__P#2N:FU9V!.YN4444@"FR2+%&TCG:B LQ]
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M[?U_7W=3;HJK87JW]KYP1HV#M&\;=49201Q[BB+4K"?/DWMM)B3RCLE4X?\
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M &%J/_0V:S_WZL__ (Q1_86H_P#0V:S_ -^K/_XQ6Y10!A_V%J/_ $-FL_\
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M8V=RVCWBR*;>XNWED"D@F/=G;DC(R!C.,\US\&AZE-8SV[V]TLCPQ6JR7#P
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M\7[R=_GKT^9Y_J?@;4[VPF@CGM SP31 L[8R]V)A_#TVC'U]N:ZG1=)DT_\
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MW*$$##$8(Z?=Z<>U)=:0MY<W'FL1!-Y;_(<,'0GU'0C'Y4G;H3S8=S3MIU_
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M=Q%#<P32Q-;R2KYF(V*E]N<[>.M9'P^\/ZOX>BUB'5&A*2WID@\J-4#+M W
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MX2O,A@2)H#"5+,?]8S]CDXQVH6PWI_7H>E17]G/*D4-W!)))$)D1) 2T9Z.
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M#CN-.:SNX_AUI\,,+6^I1K$UM&D3'RY<\ C&5&"0<XP"<XH[V!=+G6"]M6+
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MJ$\EA%9I))&J+$CJK!8U7.'13VQT[8R<9H6H,ZJBBB@ HHHH **** "BBB@
MHHHH I:PEM)H]XEXJM;-$PE5I-@*XYRW&/K7G']F>!/^?*S_ /!P/_BZ]'U>
M5H-(NY4**R1,P+RF-1QW8?='O7GG_"0WO_/UI7_A0/\ _%5K2YM;'M96JKIR
MY)-:]&UT(_[,\"?\^5G_ .#@?_%UZ7IRPII=HMLH6 0H(P'W@+@8^;OQWKSC
M_A(;W_GZTK_PH'_^*KT?3G:73+61BI9H48E9-X.0.C=Q[]Z=3FMJ+-%54(\\
MF]>K;Z%FBBBL3Q@HHHH *H:K8RZC;Q6Z2F*,RJ\KJ<,%4[AMX(SN"]>V:OUF
MZ[=26NE2>29!-*5BC,2[G!8XR!W(&3^%"-:/-[1<NYCV^@ZK;B\L=UK)8W!"
M"=YF$J1@GC8$P3R1U':KPTW4&O7C=;9;(W8NA(LK&0XP0NW: .1UW'Z5DVVI
M75S975Z;N=+BS2)#$?E5I 2&!0_WB/KR*T/.N([QK@7<Q8Z@+<0ELH4.,@#V
M&3D>E7K<]"I[6[YFK^G7[^W7;R+UO;Z@=;FN;J*V: *4MW6=BR+QQLV 9)')
MW'H*U*QHYID\1JGVEY;>:.7C<I4.I7Y0!R"!GGOGGM6S4OH<%>]U?LM@HHHI
M&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!GZW?RZ
M9H]Q>01I)+&!M5R0"20.2/K7+/XUU.">.VEL;=I9YI8(C#O< QR^6S%<9(/4
M ?G7;2PQ3QF.:-)(SU5U!!_ U5GT;3+F-HY].M)$;=N#0J<[F#'MW8 GW&:
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M4AAR-J]>P'IZ^M;52SBJI)JTKZ+_ (;Y!1112,@HHHH **** "BBB@ HHHH
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MNCF[?7+V[LIM0BN8O+MHHV>$(&5VY#C=UZ@XJ[]NO4NGF,ZM +T6WDF,?=.
M"&ZY!.?I4G]CZ(-3>;.+F=Q*T0NG"R-V)CW;3Z]/>IH]/TO^U7G1RUWO,AC-
MR[*K8QN\LMM!QWQ5W1VSJ4=>6/3M^'_!(;:\O3K\\%R)H[=BPMP8EV. !G#
M[L]3R /3.*V:HPV-C%J,D\?_ !\D$LOF$A=V,D+G S@9('-7JEG)6E&37*K:
M(****1D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN9&\U'*L26+9.=B\DY &.E9KCX?:O?M.UW:3S:@S0;1=. [$!20H.%8@J-P
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MM  J*2NPJ^/FR, C)^[T&.>DHHI-G/5JNHTVN@4444C(**** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KB?$O]I7OC;3=)M-6N;"*:U>1C">X)[?A
M7;5P^NWMKI_Q,TBXO+B."%;*0%Y&P!DMCFJCN>AEJ?M9.*NU&5M+ZVTTL_R,
M6QN;34;V*SM/B'J4EQ,VU$^S2#)^I&*Z+P/>:C-H6K>?<2W]S;7TT,1E;EMJ
MK@9[9/\ .N'\/Z!IVD:]9:A+XHT=XX)-[*DIR?I6EIMJ-5\+7WD:A;6K?\)"
MTL,TQ^1FPNT#U)S6DDCW<90I2BX1E>/NZN-K.[OM"+V6IMZE/KEW82WVMW$W
MABVL\?/;2"?SMY Y"DD8./\ OH^E4['QG+IOBJY7Q+.UC;FU3R8LF56.1A_E
M!P2.:N^(M:MK?PX^FZY&^JLH U![$A1"=P*;NFW)QCUP:AT6Z;2]&U;^SO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:OX?:;5+-K*.=EDAU61R41#C"[ ><^N.]>BP>#](\/MK=Q<,B:+=0HK0$O\
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M-&=\ 64E92,<%HU9<XY)6HK&;Q);W^BVAAU VK:7$DELMN8TC;R3NS\A4X;
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MKUEJ$OBK0WC@DWLJ72Y/TK;\-ZK:6?AS5C,KS6]]K<MJ#"PZ2*H!!],5UO\
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M@# R?84.9-7-92ARINZO9^K^&VUDDK=4UV.5^'"F+2=4AWNZQ:G+&I=LG 5
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$T\*_\ 0RZ-_P"!\7_Q5 &Y13(9HKF".>"5)895#QR1L&5U(R""."".]/H
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MDT^^2X99-@A+DY!SL7&7QC@<]ZYZW\ 3Q^6LNL>:D4/DH6A;./D[&3:!\G
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M^'O^P9;?^BEK<K#\%_\ (B^'O^P9;?\ HI:W*0!1110 4444 %%%% !1110
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M]FNM/@NDL3<2>2JS(_D$39)+>9C&T8^7>, @<'GTP@$$$9!Z@T*H50J@ #@
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M"V^V?VA]A8DMY9/]X=^G;UR,]ZU7T72Y;J:ZDTVT>XG0QRRM"I9U(P03CD$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !%'_"EO#G_/[JO_ ']C_P#B* T/3?\ A-/"O_0RZ-_X'Q?_ !5'_":>%?\
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M_G]U7_O['_\ $4?\*6\.?\_NJ_\ ?V/_ .(H#0]-_P"$T\*_]#+HW_@?%_\
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M_P _NJ_]_8__ (B@-#TW_A-/"O\ T,NC?^!\7_Q5'_":>%?^AET;_P #XO\
MXJO,O^%+>'/^?W5?^_L?_P 11_PI;PY_S^ZK_P!_8_\ XB@-#TW_ (33PK_T
M,NC?^!\7_P 51_PFGA7_ *&71O\ P/B_^*KS+_A2WAS_ )_=5_[^Q_\ Q%'_
M  I;PY_S^ZK_ -_8_P#XB@-#TW_A-/"O_0RZ-_X'Q?\ Q5'_  FGA7_H9=&_
M\#XO_BJ\R_X4MX<_Y_=5_P"_L?\ \11_PI;PY_S^ZK_W]C_^(H#0]-_X33PK
M_P!#+HW_ ('Q?_%4?\)IX5_Z&71O_ ^+_P"*KS+_ (4MX<_Y_=5_[^Q__$4?
M\*6\.?\ /[JO_?V/_P"(H#0]-_X33PK_ -#+HW_@?%_\51_PFGA7_H9=&_\
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M?_Q%5K_X3>$-+M'N[[5M1M[=.LDD\8'T^YUH#0]6_P"$T\*_]#+HW_@?%_\
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M=&_\#XO_ (JC_A-/"O\ T,NC?^!\7_Q5>&?\(3X6_P"@=XW_ / '_P"UT?\
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M?\_NJ_\ ?V/_ .(H_P"%+>'/^?W5?^_L?_Q% :'IO_":>%?^AET;_P #XO\
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M0I( K [1_='3//UJ1(K+0X/ VKW<"IIL=LPGE6+(61T!5FP/4GFG_P #]?\
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M4*%H[Z-6&1C((;@US>FQ:%;:I9WNH>/;;4A8AA:QSW4(V;A@EF!RQQW-7_\
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M_C1_PEGAS_H8-*_\#(_\:Q?^%!^%?^@AK/\ W^B_^-T?\*#\*_\ 00UG_O\
M1?\ QN@+&U_PEGAS_H8-*_\  R/_ !H_X2SPY_T,&E?^!D?^-8O_  H/PK_T
M$-9_[_1?_&Z/^%!^%?\ H(:S_P!_HO\ XW0%C:_X2SPY_P!#!I7_ (&1_P"-
M'_"6>'/^A@TK_P #(_\ &L7_ (4'X5_Z"&L_]_HO_C='_"@_"O\ T$-9_P"_
MT7_QN@+&U_PEGAS_ *&#2O\ P,C_ ,:/^$L\.?\ 0P:5_P"!D?\ C6+_ ,*#
M\*_]!#6?^_T7_P ;H_X4'X5_Z"&L_P#?Z+_XW0%C:_X2SPY_T,&E?^!D?^-'
M_"6>'/\ H8-*_P# R/\ QK%_X4'X5_Z"&L_]_HO_ (W1_P *#\*_]!#6?^_T
M7_QN@+&U_P )9X<_Z&#2O_ R/_&C_A+/#G_0P:5_X&1_XUB_\*#\*_\ 00UG
M_O\ 1?\ QNC_ (4'X5_Z"&L_]_HO_C= 6-K_ (2SPY_T,&E?^!D?^-'_  EG
MAS_H8-*_\#(_\:Q?^%!^%?\ H(:S_P!_HO\ XW1_PH/PK_T$-9_[_1?_ !N@
M+&U_PEGAS_H8-*_\#(_\:/\ A+/#G_0P:5_X&1_XUB_\*#\*_P#00UG_ +_1
M?_&Z/^%!^%?^@AK/_?Z+_P"-T!8VO^$L\.?]#!I7_@9'_C63K%]X8U.6*[@\
M4:=8ZC "(KN&\B+ 'JK G#+[']*C_P"%!^%?^@AK/_?Z+_XW1_PH/PK_ -!#
M6?\ O]%_\;H C3Q1=1KL;Q/X1GQTD-QY98>XWG!_&G?\)9/_ -#!X1_\##_C
M3O\ A0?A7_H(:S_W^B_^-T?\*#\*_P#00UG_ +_1?_&Z &_\)9/_ -#!X1_\
M##_C0/%<X&!K_A ?]OA_QIW_  H/PK_T$-9_[_1?_&Z/^%!^%?\ H(:S_P!_
MHO\ XW0 W_A+)_\ H8/"/_@8?\:/^$LG_P"A@\(_^!A_QIW_  H/PK_T$-9_
M[_1?_&Z/^%!^%?\ H(:S_P!_HO\ XW0 W_A*Y\Y_M_PAG_K\/^-'_"5SYS_;
M_A#/_7X?\:=_PH/PK_T$-9_[_1?_ !NC_A0?A7_H(:S_ -_HO_C= #?^$LG_
M .A@\(_^!A_QI/\ A*Y\Y_M_PAG_ *_#_C3_ /A0?A7_ *"&L_\ ?Z+_ .-T
M?\*#\*_]!#6?^_T7_P ;H ;_ ,)9/_T,'A'_ ,##_C2?\)7.>NO^$/\ P,/^
M-/\ ^%!^%?\ H(:S_P!_HO\ XW1_PH/PK_T$-9_[_1?_ !N@!I\5SGKK_A#_
M ,##_C1_PED__0P>$?\ P,/^-._X4'X5_P"@AK/_ '^B_P#C='_"@_"O_00U
MG_O]%_\ &Z &_P#"63_]#!X1_P# P_XT?\)9/_T,'A'_ ,##_C3O^%!^%?\
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M  1-<\5:]I%]K"?9-->VT^S^V@EY-[(2X4=,9RO-6=+\67-W+I:.;"<7MW)
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M4#'R[47MZYZ5#<>#K273-)LK>^OK+^R\?9Y[9HQ(<(4^;*$'()["F[7NMO\
MA_\ @$K8P-0^(%]9:U;6$<6FSL\-M+Y:R2"6X\TD'R1M.<8SSC@TVU^(=W="
M[2%-,ENEN_L<-JLKAUD,I16D)& N 6XR:Z&;P997)DDN+R^EN76W'VEG3S%:
M$L5<$+C<=QSQ@CM4S^%+%M .D>=<K&)VN8YU<"6.0R&0,IQCACQQTZYHT_KU
M&<UJ7C[4=+@%O=Q:7;7T5\UG/+/,XMQ^Z\U6# ;AD$#&.#5AO'EX7T&(:;''
M+J,.^X,KD+;LYVQ9XSM9_;.*UK?P3IT8A:XGNKN99Y+B:6=E)N'>,QG?A0,;
M3@ 8Q@51'PST)XF^T27ES.J1QV]U,ZF6V5/NB-@HQCW!/K0K=0?D5+/QKJR7
M%L=3M+!+:6YNK=FMW<LOD*Y8\C'.SCZU1U+XDZMHEE97>I:1;&/4(TN+5+>5
MG81ET#*W'W]K@C'&<BNL3PAIR26SM)</]GN;BY"NRX9I@P<-QT^<XZ?C6?#\
M.]-22W:>^U"Y%HT?V19I%(MT1U<(OR\@E5!)R< #-"Z7!VUL;/A_65UVRGNH
M]AB6X>.-D.0Z \-^(KD+CXA:K8V,][=:?9?9Y$N_L9CE8L7@8@B0$< @$Y!-
M=-H/A>'PY-Y6G7$RZ?B5OLSL" [N&R, 8 &0.O!K./PZTQXKJ&;4-3FBF6=8
MT>1,6_G-N<QX3J2?XLT@16E\6:S_ ,(\NJ6G]C70%TEN^QY0HWLBKU4'(+9/
MM34\?S03ZW%>V,6=.@WPO#(=MRZX60+GH [*/QK='AA)-)?3[S5M2O4:>.82
MW#Q[U*,K #:@&,J.V>O-9R_#7PZHW"*;SG65;B<,!)<B3.[S"!SR<C&,$"GU
M#HNXR?Q7JFARV*>([2RMH[FY:+[1!*SH5\IG! QD$,-IR/>K-MXM>7X>KXE:
MW0S/"7C@5N'<L5103ZG _&IK'P=;6EW;WDVHZA>74,YG$UQ(I+'RS& 0% P%
M/;'/)S3F\&Z7)X<L]!F:>;3[:19/+D93YN"6"OQR,G/&.@I/;^N_^0+?^OZW
M.?G^)7V6/26GLT0WUE/))\QQ#<1\>6?8ME<^N*LV?C34Y=3C,]C:#3'O8[ R
M)*WFK(\2NIVXP5RV.N:GD^&>@/;W5L!<+:SQ2Q+;JR[(1(R,=GR\89 1G/)-
M6K3P/86NJK>B^U"5%F6X6TDD3R1*J! ^ H.0 .^,TU:^HG>VAF^(/'%WI'BO
M^R((+&4!8&$+R.)Y_,8@B, $$KC/.*I+X\UBYL]3NK1-&;[ +AWMG>42[(F9
M<_=VY.!W[UU.H^$[#4[RYNY9;E+B?R")(V4&)H68HR9!P?F.<Y!%5(/!,$%I
M?67]L:K)97B3(UL[Q;$\TDL5Q'G.6.,D]:2V*TOY%)O%^J6D%^+RTLS/:QV<
M@\EV*GSY"O?G@ ?C5;1/'UYJFLW-F;>QDCB6Y+"WD<R0&)B!YH(P V.,&MK4
M/!=EJ&H1W37E[$FR%)X(W4)<")MR;\KG@^A&:?;>#M.LYHIH)KI9(UN$9@Z_
MO$F<NRM\O(#'(]/?G(^MOZW_ . )=+_UM_P3-\)^-I?%ELIM[:*&X-CYS)(3
MA)MQ7:>^T\'/7!JI;^.=0M6M9M;BT^WLYKZ>R,D+2,5,0?)Y'0E!CZUOZ)X0
MTSP_?F\LC-YK6D5H^]@0ZQC"L< ?-C )Z<=*D@\+6,$UK*DMP6MKR>\3++@O
M*&# \=/G./PY--VOI_6__ !;:_UH<IHWQ$O-7U"QM]NFVRW$44N)6DW/O=UP
MF 1_#WQUK2\:^-+CPO>P0Q)9%7M9;@FY=UW%"HV+M!Y.[OQQ5C3_  %:Z5<0
MS:?K.K6XCC2-XTDBVRJC,P#9CS_&PX(XJ[KWA2#7[N.Y?4=0LY$@DMF^R.BB
M2-R"RMN1O[HZ8I/I8:W=S%N/&>K%I[NTTZS.F074=B[2S-YGFOM&[ &-@9U!
MYR>2*@;Q7XJ729=1^QZ-Y4=Z;(KYLNXOYPBSTZ9.?I6PO@338[Z.6*YO([-9
M(YFL%D'DO+& %<@C=D;5XS@D XJZWA>R;2I=.,MQY,EY]M+;EW;_ #?-QTZ;
MACUQW[T]/Z]?^'$MM?ZT_P"&,3_A+M7BN9)IK"R.FVM['I]U)'*WF&5MH+("
M,; S@8/)Y-9^G?$N>^URSTHV$:S2ZE-:28)^2),;7_$G'X&NCG\&V5QK+7S7
M=XL$EPEU+8JX\B29<;7(QG/ . <$@<5!:?#_ $>SUA=4BDNC<JX?YF7!(=W_
M +OJY_ #\1=+_P!?U^0/R,R7X@36_C"YTJ6&R:V@G>)ECE;[0JK#YGF%,8V=
M5SGK5+4/B+J^DV=E/J%AIUNNIQI-:.9W*1(70$2G'! <'(XZUW-IHEG9RZC(
MH:0ZA,99A)@]552HP.F%'KWK!@^'FFQRV[S7VHW(M&C^R+-(I%NB.KA%^7H2
MJ@DY. !FDNEP?4H6_C#Q#>VFESVUEI6V]NWM%D,LI1V =O,0[02A"\''6GVO
MC+6=4AM8=-T^R:^>.XGF$\K+&J12F,!< DLQ'T%;UOX4L;5;6.*:Y$5I>O>P
M1EEVHS!@4''W/G8@=??'%4G\"60M;>*TU'4;.6'SE^T02('=)7+NARI&,GCC
M(QUHZ#T,;P_\3X]>U!;1+,0N]S#'&')^:-X]S'W96X/U%6=>^(+:#XL72Y[1
M&L_-@22<$[D617)8CI@;!GVS6A:?#W0K*YLY[=9D>SNOM,&&'RGRUCV]/NX5
M3ZY'6I[_ ,%:5J>N2:K=-.\DBA'A++Y; 1O'C&,])&[]<4W:^A/<BN?$6H_\
M((?$%G;VC3)"\\D4K,%**&R 1WX%8U]\0KK1Q<VVI0V0OTAMI88XF<K)YKD$
M9([  UU$'AJRM_"7_"-I)/\ 8OLS6N\L/,V$$9SC&>?2H+WPAI]^MXLLUR!=
MQ6\4FUEX$+%EQ\O4D\_TH5K^7_##>WF4?"OBRYU_4[F"5M/1(7F7R8C(9ALD
M* MD;<'&>#W%947Q!O9-.UJ]V:<QT^.X=;9&D\T^6Y4;LC;@X['N*Z;1?#"Z
M'=220:MJ4MN[2.+29XS$C.Q8D80-U)[]ZI)X%MDLKZQ.L:L]C>+*&MFDBV)Y
MC%F*_N\YR3C)/6E_D/K\_P #.M_'MUJ[06^CVENUS=.BP_:795C_ '1DDWXY
MRI!7 [UKZ=XCNWN-1AU6R2TDL+**YF1)-^"WF;AGH1\G'UJ%_ .F+-=7%E<7
M=E=3W7VM9H&4&*39L;:"I&&!.0<]>U.@\#6EK=QSV^JZI$@AC@FA$J,EPB%C
MA]R$G.YLX(Z]J.@EYF;%XTUJ*T\Z[T>!FNM.?4+"*VE9V(7;\C\=<.IRN>XK
M,A^)5[-):PA]$7S5E)N#+*8VVE!@*%WJWSG(8#I[UT5MX"L((IHI+_49U-L;
M6W\R89M8B0=L9 !SD+R<GY14$7P[MX;\ZC'K^LQZE(&$UVDD0>4';P08R,#8
MO0"GI?R_K^F'0%\7:E'K[P36=H=+745TWS4E;S1(T:LK;2,%<MCKFFZSXQNM
M/\52Z1$=/C2.&*4&X,F^4N6X7:"/X>^.M:$7@RS36VU-[_4)<W N_LLDB>3Y
MP0('P%!S@>N,T_4?"<=_K$^I1ZOJ=G)/$D,T=L\8215W8R&0G^(]Z3VT_K3_
M #!;_P!?UL<WIOQ,DU*RL;Q;*-(V6'[:I8[H2\OEDCVY5AGL:?<?$"]6XM%1
M-.MH;O[0\,MTTF&2.0(OW0>6SGTK6C^'FB16UY AN0MYI\=A,=RY*(,*_P!W
M[^,<].!Q4TO@JUQIOV+4]2T]M/M3:1-:O&"T9VD[MR-DY4=,4]+_ ->?_ ^\
M73^OZ[B1>*V7P5=:_<6REX&F40QM@.4D:-1D],D#\ZYW5_B#K.A7T>EZE;:/
M;7S[9!-)<.+?RV5R,MMR&W(5Z<Y%=%9>"+6UL;RPEU34[NPNDD5[6XDCV*7;
M<S+M0$')..>])9>!K&WU.#4KJ^OK^^A?<)KID8E0C(J$!0, .3Q@YY)HZ_UV
M_P Q]/Z_K8R;/QY>7VL6%GY5C9K<VUM.4N6D\PF7.57 QQCOCJ*Z'QA)K=OX
M:NKGP^Z"_@7S%1XPXD4=5QZXZ>XIM]X66[UN758-9U2QFECCCE2U>,(X0G&=
MR$_Q'O6U;0FWM8H&FEF,:!3+*07? QEB !D_2E+5:: M&>0?#/QOXR\9^(&C
MNIK9=-M5WW+);@$Y^ZH/J3^@->R5F:-H&FZ!'<QZ;;B%;F=KB3'=F_IZ#M6G
M3;T0NK"BBBD,SY-9M8[>&=HKXI+NVA;"=F&#@[E"97VR!GM1/K-K;^7OBOCY
MD8D7R["=\ ^NU#M/L<$=Q6A13NNQIS4_Y?Q_X!2CU6WEO3:+'>"0,5W-9RJF
M1G/SE=N..#G![5$FNVCK(PAU !%W'=IUP"1D#@%.3ST'.,GH#6E11==@YJ?\
MOX_\ S_[9M?LGVGRK[R_,\O'V"??G&?N;-V/?&.V::^NVB+&QAU AUW#;IUP
M2!DCD!.#QT/.,'H16E11==A\U/\ E_'_ (!2DU6WBO1:-'>&0L%W+9RLF3C'
MSA=N.>3G [T+JMNTT\0CO-T"LSDV<H!"]=IVX<^@7)/;-7:*-!<T/Y?Q_P"
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M>"].\)ZS>VNC>7<6]C/-$_VJ8[75"0<%\'D#K78^"_\ D1?#W_8,MO\ T4M
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M7]FWEXNX#YO^KQ(/G^GK0!8HJM87]KJ=J+JSE66$LRAAZJ2#^H-6: "BBB@
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MI""Q5%"@G  S@>E %JBBB@ HHHH YOQ#HNH7US))8?9CY\"P2&=V79M?>",
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M:3+""DTK*8B2"K.6!.0,'!Y'/U-:E%%(84444 %%%% !7#^&/^2I>/?^X?\
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M%+6Y573-/BTG2;/3H&=H;2!((VD(+%44*"< #.!Z5:H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>G;-;/A[1_[!TA;#S_/VRRR;]FW.^1GQC)Z;L?A7-_\ "W_ G_0=_P#)2?\
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M5(Y_/M[8?O/*&6!.,<>^0?H<TRV\4:7/+>127"0/:LX<2'&57&6_\>''7D4
M;5%9MQK=K%HD^J0$W$42L0L?#.P.-F#T;/&#WJI%XPT1H('FO4@DEC63RG!W
M+N&0IP.O!X]CZ4 ;M%8FH^*])T]#_I4<DV$*QJWW@_W<'IR,D>N#51O%^))&
M73S):P^5YTR3K\OF,5& ?O=* N=-16%8>*;#488C"Z^:\HB>)FP4RS 'ISRI
MZ5NT %%%% !1110 4444 %<I=>!-/NQK<DH@-YJ<I=+O[.OFP#:@"ACR1E,X
MX!R1727MY!IUA<7MU)Y=O;Q--*^"=J*,DX')X!Z5QW_"W_ G_0=_\E)__B*
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ME)-;01PZNB2Q000+*;9@R^7&4WJ5D#*W.>N.,$,*M?\ "W_ G_0=_P#)2?\
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M.F587"%]X8%5$@ X4#YMWJ,9-8C^)KV.^FNUU"!Y7BACG0;5%CF60$-N( /
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M^9<%AQQ5FSUW4[&PGECN?M+R7GV98F7/DM)"GD^X7=@?\"S0M?Z[A>W]>O\
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M744;I%+\I(?E5)Q@'K@=\'%9FG^ Q::REZVH*Z0036\<:Q'=MDY^9BYY''0
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MTR[@NIKR.62(L,1PLH8; @Y9V.>">N.< "A>8V,A\2:'I9.G!6AMXKB6W=Y
M<!E4.3WR/FZ^WI6C:>)M(O/*B^V0"64;@F[<,<D<].0I/X'TJM)X8>2]NIC>
MKY<SS.J>3ROF1A#D[N<;<]!Z>]95MX*AT7PW]CN-262.-(U,C((MVU&3&2Q
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M=3#/%<1++!*DL;='1@P/XBJ=NA*OU'@!1@  >@I:**0PHHHH **** "BBB@
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M@)*DDA6(^9YA^8D%" >  5Q@5MV6@VMA+')%),S1O(XWD<EP >@_V16I10M
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M/_HSC9$WEE=I*X+!2^ ,G((QFLK3+&^'CK1;I8=5.FJ]ZWFRP2+\SL=A?(R
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M0!YEH'AO2?"_QF>RT:T^S6[^'C,R>8[Y<W !.6)/11^5>FUP_P#S77_N6O\
MVYKN* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4PRNI&"""F"".U=W10!5TS3XM)TFSTZ!G:&T@2"-I""Q5%"@G  S@>E6J**
M.5U_P+:Z_KJ:S_;&LZ=>);"UW:=<B'=&&+8)VD]3ZXX%4?\ A6W_ %.OC+_P
M:_\ V-=Q10!RN@>!;70-=?6?[8UG4;Q[8VN[4;D3;8RP; .T'J/7')KJJ**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D"A<X &3DXI:* "BBB@
M HHHH 145<[5 R<G ZFEHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV^C31.C7%L]Q',2-AV$;E]<@$&@#6HK"T+Q9IFN6MK(D\5O/=*TD-K+,HF9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>5_'S_D1;'_L)Q_^BI:]4K)\2+I"
MZ'<76M6,%[9VJF<Q30K+R 0,*PQNY('UH&CRJZ^('AV717AE\2?:+)M(%JVD
M+ISAFFV8SYQ4=^V<5S_P#_Y'J^_[!DG_ *-BKT>1/#-CIKW>K^ ;#3MES#"1
M+9P,I60@!PP7!QGD=1BMK2KOP/87L3:2NC6UU<PDHUK D;.G)QE0/[A.#_=]
MJ'K)R_KJ_P!11TBHK^MD4O&GA&X\3Z[I[+'M@AL[@"Y# &"<E#&P&<]5[5PF
MG^ _%%OI5U;7^B17=YJ4'E+<-/'_ *"_G.Y?KT.X-\O.1C%>J#QIX::U-T-9
MM/)#!"V_N5W#] 3GVJY9>(-(U&\^R6>H037'EB7RT;G:0#G\F7\Q3CIM_74&
MSB;OP=J,FKW%ZMBDDS:W9W"W!9-Q@CC4.V2<CD-QU/I1XN\&^(I]'CDTW4YM
M2U6*Z<Q//LC,<,B%'4'@8 (/KQ74:UXST31(K\37L4EU9PF5[5&&\X ./KR/
MSS4.J>,[72-(TB_N;=S_ &B\:A(VW>6K#)<G^ZHZFENE_7]7M^8[V./3P/J-
MCJHT^UTJ-H/M]K=0ZMYB9@BB508\?>S\I  X.ZIK/PIJT#6\":0L2V^OSW;2
MJ\8#PLLFUASGC<HQU]N*[2?Q7ID7B&VT5)TENI"XD"N/W.U-_P WX8_,51A^
M(?AR6\N(6U&".&,QJD[/\LK,"<#Z ?K1N+8\[U7P?>Z-I.CW<]C:V\-II\"7
M:RS1HLTPN$<Q,V<<C/S'Y?>NN^'W^F:'XE>"TBMQ/J4_EPPNK(,HHP&7Y3SW
M'&<UT,_BGPQ<:<99]2LI;.1S$V\AE)QN((],8.>F.:M:=J6B+=-H^G3VB2P*
M3]F@ 4*.,X XXW#..F:;U33ZAM9]OT/,;;P)KL>ERV?]EI'<7/A]+3S_ #(_
MW<RLQ*$@_P 0*C(R,?2K6E>"]5DN+"XN]+E$7]I>?/%<O;_*JP% VR,!1\V!
M@9)P"<5ZS69JNJ3:?-9P6]G]JFNG957S0@&U2Q))]A2;_K[PZ'E/_"OM8ATW
M3%_L1M\&G;)_LUS%'(LPN X()R&8+SSP>F17HW@>QU+3O#,5OJD,<-P)9&"J
MB(VPL2"X3Y=YZG%&B>-=+UBQCN&?[(TLSPI%*P+$JP4GC(QN(&<XY'K5\^(]
M'Q,?M\9\HA6 R3DD@8&/FY!'&>A]*=_Q!ZFI15"UUK3;VY^SVM[%-+LW@(V<
MC /!Z'AA^8]:K_\ "4:)Y3R_VC%L1@A//4D@ <<\@CCN"*0&O16)'XLTEHOG
MND6;87,2DL< $]<=2%) ]CZ5:@URPFTZUO7F$,5Q;FX02<$(%#'/T!H T:*S
M8-?TJYD\N&^B=]X3 SR22!CUY!&?4&E@U[2[F1TAO(W9(O/<#/RI_>- &C16
M2/$^BM:_:1J,/D[]F[GKMW=.N-O.>F.:F_MW2]X3[;%N.<+GDX<1_P#H1 _&
M@#0HJE-K&GV]\ME-=QI<,,A&/L3R>@. 3CV-8K^.](#W"1RB1XI8HD49S)OV
M\].!\XY/7M0!T]%94?B71I614U"$EW,:]>6! _F0,^IQUI&\3Z*N[.HPC:V#
MR>.O/^[P?FZ<=: -:BLNZU^RL=9BTVYD$3S1"1'8\'+;0/;DCKZBF2^)-.61
M4AG29O/6%]K8V9)&[GJ,J1D>AH UZ*R8/$VBW,C1PZC SJT:%<X(+DA.O]['
M'K6C;W$5W;QW$#B2&10R..C ]#0!+1110 4444 %%%% !1110 45S5GXO6ZN
M99)--N(-)3S0NINR^4?+)#%AG*#(.">N*F;QMX92**1]:M%27.UB^!P<'/I@
MD=?6@#?HK"E\9^'(8H)9=8M4CG!,;,V 0&VGZ8;@YJ1O%F@+#;3-JUJ([DD1
M,7^]@[3],'CGOQ0!LT5S5WX]\.6NF?VB-1CFMA/% [Q'.POT)]L9.?0&MC3-
M7T_68&GTZ[CN(U;:Q0]#@'!_ @_C0!=HHK!U#Q(UAJ$\'V!Y+>V\GSIEE4%?
M,) PIZXQZT ;U%8]EXETV[2$/<)#-*I81.W( +=3T'"D_@?2E@\4:)<SI!%J
M,+2LP4)R""<;<\<9R,$]<\9H UZ*HP:QIUR;GR;N-_LP)EP?N@9!/N,@C(]#
M51_%6C"U$Z7\3AR5C&2-[;=V.GH0<^ASTH V:*P+CQCH]M93SM<AW@C\R2*/
M+,.F0.QQN7\Q6G/JEC:[O/N4CVHKG?QA6;:#^)XH#<N45F1>(=)FC,D=]$R@
M,3UX"KN)_P"^2#[@TZTU[2[[3'U*VO8I+) 2TX/RC SUH T:*RD\2Z-(RJNH
M0EF!..1C&<@^A^5N#SP?2HE\7: ZLPU2#"C<QR1@8!]/0@^XYZ4 ;5%9$?BG
M1)4=DU&)MGW@,YSG;C&,DYXQUS1)XGT:,[1?1N_E>:%3)++M+#';D D#O@T/
M34#7HK+TCQ#INM1QFSN%:1XA+Y9X8 XS]<9 ..F:@L?%>E7M@UR;E8BAVO&V
M2P)8J,#'.2".,\\4/1V!.^IMT5BCQ1I:R3>;<QI"@0I-NRL@9=V1CL .3VJU
M_;NE[PGVZ+<<X&>3AQ'_ .A$#\: -"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HKAK;XGZ9<7EM:?994EFU*73R&<?(4QES_L\BM_\ X2[P]]B^V?VO
M:_9_,\KS-_&[&['Y<Y].>E"UU_KI_F'6W]?UH;5%<N_CS1UO9X#(%CMKEK>X
MFD8*J;8S(6']X<$<>A/2K[>+- 33UOVU6V%JTAB$A;C>!DC\ ,_2CS#K8V:*
MY[7O%]AH5EIMVRO<0W\R)&T79",F0_[(')^M0?\ "?:(-:_LHR2+<"\:S)*X
M4,$WDY].WU]N: .HHK#;QCX=6S%V=7MOLYD,8?=QN"[L?]\\_3FH+OQQH=KJ
M=O9?;H',BN\DBR#;"JQ[\D^XQ^8H Z.BL1O&'AY([>1M6ME6XR(B6QNPVT_3
M!(!S3SXKT$"Z/]K6O^B,%FP^=I)V@>_((X[\4 ;%%16US#>6T5S;2I+!*H>.
M1#D,IZ$&I: "BBB@ HHHH **** "BBB@ HHHH *QO%/]ER>'[FTU?48-/MKI
M3")YIECPQ!(P6(&>,X]JV:X3XGPQ7,'A6">))89?$=HDD<BAE=2'!!!X(([4
M BL+S2+JT":K\0M&NIA>6]R"DT21JL3 [57S#@MCDYZGI63#IGAZ+4K:X;X@
MZ/)!;NSI$TZ?*6\S('[W:!^\ZX)R.N.*[[_A"_"O_0M:-_X 1?\ Q-'_  A?
MA7_H6M&_\ (O_B:&!YCK,>CZ7!:7.D^*=,O;J*VCL_W5Q;\*L+1EBKRJ/FW#
MO\OHU:_A.W\,Z#J$%]-XPT-RD/$/VQ-R2,B*_P WF;2OR\84'GDG KM_^$+\
M*_\ 0M:-_P" $7_Q-'_"%^%?^A:T;_P B_\ B:=W>XK(X?5K'PQJEQ? ^.M&
MCM+AYIXXO/B+1S2Q^6S%O,&Y0"2%P.O7BK_B!?!WB2YB:]\::>EO#:/;QQ0:
MBD?S-C<S$/\ ," !M(Q74_\ "%^%?^A:T;_P B_^)H_X0OPK_P!"UHW_ ( 1
M?_$TNEBKZW.'LK3P]!=QM=>/]%N+=?,=T$L2N\DD/E.V[S#@<9 QQD\]*AM=
M+\-K?07-]X^T2?RHA $CDBCR@A>(<^8></G..HZ>G??\(7X5_P"A:T;_ , (
MO_B:/^$+\*_]"UHW_@!%_P#$T/4226QYT=$\-_V0MJOCO05NEE#"Y6<!E4($
M4J?.W!P!G.[;VVXXK<TN7PWIOBJXU?\ X3C1WBF0JT*W:(9&(4;I/WFTD;>"
M%!YY)KJ?^$+\*_\ 0M:-_P" $7_Q-'_"%^%?^A:T;_P B_\ B:=PTV,8W7@
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M"O\ T+6C?^ $7_Q-'_"%^%?^A:T;_P  (O\ XF@ _P"$T\*_]#+HW_@?%_\
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MYE2^A"."!A<%R<[PK#TV]:Z;_A"_"O\ T+6C?^ $7_Q-'_"%^%?^A:T;_P
M(O\ XFF))+8Y&XDT2Y1Y7\=>'A>2(8&D$D>SRC&4X7S?O<YSG';%7K&]\+67
M@JV\/#QCHSM;Q*BW'VJ( LIW E=_3('&?QKH/^$+\*_]"UHW_@!%_P#$T?\
M"%^%?^A:T;_P B_^)H#0Y-Y]$N7N/M7CO0'CNI?/F5)(E(D"E5"D2<*!MX.2
M<'GGA+J/PK<H%_X3;1EQ.DW_ !\1'[L"Q8_UG^SG]/>NM_X0OPK_ -"UHW_@
M!%_\31_PA?A7_H6M&_\  "+_ .)H6FP/7<Y"]C\+W,L4Z>-=%$L,T\T8:Z3:
M3)*),';(#@#(X(ZY]JL6LGA2WM_*/C'13EHV)6YB7E493CYSC.XGV]^M=/\
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M]#+HW_@?%_\ %4?\)IX5_P"AET;_ ,#XO_BJ/^$+\*_]"UHW_@!%_P#$T?\
M"%^%?^A:T;_P B_^)H /^$T\*_\ 0RZ-_P"!\7_Q5'_":>%?^AET;_P/B_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.H&.OK6[_P );IP9A)'=Q["4D+P$"-\$A&/J0..W(YY&8+'QOI=[ \WDWT"
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M1-+J]C C%\3D(P9A$'$?!(SGMG.#CKS6[JGB"\L]5T:)G2&.[6/S(0H:3<S
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M6\2, 2,H.$R/ER1ELC^X>Q%=O%+'/$DL4BR1NH9'0Y# ]"#W%/I?N+2YS_\
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MRH'Q( &!X)\8@?\ 8*_^RKN** .&'Q("C \$^,0.O&E?_94O_"R?^I*\9?\
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MBB@#AQ\2 H '@GQB .@&E?\ V5'_  LG_J2O&7_@J_\ LJ[BB@#A_P#A9/\
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M5(OC'3$NXKM?AUXG6XA4K'*-%4,@YX!W<=3^9]:]%HH \_F\=6=Q+YLWP_\
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M_P!L/_1\= '<4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8?C3_D1?$/_8,N?_135N5A^-/^1%\0_P#8,N?_
M $4U !X+_P"1%\/?]@RV_P#12UN5A^"_^1%\/?\ 8,MO_12UN4 %%%% !111
M0 5E:_X;TGQ18)9:S:?:;=)1,J>8Z8< @'*D'HQ_.M6B@#A_^%0>!/\ H!?^
M3<__ ,71_P *@\"?] +_ ,FY_P#XNNXHH X?_A4'@3_H!?\ DW/_ /%T?\*@
M\"?] +_R;G_^+KN** .'_P"%0>!/^@%_Y-S_ /Q='_"H/ G_ $ O_)N?_P"+
MKN** .'_ .%0>!/^@%_Y-S__ !='_"H/ G_0"_\ )N?_ .+KN** .'_X5!X$
M_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZ[BB@#A_^%0>!/^@%_P"3<_\
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M'_"H/ G_ $ O_)N?_P"+KN** .'_ .%0>!/^@%_Y-S__ !='_"H/ G_0"_\
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M<(\Z5NK,:F&HK%TXJ*LZDE\ERZ>AE6OC;6I?AU>ZTTL7VV&]$*,(AC;A.W_
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MT^.,B:V S\S'=SC SE0.>*M7.JZM<7>JO826D-OI9VM'/$6:=@@<_,&&P8(
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M$$%@N0P]"=X/LWK2Z$0EJOWMMOZVZ&EH-A8V=LBV-^U['#$L",9$;8J]!\H
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M\J5^_P"IM/&X=X>G%35U[7\5*W3K='"?\T7_ .XA79?$[_D1!_UVB_K57_A
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M(5.G*FXWYEO=^7Y"7(=K698_OE"%^N*XF%TD\'>%8(6'VC[5;*%!Y#(?WGY
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M:B*/#_/NQ&.1C_9-=W5)^ZO3_,4M9/Y?D@HHHI %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>card2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0- R$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHI%544*BA5'0 8 H 6BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ&J%"@B.](_,$460<80  Y]"35;XC7ET1::5;Z3J4]O>!EO;NQLFG>.#O&I
MX+=.O YI/I\O\RDM7<WT\7Z+)KR:,ERS73@;6$;>66*[PN_&-VWG&>E1OXTT
M<6M_<PO/<Q6-P+:8VT+2_.0#P%SD#/)KA[?2;R3Q?!8QZ7>Q6_\ :Z:FLKPE
M8UM_LP3:6Z!L_+MZUMV]G=^'M-\:G2M,EB(D!L(H8#A_W"*"@ ^;YO3N#0]K
M^OYK_.PEJ[>AU>A:]9>(]-^WZ>93!O:/][&4.5.#P?>K5WJ%K8R6T=S,(WN9
M1#"IZNY!.!^ )_"N?OM/;1OAM-865E+=O!8>6($9E>5MOS<K\V223QR:\STW
MP]*KV4MSHUX]A;ZW%+&D=C-$JQ/#R5C)+!=X7)R>F3C-.RYN45_=YCUK7O%>
ME>''A34))@TJLX$4+2;47&YVV@X49&2?6GZA/H^B)<^(K@!6DBCC>9 7:1<_
M(H4=3EN,#O7%_%'3KR]O+0Q6NH21?8YXXWL(RS/,Q7;'+C_EDV.0>.*GUVQ9
M]*NI[;1+Q+^VO+"ZOMD;%;GR]I/DC)W!0,8 '([TEJK^93WMY&]/X_\ #UMI
M]G?27,OE76_:%@<L@0X<NN,J%/!)Z5TRL&4,I!4C(([UXA<Z/J\%C/>?V5?R
MKJ\&HPP1+ 2\332AH]Z_P @9R>G>NN\=6$[>&-$TU]/>]4,L<T@@DG$;",@$
MQHPW9/ R< X-#TC<76QZ%17E<L>HZA\.M&T*XTK5FNXOL3SN]NX&WS@&7=UW
M*%R?08.:B\.^';C2/$^G74.F7L,<>IZA$QV/M6VVDQKSP$)Y'8FG;5H72YZ9
MJNJVNC67VN\9EA\Q(\JN3N=@J_J15VN+\9SW&K> 8[NVTS43(T]M/]C-N3<*
M%E4D%!DY !K,\3:C_P )+8Z=--H6N?V/;WO_ !,+2:S>.25-AVD(.74-C.*7
M^8ST>JNHW]OI6FW.H73%;>VC:60@9(4#)XKQO2=)U&WOX&U_1=8O 5C_ +%6
M+>'M%$S':[9PC!2I.[^$8J&?3-6N-5UV>#1;V!KFRU"*:-+28[WS^[#2,2)"
M>HP !T&:&-;GK^IZ_9Z3I,>ISI<R6\F"/(@:1@",Y(49 QWJIHGC'3-?EB2R
MBOP)D+QR36CQHP !R&(QW&/6K1AE_P"$2,/EOYOV'9LVG=N\O&,>M>9ZQHVJ
MR^%M!ACTV]:6+PY<02(L#EDD*1X0C'#'!XZ\4WI)K^NO^0HZQ3_KI_F>Q45X
MK=^$M0L[R[FTG3KZ*YBU*S-G(%D(0-%^]<9XP6^\?SK<^%>G:C9W=X]U!<VX
M-M&MPDEK)$KW )W,6=SO?U90 >*$A-Z7/3J***0PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF21V$JLY ')YW&JE]XGDG\8:/K">&?$OV:VM[B&0'2Y-^Y]F./3@T[*]O/\
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M>AZ<]]?.RQ*RH B%V=F.%55')))Z5Y;XETV^EU#68IM&N9[:[U.-A*UK+,@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7FGQ$^(NM>!]5AB32;:XL;A-T,[.P.X?>4X[C
M@_0UZ76%XL\*V'B_1QIU_E5619$D7[R$'G'U&1^-)WZ#5NIG^#O$^IZ[X2DU
M[4]/BM4*M)!%$Q)=%'WCGU(.*7PWXV'B6\$5OIIBA"J6D>Y3<"8U?[GWB/F
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MTFMZG%?7,TMMO(M L9AA?<(]A8_>R<DGOTXJK)\,8+F+[)<ZM<'3X(IHK*"
M&(PK(V2&8-^\ P!@@<#G- %P>.+F._DMKK09H%BO8;*23[2C!7DV[>!U&&!J
M"_\ B3!IUM-?3Z3=#3=TT=M=[TQ</'G*A<Y7.UL$]<=JMKX+E:)O/U3S97OK
M6]>3[/C<8512,;OXMF<]L]ZSK_X<3:A9OIDFL@:5&\TMG +;YHGDW?>;=\P7
M>V!@=>3Q1;H,Z?0_$-KKXF>S!,*)$ZR$_>#H&'TQG%94WC=;;6+BTFTJX6TA
MNC9_;1(A0S; X4KG<,@XSC&:?HOA6;PYJUQ)IUT#8WMTT\T#1_ZM=F JG/\
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MV0NY0I^7]372V$5U!9K'>W*7,X)S*D7E@C)P-N3C P.O:D]5H&S/(_#/Q?\
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M<<<?0>O7U /3J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4[QK)&Q!9'"D;E.T9!XH$4+KQFMK?:U9_8&DET^XM;6$+*/](DG52@Y&$&6
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M8;?;'IK.UNNXGEE96+9^\2';.>YS0!6\-^*8?$EWJ4=O"HALY J3)+O$RDL
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M_H8+7\F_PH ZRBN3_P"%G>"_^A@M?R;_  H_X6=X+_Z&"U_)O\* .LHKD_\
MA9W@O_H8+7\F_P */^%G>"_^A@M?R;_"@#K**Y/_ (6=X+_Z&"U_)O\ "C_A
M9W@O_H8+7\F_PH ZRBN3_P"%G>"_^A@M?R;_  H_X6=X+_Z&"U_)O\* .LHK
MD_\ A9W@O_H8+7\F_P */^%G>"_^A@M?R;_"@#K**Y/_ (6=X+_Z&"U_)O\
M"C_A9W@O_H8+7\F_PH ZRBN3_P"%G>"_^A@M?R;_  H_X6=X+_Z&"U_)O\*
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M)%K97E[Y>DW]SIEA,(+S48@OEQ/D \9R0,C)%4U9V_KI_F):J_\ 77_(UO\
MA!/"?_0MZ5_X"I_A1_P@GA/_ *%O2O\ P%3_  K*U/XBQ66H:I:6FC7NH-IT
M23S20,@3RF7=NR3V';J:ZK2]0@U;2K34;;=Y%S$LJ;A@X89&?>ETN']?U]YE
M?\()X3_Z%O2O_ 5/\*/^$$\)_P#0MZ5_X"I_A7044 <__P ()X3_ .A;TK_P
M%3_"C_A!/"?_ $+>E?\ @*G^%=!10!S_ /P@GA/_ *%O2O\ P%3_  H_X03P
MG_T+>E?^ J?X5T%% '/_ /"">$_^A;TK_P !4_PH_P"$$\)_]"WI7_@*G^%=
M!10!S_\ P@GA/_H6]*_\!4_PH_X03PG_ -"WI7_@*G^%=!10!S__  @GA/\
MZ%O2O_ 5/\*/^$$\)_\ 0MZ5_P" J?X5T%% '/\ _"">$_\ H6]*_P# 5/\
M"C_A!/"?_0MZ5_X"I_A7044 <_\ \()X3_Z%O2O_  %3_"C_ (03PG_T+>E?
M^ J?X5T%% '/_P#"">$_^A;TK_P%3_"C_A!/"?\ T+>E?^ J?X5T%% '/_\
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M*G^%=!10!S__  @GA/\ Z%O2O_ 5/\*/^$$\)_\ 0MZ5_P" J?X5T%% '/\
M_"">$_\ H6]*_P# 5/\ "C_A!/"?_0MZ5_X"I_A7044 <_\ \()X3_Z%O2O_
M  %3_"C_ (03PG_T+>E?^ J?X5T%% '/_P#"">$_^A;TK_P%3_"C_A!/"?\
MT+>E?^ J?X5T%% '/_\ "">$_P#H6]*_\!4_PH_X03PG_P!"WI7_ ("I_A70
M44 <_P#\()X3_P"A;TK_ ,!4_P */^$$\)_]"WI7_@*G^%=!10!S_P#P@GA/
M_H6]*_\  5/\*/\ A!/"?_0MZ5_X"I_A7044 <__ ,()X3_Z%O2O_ 5/\*/^
M$$\)_P#0MZ5_X"I_A7044 <__P ()X3_ .A;TK_P%3_"C_A!/"?_ $+>E?\
M@*G^%=!10!0TS1-+T5)$TO3[:S20@NL$00,1TSBK]%% !1110 4444 %%%%
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MJ_![G/ R1BH;WPWXJM;37O#-AID%QI^L7;SIJ+7"J(%D(+AD^\2,<8]:W/\
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M$_Z#O_DI/_\ $4?\+?\  G_0=_\ )2?_ .(H [BBN'_X6_X$_P"@[_Y*3_\
MQ%'_  M_P)_T'?\ R4G_ /B* .XHKA_^%O\ @3_H._\ DI/_ /$4?\+?\"?]
M!W_R4G_^(H [BBN'_P"%O^!/^@[_ .2D_P#\11_PM_P)_P!!W_R4G_\ B* .
MXHKA_P#A;_@3_H._^2D__P 11_PM_P "?]!W_P E)_\ XB@#N**X?_A;_@3_
M *#O_DI/_P#$4?\ "W_ G_0=_P#)2?\ ^(H [BBN'_X6_P"!/^@[_P"2D_\
M\11_PM_P)_T'?_)2?_XB@#N**X?_ (6_X$_Z#O\ Y*3_ /Q%'_"W_ G_ $'?
M_)2?_P"(H [BBN'_ .%O^!/^@[_Y*3__ !%'_"W_  )_T'?_ "4G_P#B* .X
MHKA_^%O^!/\ H._^2D__ ,11_P +?\"?]!W_ ,E)_P#XB@#N**X?_A;_ ($_
MZ#O_ )*3_P#Q%'_"W_ G_0=_\E)__B* .XHKA_\ A;_@3_H._P#DI/\ _$4?
M\+?\"?\ 0=_\E)__ (B@#N**X?\ X6_X$_Z#O_DI/_\ $4?\+?\  G_0=_\
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M/8:_I4VF:G!Y]G-M\R/>R[L,&'*D'J!WJ]03@9- '#_\*@\"?] +_P FY_\
MXNC_ (5!X$_Z 7_DW/\ _%UU":[I,FGQWZ:C;-:22"))A("C.3M"@^N>*T*
M.'_X5!X$_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZZ^[U&RL8Y)+JZAA2
M/;O+N!MW'"Y],G@59H X?_A4'@3_ * 7_DW/_P#%T?\ "H/ G_0"_P#)N?\
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MAI4FK6:Z@2 +<S*'R>@QZ^U78KVVGN9[:*>-Y[<J)HU;)CR,C([9'- ''?\
M"H/ G_0"_P#)N?\ ^+H_X5!X$_Z 7_DW/_\ %UW%% '#_P#"H/ G_0"_\FY_
M_BZ/^%0>!/\ H!?^3<__ ,778W-[;69A%S/'$9Y!%%O;&]ST4>IX-3T </\
M\*@\"?\ 0"_\FY__ (NC_A4'@3_H!?\ DW/_ /%UV-S>VUF81<SQQ&>011;V
MQO<]%'J>#1->6UO<06\T\:37!*PHS8,A R0/7CF@#CO^%0>!/^@%_P"3<_\
M\71_PJ#P)_T O_)N?_XNNXHH X?_ (5!X$_Z 7_DW/\ _%T?\*@\"?\ 0"_\
MFY__ (NNXHH X?\ X5!X$_Z 7_DW/_\ %T?\*@\"?] +_P FY_\ XNNXHH X
M?_A4'@3_ * 7_DW/_P#%T?\ "H/ G_0"_P#)N?\ ^+KN** .'_X5!X$_Z 7_
M )-S_P#Q='_"H/ G_0"_\FY__BZ[BB@#A_\ A4'@3_H!?^3<_P#\71_PJ#P)
M_P! +_R;G_\ BZ[BB@#A_P#A4'@3_H!?^3<__P 71_PJ#P)_T O_ ";G_P#B
MZ[BB@#A_^%0>!/\ H!?^3<__ ,71_P *@\"?] +_ ,FY_P#XNNXHH X?_A4'
M@3_H!?\ DW/_ /%T?\*@\"?] +_R;G_^+KN** .'_P"%0>!/^@%_Y-S_ /Q=
M'_"H/ G_ $ O_)N?_P"+KN** .'_ .%0>!/^@%_Y-S__ !='_"H/ G_0"_\
M)N?_ .+KN** .'_X5!X$_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZ[BB@
M#A_^%0>!/^@%_P"3<_\ \71_PJ#P)_T O_)N?_XNNXHH X?_ (5!X$_Z 7_D
MW/\ _%T?\*@\"?\ 0"_\FY__ (NNXHH X?\ X5!X$_Z 7_DW/_\ %T?\*@\"
M?] +_P FY_\ XNNXHH X?_A4'@3_ * 7_DW/_P#%T?\ "H/ G_0"_P#)N?\
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MYV.<L>3][-0V?@CP[I^HI?VNG+'<1R/+&WFN0A8$-M7. #D\ 8]J7]?A_7W
M<#9>*O%3:%/JS37;PW6EW%UOEAA6.WE4;D\K'++U'S ]!5O4+SQ;9:+I5T=5
MU&\BNH6NKE]/MH#/$2BE0L;#YHQ\V<<^]=C!X%\-VYO/*TT 7<3PR+YKX$;?
M>5!GY ?]G%6-0\):+JEM:07-HVVT3RX&CF>-T3&-NY6#$$ 9!/-#VT_K?_@
MM]?ZV+'A^_74_#]A>I="Z$T*MYXB\OS#CD[<G;SVK2J&SM+>PLX;2TA2&WA0
M)'&@P% Z"IJ;LWH):+4****0PHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&8*I8G  R32U'/$)K>2(D@
M.I7([9%)WMH-;ZG"?\+!U)K)]>3P_N\,I*4-U]H_?% VTRB/'W<]LYQS5B?X
MB6L>OZK:1FQ:RTRU\^65KL"21B,[57'8X4DG@L*YI7UR'P,_@+_A'M0;4BC6
M:78B_P!%,18_O3)G ^7MUS6Q'H$MO<^,HA82.KZ=!%;OY!_?,(6!VG')SCIW
MQ1+1-KL[?=_G_6@)7:3_ *U_R_S-CPEXLN?$*Q27$>FQ1RVGVD"VO1*Z_-C#
M+@8QT)Z9!%;-KXCT2]MKFYM=6LIH+7_7R).I6+_>.>*\\7P]JD]M+;6UE-!)
M+X2CME9HRB^=DY0DC ;U'7FHM0MKC6O#4L6E^$[NQDM(+19I9(/+DF\MP6B1
M"/G  SG)!Z5<K7:7]:M7)CM?^MCT<^)=#&E#5#J]D+ MM%SYZ[-WIG/7VJ]:
M7=M?VL=U:3QSV\@RDL3!E8>Q%>42Z0\NFSZHD/B*-WU)9X[A;%%DB81[/-^S
M@9*$<$8SQGI7:>"XM3;P:(KZW2TNF:41E+86Y8$G;(T8^ZQZD5+V;[#ZHUX_
M$.C37-U;1:K9O/:J6GC6=2T8'4L,\8[^E9?@WQ2WBO3;G43':Q6ZS,D0BN/,
M8*"?OC VDC!QSP17%^'=)NWN?#&G#0+JSN](>4ZC=RP;8Y%*L"%?_EIO)!XS
M77^ M-EM? MO:7%L]K,QF#H\91AF1L$@\],4/1-KL'9>91M?'&K7KPZC:^&Y
M9_#\USY"7,4NZ<C.WS?* ^YGWSCFNJNM;TJROX;"ZU*T@NY_]5!),JN_T!.:
MX3P[JFOZ#I6G^%(?#UX^H6LPA>ZDB_T0P;R3() >NT].N:H^)=+O/M_BFP?0
MKN^N]9:(Z?>1P[HT 4##/_RSV$$\T]-$OZV_S?W6#O?^M_Z_$])NM;TJROX;
M"ZU*T@NY_P#5023*KO\ 0$YK-TWQ5:SV&IWNHO!86]C?2VADEE 4[" "2<8)
MSTK@]<TB_BE\2:9/HEWJ-_JP@%C?1P[XUVHJ_,__ "SVL"W/6F2:)K-OI$<T
MEO>XM/$4]Q/Y=MYDC(5*B58V'SC)SP#Z]J2_K[_T_4/Z_#^ON/5+?5]-NWA2
MWO[:5IHC-$$E!+Q@X+#'49[U7O=;MX?#=WK5F\5Y!!;R3(8Y 5DV@G 89[C%
M>7ZM8WN@>$M/US3H;Q;O[7<1+%=HL<FRYRH^5>@W[6"]1GM7?7VCG3OAK=:/
M:1/*\6F/ B1J2SMY9' '4D_SI2TBVOZZE1LY)/K_ )V+AUXCP8?$'V<9^P?;
M/(W_ .QNV[L?AG%#:\P\%GQ +<;OL'VSR=_'W-VW./PSBN2M-:FOO ,N@+H&
MO0WB:.\.Z?3W1&=8L;03U)/0=Z+36IK[P#+H"Z!KT-XFCO#NGT]T1G6+&T$]
M23T'>JJ:<W+\OQ%3UY>;Y_@:&A^-]3N]4TFTUC0X[*/5X&FLYX;KS0V%#;6&
MT8X-=O7&>#?!=CIMGI6J7 OI=2CLT0"\G=_LY91N55;[GICM79TY))V7G^9$
M7=7"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,\MW9ZS#:?:8($7[2DB%U#CHH]2O/ K>@\<Z?-K LOLMVEL\[VL5^RKY,DR
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ IKKOC9=Q7<",@\BG4C':I/H,TGMJ!Y\GA+
MQ1?7VE6^LWVFSV.EW8N8[Y0YNYMIRJMD87KS@U#'X#UH^(K?4+B33IFM]0DN
M/M;R2&>6)PP"<KA0NX84'!QVQSHZ7\2[+49K#S='U2SM;^;R+:\FC7RGDR0%
MR&)&2".E=J)$+;0Z[NN,T[: ][?UU.)T;P9J&G6GA&*::U9]&>8W!1F.X.K
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M?TN/PO>:G;W5Q>[+_P .S[GCMH\GS&&5^3&0<@]Z]F1%CC6- %50  .P%+@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BB@D 9)P* "BH+>]M;O=]FN89MO7RY V/RJ>@
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M?=M96VG#8.<'TH>1(E+2.J*!DECB@!U% (/0YIHD0OL#KOQG;GG'2@!U%%%
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MD=XF\YNQP!U!^;@9R>*PK?Q!K%Q#J31ZS(5TZ*::,QO%*)=OEE0SA &'S,.
M/J<9KT_SHFX$B'.1C<.<=:KW>I6MC;I(Y+(TJPJ(QN^8G %*]G=@UI8X_P -
M7SW_ (MADN-3:YO/L,YN+4[/]$;SD&S  (Z8YSG&>]0ZUK>L0>(O[+-^]G90
MW0ENKS:OR6\H C&2,#Y]XR>FT5T#^,--@EE$MO>Q1I(L<DYMSY:NRJ0I8=#\
MRCGN<5K1ZC;7-C!<Q!I8KC8 %7)&[&-P[=>:.WD'?S//;O5]0C-OJ<=^TEP+
M"\2V=B@6=%G0"7&WD[/GX&/ESC%:#WMWJ7P[\0&?4%G6(2+%<P3"0E H)!<(
MJMSN&0.G&<@UUFJZS!I!M4D@N9I+ES'%';Q[V)"ECQ] :=IVKV6H6PFMMRP!
M5(9TV#DD;>>A!!!'8T_Z_$?4\_O=1U+2([V_TK49)UGO98PC;#'M%NK>:"%S
MGC.>1CM6Y8:O?R^#M6N3J=NS0.RV]X)/-51M7[TBQA3@DC<%('?.#79%T#A"
MR[B,A<\D5"EQ#YXMD7("%MRCY!@X(SZ\]*72PDK'FHU.^NHFU.#5+E9[&PN6
M$@,4@F*2KA2X7#IVR "?8T]/%.HSR:K]GU1R#9S2IN:)GA=954?(%^3 /W6+
M$XYQW]+66!40+)&%/"8(P?I2[XEWG<@V\OR./K3%9GF5WKNN6.H7EG_;<:/
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MGL+2U9K&VO)KZ6V:[F0>6$2+S.460[6/W<;O>H'N[L?!_P /7$=T([EI[/\
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M2&6=G:3;"48G.642%N3D G%;<+^(V\;QM);ZHAV217)Q,\3#[/E6!_U0!<'
M )SU/.*36G]?UT_(.O\ 7]=3TA=%TI84A73;,1)"T"IY"X6-OO(!C[IP,CH:
M?>:7I^H6B6MY8V]Q;H05BEB#*".F >.*\HBM=>T;1&U!I-7!M=,L]1E%W-*0
MTR.WFQ_,>"4X*_3BNEN8-9C^&UBV^^DN9I8KB_\ L[,9Q$[[Y%3'S<*< #G
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M=;DNGMKW[<K^889#NS;B$?=/&.$[9!KHO%VB$:7X56.WU&9+.<*XA,CNH,3
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MBR0K&P(*CC*Y![YZ"N?NO .O2VGV1&TH1V=TUS;3 NL\^Z;S-K.!F,<]MV2
M>U-V3LA+8['5_&?A_1-+74+O4[?RI(C- J2!FG4?W!GYNHJ4^*=%VVJ_VE:"
M>[A$]O"TZAI%(R,<]ZY";X=WMQI,5LYL=ZZ9=VY5G=PDTKAU(+ D@8.3P<]!
MZ&L^"_$>K7ME)YMA%#$MJS(L[J$:/.]<!/WF<\%CQZ#.:3_K\1HZ6W\0^';B
MZTVZNKJPMM5N+=1#$]PC2!9,':I!PP)4<C@XI==\2W.EZQ9Z78Z-/J5U<PO,
M%CGCCVJA .2Y _B%<U#\/M333_)::Q,PL].@5MS<-;R;G.=O0CI^N*W]=\(6
M_B#Q3IU_J%O:W6GVUM+&T,P))=F4J0,8X /?O5-*^G?\-1+;^O(;?ZQH&H64
M\'B>.RM8(+E8_+O+B-E,@17['@C/0^F>AJ>\\<^'+/2&U)-3MKBU6=+<M;RJ
MP#L< 'GCCGZ FL:Z\#7=UJTT[FP>UDU*2Z\J7<P,;6WD@%<#)W<XST[YK/M/
M NOP^';ZSDFLV<SVLMK;O</*B>4P)'F,FX*0,!3NVCO25OZ^0?U^9UWBKQ79
M^%-+AOKF-YDFF6)5CZX()+?0*"3]*LW?B;0M/N5MKS5[*WG90XCEG525()!P
M3TX-8WB;PA<>*=5M#<WSVFGV]K*F+9AYC2R84Y#(1MV9'KSVK%@\!:VR1&]N
M+"65%L(]X=SN6WE9F)RO4J1^.?K0M=_Z_K<'_7]?@=I#XDT2XFM(8=6LI);M
M2]NBS*3*!W49YZ'\C3+?Q#X?GN[I+?5-/:XA0M<!)EW*J$@EN^!SUZ5P6E_#
M35M/\0M=R7%K-:SWHNY!]HE'D[97=0J  -PPZG .[K5NZ^'.H7.GBV^TV<;%
M-05W4L<F>0/'_",@ 8/Z9I=+CMK8Z*U\?>'[EKUWU*TAM+:58DNGG7RYB4#_
M "GVY&/:KQ\6^'1;RW!US3_)B=8WD^T+M5CT!.>I_H:Y*W\$:W/JAU"^&EPM
M)>?:&A@D=E4?9C#@909.X@_2LFX^%^MK<Z=>07%FTEG80VC0"XDB61@CJ[;E
M7/\ $,>HW#BF(])N/$6BVM]%8W&JV<5U-M\N%YE#/N^[@9YSCBL^+QOHLWAW
M4==CGW65A))'*0022IQQSWXQZY%84_@*]:.9(I;/FVT^"(EGRI@DW/U!(!&,
M<D^OK5Z'PK?CP;X@T.3[(KWLMTULZL2"LI+*7XX()QQGI2>SM_6O^0UTN;MG
MXDT:^N+>V@U.T>ZGA6>. 3*7*$9!QGTK/UOQ:VEZD]C9Z1>:G+!"+B[^S%?W
M,9) ."068X/RCGBL+3?!>L0ZO:RW)T]+5;U-1DDB=C*L@B$9B7*@%,CKD<<8
MK4UC1/$,6OW>I>'KBRC;4+9+>=KHMF H6VR( "&X8_*<<@4W:XEYFZ->TK[<
M+!M0MTO3'YOV9Y LH7&<E3R..:KVWB[PY>310VVN:?++*XCC1+A268C. ,]:
MYB?P1JLNM2,9[-[-[[^T#<MD3F3R?+\O &-N><YZ<8JO:_#W4H(;93+8[HHM
M-0D,W6WD+28^7N#QZ]\4))[@]CK6\8>&DF>)M>TY9$?8R&X4$-G&",]<BKCZ
MWI4>I'37U&U6^">8;<RKOVXSG;UZ<UP=Q\.M3EL[B(36'F26M_""6;[T\PD0
M_=Z #!]^F:MS>"-4DUF0B6R^Q/>_VAYY+>>'\GR_+QC&W/.<].,4N@^IV&F:
M[I.M>8-,U*UO#%C?Y$H?;GIG'2N9/Q(M(VOYY]+O$TRT,J?;5*.I>,X*LH.4
M)(PN[&>*L>%/"EWH-Y;2S/;%(](M[)Q"3S(C,2W(''S<'K[5S>I?#O6]2U"^
ME=M*B>2*Y3[;"&26[$BD(LJ*H7Y<C+<D[13>CT!>9WMGXDT:^G@MH-3M&NIX
M1.D F4N4(R#C/IS52Z\8Z1'9?:K*Z@OT%W%:2?9Y5;RVD<*,_3.:Y>'P'K$E
MTD=R^GPVKW(OI)H68S))Y/EF)<J 5SSG(XXQ0W@/5[_PM_8M\-*@5#:0B6UW
M"22*%OF9GVYW$=%Q@'//-#W_ *[_ -?F);?UV.OO_$EE::7;ZC PN[>>YBMD
M>%P02[A,Y[@$_I3F\5>'T%V6UJP LSBXS.O[HYQAN>.>/K60WAG4Y?!^EZ/)
M+:&XL;JW;S%)"O%%("#]WABJCCIGOWKFI/A_X@,U\4DLA;L^^&W6[F W>;OW
MQMC= <9X!<;CG&*'Y?UM_P $/Z_,]".O:0($G_M*U\IX&N5<2C!B7&7!]!D9
M-1R^)]"@NI;:75[))X8O.DC:90R)C.XC/3'-<5>^!_$<VBV=NEU83W?]G7-A
M</.[*%$K!@P*I\Q&T D@9ZU5UWX>>(]7O9R+JP$.V41%IW48>#RP"@3&01RQ
M))'IC%%E<#O/^$K\/_V<VH?VU8?8UD\HSBX78'_NYSUJRVMZ6E[;63:C:BZN
MDWP1>:NZ5?51GD5QM[X*U:/5Y=4L/[-E=;M9HK6=F$;+]G\EMV%."#R.#D>E
M-D\"ZFWB2RO2]D;8+:F=8WDA6)H<\1Q+P0>V3QSP:%:Z#H=)KWBRR\/ZII-A
M<QN[ZC-Y89>D0R!N;VW,H_&KDWB+1K?4O[.FU2T2]X_T=IE#\C/W>O09KF/$
M_@2]\3:KJ%Y)J;VJ_9$@L4@88R#O)ERA(&\+]TYPM<O)8:K)XRBTIX8Y)GU$
M7LT@@E^4FV*,1(5V&//0YSSC Q4K;S&TCTFS\6^'=0NHK6SUO3YYY21'''<*
MS,0,\#/I3Y/$^@PFZ$FL6*&T8)<;IU'E,3@!N>.>*X;3OAOJ-AJ6F2;[-H$B
MM/M16:1=LD ZJJ@!\\8+$8YR#TJ.W^&NK)> R36C1072R12/<2LTD?V@2ME<
M;5.!C'.3SD55E>W];BZ'?6GB;0K_ ,W[)K%C/Y47G2>7.IV)_>// J)_&'AN
M.W@N'UW3UAGSY3FX4!\'!P<]B:XZ;X<:E-9S0?:;2,R6U[%N1F^]+.)4S\HX
MP,'],U'!\.]5=+V:<V*375C=PE#<22[9)1&%)9ASPAR0!U'!ZTAVUL=SI?B+
M3M8U+4K&SF#S:?((YL$=2,\>W4?4&H/$'BO3/#JQQW$\37<K(([7S0)'#.%R
M >H&<_@:R=,TG6_#MSJ,L$%G<+>W-J5(9RVW:D<N1CC 4L#GZU6\2^#]6U/7
M+JXL6L&MKW[(96N68/$8)-V$PISN!]NE.RNA=&;][XPT&RM-2G.I6\QTU"US
M%#(K.G;&,]<\?7BIK;Q1H=UA8]5L_,^SBY:/SUW+&1G<1GI@]:XH> M?N)]8
M>[N;(BZL+FTB(F<@M)('1MFP*@[$#)SSSFJ4_P ,=9OVNTN)K.))U>972XE;
MRY6B"; F -N1]XYRN!BDMM1NUST#0O$MCXBN-033W2:&SD2,3QN&23<@;((]
M,X_"DN?$MG9^)5T:Y(A9K99UF=P%):3RU3ZDU3\*:-J>FW.KWFII912W\T<B
MQ6CLRH%C"8)*CGBN=O?!OB?4[Z;4KZZTZ6\MQ"EKM9E$ZQS^;E\+\A(PO -/
M2Z%T9V-SXJT"S"FYUFQA#LR+YDZKEE;:P&3V/!JTFL:;+J;:9'?VS7RIYC6Z
MR@N%]=O7%<&O@#5I;:X%S)IYFFM-0BPKN562XD#J02O0#()Z_6K.B>!]2TWQ
M:E_/+!+:)(UP)//D+AVB$94)PO8_,<\8&*%Y@_(W)?%IA\0MI+:/? ,7CM[A
M@JK/(B;RJ@G.,?Q8QFI?#OB277KB_@FTBZT][)UCD\]T;+$9P"I/(!!/U%4;
M?1O$#>/I=8O1ILVGJAAM1YTGFV\>.<+LV[F.,G/3@58TBQU30X+*V,<$\EW?
M3S7TJEB%#%W!!P/]A>?PI1VU_K7_ "!^7]:"ZSXOCT/5HK6YTV\-H3&LE\ !
M$C.2% R<MTYQG'&:J67Q"T^YT:_U*YL[JT6TCCE$4@#/*D@S$RA2?O=,=N]1
M^(?#VO:SXHMY_P#B6R:-!'M2&:60.CL"&EVA"&8 D*"<4SPQX2U/3-.U)-0D
MM#<36<5C#Y+,5V1(RJS$C()W$D#./>EKRM]=1Z77R%E\5I=WOA^63PU=3)>F
M.2SN=\9$;21DG SN^52V3CIFNEUS54T/0KW5)(FE2UB:5D4X+ =A6-H_AN\L
MKO07NI8'BTO2_LNU&)S,=@+#('&U2,]>>E2:G9:IXD\$ZII\T<%O>W2S01[M
MP3;N(1CP2,J >G>JG;51\_S%'=7,;4O$4FK0V^F:EX*N+FYN"+B"Q>Y@</&F
M"9"=V  2!@\DFK3^/Q*NG+I6B75])=P2S&$2QQ-"(F"NK;B!D$XP#4;^#+C0
M+VQU+PG::9#<1P/!<V\Q:..4-M.X,H)R"H[<BLR;X5C4(;&#4YK>=([:Z\Z1
M=P*W,SAPZ#'0'/4^G%)^7];_ *6_(%TO_6QWNC:I!K>C6FIVRNL-U$)%5QA@
M#V-7JSM!MKNRT&RM;];874,2QO\ 9>(R0,948&![8XK1IRM=V$KVU"BBBD,*
M*** "BBB@ I';8C-@G S@#)-+4=Q ES;2V\F=DJ%&VG!P1@\TG>V@UOJ<?#\
M1["6SNYO[.O!-;3P0M;JT3N3*<)]UR <]02"*27XD6D<:D:1J3S*D[W$*"/=
M;B%@LF[YL'&<\$YJI=?#9;726MM,O[MYI9[/?),\:F..%\C9M0#<%)ZYR0/>
MEN?ASYNI6R1ZC>)9FVN5O+A95$T[RNI8-\N,$ C@#'&*K3^OZ_KH+^OZ_KU+
M4OQ'M?[3:PM-'U*\D,GEPO"L>V5O+60@%F&,(V>:L6_Q!TRZ:)(+>Y9YS;B!
M" &D$Q(R!G^$JV[TVGK4DO@/32':UN[VSG^T_:8IH'7="WEB(JN5(VE5Q@@U
M-;>"-&M-0T>]BCE$NDP-!;Y8$$-W;C)/).>/O&C2XM;&+JOQ""ZB=+M+:6VO
M$NX$S/L;?$TZQN=H8E>O&X#CFMG5O&=EI&K&QDM+N98A$;JXB53';>8VU-V2
M"<GT!Q6=%\,M)CODNC?:@QCE\R.,M'M7]\LV/N9/S+U))P<9Z5IZKX-L-6U;
M[?+<7<8D\L7-O$X$=SY;;DW@@G@^A&>]"V5_G^'_  1O=V*'ACQ)J5_HVLZM
MJ5M-LM[J9(;>.-=P2,D;00QW'C!)QSGMS5,?%.P:%FCTF_F>))GG2%X7\I8M
MN\E@^TC#@\$^E= WA2P;P[?:(9;C[->R2R2-N&]3(Y<X.,8!/&0??-9=M\-]
M+M_MC-?:A+)>030RNS1CB4(&("H #\@QV'/%)?HOR'I^/X7_ ,C5U[Q-!H6C
MQ:D;6:YADP1Y;(@5=N[)9V ' ]>3Q6$/B;92R!;71]2N4=MD4B>4 [^4)=O+
M@CY#GGCBMG6O"5GK=G86TEU=0?8LB-XBFX@IL(.Y2.0>N,CMBJ=A\/=)T^.W
M2*XO6$$WG+O=.3Y'D<X7IM&?K[<4=_P$ME?YD$OQ,T2.YLX@D[)<PQ2F3*#R
M_-&44J6W$GO@$#(S3+;XE65Q9F9M*U&*5XX)+:!Q'NN!,Q5-N&P.0>N/6IX_
MAUI<,UH\-Y?QI!;Q0.BR*!.(P0A<[<Y&><8!XR*=)\/M+:UAB2ZO4>"U@MH9
M5==T?DL61Q\N-V3SV]J;L!CVGQ+:ULYI-2TR]ED6:Z=EB6,&"&*0*=^6Y(W#
MIG-:-Q\2-.M;%II["[CN5N6MC:NT2N"J"0G<7VXVD'KG)QUJ1?AQI7V6:![W
M49#-#<0R2/(FXB9E=S]SKE1C\>M2WW@'3KPRR+>7L%Q)=&Y$T;)N1C&(R!E2
M,%5'4$YYS2Z#ZE2+XDV-U/LL],OIH6?RHKD!!')(8?-5.6SDK[8S3)/&NI)\
M.],\0C2RUW=RPHT(Q@!W"Y'S=#VR>I&>]:<'@?2X"FR:\.R\6\&Z0-EQ%Y6"
M2,D;>?7/>G_\(=:_\(C#X=^W7GD0,C13[E\U-CATQ\N., <CM3T_+\]1?U^
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M'7'6J-S\.]*N;2WMOM-[&D7G*Y1US-'*^]XV^7[I/I@C'6A=+_UK_7Y ^O\
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M9Y<_E^4 &/S9*CKSG/'2M/P_XXTWQ%JLVGVT<L<J(SHSLA$BJVUB K$C!_O
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MK:U=FA5-L#2NZ;CELE2=N ,G&<UU&A>-],\0:Q<:=:K(LD:N\;LR$2JK;&(
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M$"_?"[0W3KMXSZ<55L]!\/VRR166E:;&JR*9%B@08=3N7.!U!.1Z9HTOY?\
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MACG\:4=+?U_6@/7^OZZGG5M\0O$-SJ&J2(VG&QTZ\BB9/)8O*CW#1##;L X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M($+2,(7*9"AB@;&"P!!VCGGI5ZW\06%SH\VJ SQVT.[S1-;NCIMZ@H1NS^%
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M[4 =#16)HOBS2/$%S);Z?+,\D<2S$20/&"C$A6!8#(.."*VZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *CN(O/MI8=VWS$*YQG&1BI**35U9@G;4X>+X=^58&U_M3.;6RM]WV?\
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M*$A%49.W"<L,\]16[X5=W\-VH;.$+QIGNBNRH?\ OD"J:L*YLT444AA1110
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M) )'(R.E&!N#8&1QFEHH 8T8:-T&4W Y*\$9[_6FVMM#96D-K @2&% B*.P
MP*EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>card3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0+ Q\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)*RM(S0J2Y7[I)QR1V]*4:B3O_6]R:690IRYG%[6Z=[G*6G_ "'5_P"NL?\
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MK>*%0H4"- H &<#CL,G\Z3G[O*17Q\:E#V2C_5V_U)J***S/,"BBB@ HHHH
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M2;:^\KRO.3=LW9V_C@?RH NT5SEMXJ^T>+9="^QA=F[]\)LG@9Y7'&?K71T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 <3XJ\<RZ/<R6-E9.9U0$SS*0BY'4#J<9'/3/%>:7VH7NHW9G
MO;AYY03SN)#$=@!CC/8=/;M[KJ.E6.K0>3?6L4Z#[N]<E?<'J/PKSGQ!\/+J
MT+7.EE[J$ YBS^\7CJ/[Q'Y^QH X8 X4YSWR6ZCZ]N3G@UR?Q$_Y'S5,#'S1
M\8QC]VM=A)%)%<2>9&\<BL >/F5L\\GGOWZ<<\&N/^(O_(^ZI_O1]/\ KFM
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MDG/R#GVZ8_+OFO1*X>QTS4(_B3/>/:RBS;?B<J0IRO3T[?\ UQT/<4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &-KGAC3-?B(NH L^/EN(P!(O&.O<>QKS[Q)X-AT;6KWQ#_9G
M]JW,RB19YP##;84+_J^=QXSN;@9Z<5ZU10!\]W%W<7TQENIYI9&8QAI#D@=<
M D^_3.!@#'0U7(&%8!5(8A.,@$XP?UZ]>:]?U[P%8:FWGV+"QN1S^[7Y&/49
M Z'/?]#7FFJZ!?Z#="&\B*)NVI)&,JZ C[N ,G&..O'TH&>J> B#X+L"!@9E
MQ_W]>M;6=5@T/1KO5+E)'@M8C*ZQ %B!Z9(&?QK)\!$GP5IY8@G]YT.?^6C5
MJ:YI46NZ'>Z7-(\<5U$8F=,94'N,T",JV\;Z==:=IUZMO=JE_J']G1H0A*R_
M-R2&*E?D/*D_SH;QOIR7:*UK>K9/<_9$U$QK]G:7<5V@[MWW@5SMQD=:BMO
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M&TC?>(8KN4$\D ]:JZ5X).CZ7?V-KJ\RI=#"O]D@W1_,2<_)\X.XC#YX/&*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_L+4?\ H;-9_P"_5G_\8KA?"/AW55UBQDU>VFACGLI;F8QQR@S/(3NAG);
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MXJM8])OYM*U)H=)N4,D:!B\LDCEIV\L#<X&\*"./E)H$>F?V%J/_ $-FL_\
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M_?JS_P#C%>.6MEXOM)+/[7IFJS6UMJ(OVBCMY"9I'B#[#@<*K#:2>,M[5O\
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MP6Q^%+X3_P"0/<?]A.__ /2N:FU9V!.YN4444@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HIDLBQ1-(^[:HR=JEC^0Y-4O[9L_2Z_\ Y?_
M (F@N,)2^%&A16?_ &S9^EU_X!R__$U>C<21JZYVL 1D$'\CR*+"E"4?B0ZB
MBB@D**** ,"/PU<6QF%GXCU:VAEGEG\F-+9E1I':1@"T);&YCU)I_P#86H_]
M#9K/_?JS_P#C%;E% &'_ &%J/_0V:S_WZL__ (Q1_86H_P#0V:S_ -^K/_XQ
M6Y10!A_V%J/_ $-FL_\ ?JS_ /C%']A:C_T-FL_]^K/_ .,5N44 8?\ 86H_
M]#9K/_?JS_\ C%']A:C_ -#9K/\ WZL__C%;E% &'_86H_\ 0V:S_P!^K/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %+6(6N='O(46W9WB90MQGRR
M2/XL<XKSC_A%M1_Z!_@W_OJ7_&O1]7=(](NWDD$2+$Q9R0 HQUY5A^8/TKSS
M^TM,_P"@];_]_K?_ .1:UI-J]CVLKE55.7L^_9OIY-$?_"+:C_T#_!O_ 'U+
M_C7I>G1-#I=I$RQ*R0HI$.=@( ^[GMZ5YQ_:6F?]!ZW_ ._UO_\ (M>CZ<RO
MIEJR.'4PH0P((88'/  _(#Z"G4<FM?U%FDJKA'VG?LUT\VRS1116)XP4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=M7^0LRYN6/,[Z_W?_;2S11161Y(4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5M0E:#3[B
M5/O(A(^[_P"S$#\R!7(?\)#>>O\ X]9__'ZZK66=-%O&C-P'$+%?LZ[I,X_A
M'<^E>:?;M3_YZ>,O_!>G^-:4X\USU\NP\:L)-I;]?^'1T/\ PD-YZ_\ CUG_
M /'Z[&SD,ME!(W5XU8].X_V21^1(KRW[=J?_ #T\9?\ @O3_ !KT_3"S:5:,
MYE+&%"?.7:^=H^\.Q]:=2-D+,J$:48M);]/^'9:HHHK(\D**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&[2
M9[.9;?'G%2$R^SG_ 'L''UP:YW[!XD]8O_!H_P#\8KJ**:=C:E7=-623]4<O
M]@\2>L7_ (-'_P#C%=';+(EK$LW^M" /\V[G'/.!GZX%2T4-W"K7=1)-)>B"
MBBBD8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16/-XM
M\-VT\D$_B'28IHF*21R7L:LC X(()R"#VJ/_ (33PK_T,NC?^!\7_P 50!N4
M5A_\)IX5_P"AET;_ ,#XO_BJ/^$T\*_]#+HW_@?%_P#%4 ;E%,AFBN8(YX)4
MEAE4/')&P974C(((X(([T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JIJE^NEZ9<7KH76%=Q4'!-6ZJ:I8+JFEW-BSF,3QE-X&2I['% %>77;2
MVO+N"Y;R5MA%ESSO+[L  <Y^4U##XITB218VO8%:1]L6'W!QD '(X )('XCU
MJA/X8OKVRNC>WUI+?W$D;%TMF2,*F0H \S<#R3N# Y/IQ4=CX+>TBE6;57N9
M)$"M+)%\Q(=7R3NY/R_K0(W;;6M-O)YX;>\C=[<;I0#]T9(SGTR",^QJE?\
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M/-!\LT D,D!;)0*[*"3T&=A(J(>--'6TMWFNHHKN>V6X2U,@+$,I8 $<'."
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MC??'%-"55S\C,P. 0#)@+U3KSC..="U\6S7>JVL$-K&]K*(0\R;L9D0L"K$
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MK/)''?!6FM0!Y9E'_+0>A(X/KUJ/QI_R(OB'_L&7/_HIJP_^$8\=_P#11?\
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MIO\ PFGA7_H9=&_\#XO_ (JC_A-/"O\ T,NC?^!\7_Q5>9?\*6\.?\_NJ_\
M?V/_ .(H_P"%+>'/^?W5?^_L?_Q% :'IO_":>%?^AET;_P #XO\ XJC_ (33
MPK_T,NC?^!\7_P 57F7_  I;PY_S^ZK_ -_8_P#XBC_A2WAS_G]U7_O['_\
M$4!H>F_\)IX5_P"AET;_ ,#XO_BJ/^$T\*_]#+HW_@?%_P#%5YE_PI;PY_S^
MZK_W]C_^(H_X4MX<_P"?W5?^_L?_ ,10&AZ;_P )IX5_Z&71O_ ^+_XJC_A-
M/"O_ $,NC?\ @?%_\57F7_"EO#G_ #^ZK_W]C_\ B*/^%+>'/^?W5?\ O['_
M /$4!H>F_P#":>%?^AET;_P/B_\ BJ/^$T\*_P#0RZ-_X'Q?_%5YE_PI;PY_
MS^ZK_P!_8_\ XBC_ (4MX<_Y_=5_[^Q__$4!H>F_\)IX5_Z&71O_  /B_P#B
MJ/\ A-/"O_0RZ-_X'Q?_ !5>9?\ "EO#G_/[JO\ W]C_ /B*/^%+>'/^?W5?
M^_L?_P 10&AZ;_PFGA7_ *&71O\ P/B_^*H_X33PK_T,NC?^!\7_ ,57F7_"
MEO#G_/[JO_?V/_XBC_A2WAS_ )_=5_[^Q_\ Q% :'IO_  FGA7_H9=&_\#XO
M_BJ/^$T\*_\ 0RZ-_P"!\7_Q5>9?\*6\.?\ /[JO_?V/_P"(H_X4MX<_Y_=5
M_P"_L?\ \10&AZ;_ ,)IX5_Z&71O_ ^+_P"*H_X33PK_ -#+HW_@?%_\57F7
M_"EO#G_/[JO_ ']C_P#B*/\ A2WAS_G]U7_O['_\10&AZ;_PFGA7_H9=&_\
M ^+_ .*H_P"$T\*_]#+HW_@?%_\ %5YE_P *6\.?\_NJ_P#?V/\ ^(H_X4MX
M<_Y_=5_[^Q__ !% :'IO_":>%?\ H9=&_P# ^+_XJC_A-/"O_0RZ-_X'Q?\
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MIX5_Z&71O_ ^+_XJC_A-/"O_ $,NC?\ @?%_\57F7_"EO#G_ #^ZK_W]C_\
MB*/^%+>'/^?W5?\ O['_ /$4!H>F_P#":>%?^AET;_P/B_\ BJ/^$T\*_P#0
MRZ-_X'Q?_%5YE_PI;PY_S^ZK_P!_8_\ XBC_ (4MX<_Y_=5_[^Q__$4!H>F_
M\)IX5_Z&71O_  /B_P#BJ/\ A-/"O_0RZ-_X'Q?_ !5>9?\ "EO#G_/[JO\
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MIO\ PFGA7_H9=&_\#XO_ (JC_A-/"O\ T,NC?^!\7_Q5>9?\*6\.?\_NJ_\
M?V/_ .(H_P"%+>'/^?W5?^_L?_Q% :'IO_":>%?^AET;_P #XO\ XJC_ (33
MPK_T,NC?^!\7_P 57F7_  I;PY_S^ZK_ -_8_P#XBC_A2WAS_G]U7_O['_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!JZ9_Q[-_OG^0J[5+3/^/9O]\_R%7:0PHHH
MH **** "LGQ!J%EIMA'-?WEO:Q-*$#SRJBEL$XR3UX/Y5K5@>+_"&G^--)BT
M[49KF*&*<3AK=E5MP5EQ\RD8PQ[4 8G_  EGAS_H8-*_\#(_\:/^$L\.?]#!
MI7_@9'_C6+_PH/PK_P!!#6?^_P!%_P#&Z/\ A0?A7_H(:S_W^B_^-T!8VO\
MA+/#G_0P:5_X&1_XT'Q7X;(P=?THC_K\C_QK%_X4'X5_Z"&L_P#?Z+_XW1_P
MH/PK_P!!#6?^_P!%_P#&Z L;7_"5^&\8_M_2L?\ 7Y'_ (T#Q7X; P-?TK'_
M %^1_P"-8O\ PH/PK_T$-9_[_1?_ !NC_A0?A7_H(:S_ -_HO_C= 6-K_A+/
M#G_0P:5_X&1_XT?\)9X<_P"A@TK_ ,#(_P#&L7_A0?A7_H(:S_W^B_\ C='_
M  H/PK_T$-9_[_1?_&Z L;1\5^&R,'7]*(_Z_(_\:#XK\-D8.OZ21Z?;(_\
M&L7_ (4'X5_Z"&L_]_HO_C='_"@_"O\ T$-9_P"_T7_QN@#:/BKPV1@Z_I/_
M (&1_P"-'_"6>'/^A@TK_P #(_\ &L7_ (4'X5_Z"&L_]_HO_C='_"@_"O\
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M5^&R,'7]*(_Z_(_\:Q?^%!^%?^@AK/\ W^B_^-T?\*#\*_\ 00UG_O\ 1?\
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M@+&U_P )9X<_Z&#2O_ R/_&C_A+/#G_0P:5_X&1_XUB_\*#\*_\ 00UG_O\
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M*_\  R/_ !H_X2SPY_T,&E?^!D?^-8O_  H/PK_T$-9_[_1?_&Z/^%!^%?\
MH(:S_P!_HO\ XW0%C:_X2SPY_P!#!I7_ (&1_P"-'_"6>'/^A@TK_P #(_\
M&L7_ (4'X5_Z"&L_]_HO_C='_"@_"O\ T$-9_P"_T7_QN@+&U_PEGAS_ *&#
M2O\ P,C_ ,:/^$L\.?\ 0P:5_P"!D?\ C6+_ ,*#\*_]!#6?^_T7_P ;H_X4
M'X5_Z"&L_P#?Z+_XW0%C:_X2SPY_T,&E?^!D?^-'_"6>'/\ H8-*_P# R/\
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M_P"-T!8VO^$L\.?]#!I7_@9'_C1_PEGAS_H8-*_\#(_\:Q?^%!^%?^@AK/\
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M (2SPY_T,&E?^!D?^-'_  EGAS_H8-*_\#(_\:Q?^%!^%?\ H(:S_P!_HO\
MXW1_PH/PK_T$-9_[_1?_ !N@+&U_PEGAS_H8-*_\#(_\:/\ A+/#G_0P:5_X
M&1_XUB_\*#\*_P#00UG_ +_1?_&Z/^%!^%?^@AK/_?Z+_P"-T!8VO^$L\.?]
M#!I7_@9'_C1_PEGAS_H8-*_\#(_\:Q?^%!^%?^@AK/\ W^B_^-T?\*#\*_\
M00UG_O\ 1?\ QN@+&U_PEGAS_H8-*_\  R/_ !H_X2SPY_T,&E?^!D?^-8O_
M  H/PK_T$-9_[_1?_&Z/^%!^%?\ H(:S_P!_HO\ XW0%C:_X2SPY_P!#!I7_
M (&1_P"-'_"6>'/^A@TK_P #(_\ &L7_ (4'X5_Z"&L_]_HO_C='_"@_"O\
MT$-9_P"_T7_QN@+&U_PEGAS_ *&#2O\ P,C_ ,:/^$L\.?\ 0P:5_P"!D?\
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MF<M<,K-N*JN/E4#&%':M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7%R9-K"-D P%!.3O_2NKF\*V,]U=W#2W >ZO(+QP&7 >';M XZ':,_S%4I_
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MS\/36>+JU:.2>5PN%1>K ;3S[UGWWA2^:QUS4TTRZ^V?:[:,[XI#YEKY<?F
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M59+B:6V;S=C <KM7KP 0N2!GI23!Z'I%]I]IJ<"P7D(EC6190I)&&4Y4\>A
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M?!^A>*_BEXT_MNQ^U?9OL/E?OG3;N@^;[K#/W1U]*W/^%0>!/^@%_P"3<_\
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MV,\T3_:ICM=4)!P7P>0.M 'IM%8?@O\ Y$7P]_V#+;_T4M;E !1110 4444
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M1U^^UF'7M?TZXO?+\]=/O!"C;%"KP%R>!W)ZF@#L:X?_ )KK_P!RU_[<T?\
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M@VQD".  ,@D\ C(SSQFM>'Q!I,^JMI<=]"U^N0T&?F! !(_(@T[,+FG1112
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M/@U:ZTZYE$,L"JV6Z."I;C\%/'?!H UZ*S+_ %ZQT_3+R_:0RQ6@!D$0W$9
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MY==NM16YO+B.19PD'EH68I@J-QP (P,<YSG/:NLKA_\ A;_@3_H._P#DI/\
M_$5V-E>0:C86][:R>9;W$2S1/@C<C#(.#R.".M%PL9/B+PTGB.2Q6XO)X;:V
MD:5HX&:-W;:54[P05QD_7-<7%X+UG2M>T^RM&FN=-2:VE>X:- H2%F*J27W
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M>07)8<GJ7/';'>LF+P,XT--/GU)7D3>1*EN4&3MV\;R>-@SSS[5BCQ3J6FZ
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MDEA:Q_;T-Q;(NU_)949@[,20'! .XC&[CKDUEMKVO^3#*-0A'FA'VFV! #W
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M (DTGPO\9DO=9N_LUN_AX0J_EN^7-P2!A03T4_E6K_PM_P "?]!W_P E)_\
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M '5W'YGV?'^O9#G&X_=V>O.>U7-.\%&QN8I#>HR02HT0$3;MJLS88ESSR!P
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MT:[^TVZ>'C"S^6Z8<7 )&& /1A^= 'IM</\ %_\ Y);K/_;#_P!'QUW%</\
M%_\ Y);K/_;#_P!'QT =Q6'XT_Y$7Q#_ -@RY_\ 135A_P#"W_ G_0=_\E)_
M_B*RO$_Q3\%ZCX3UFRM=9\RXN+&>&)/LLPW.R$ 9*8')'6@#L?!?_(B^'O\
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M!QTP:.@=1'\3Z#"D1?4($5L[-P(Q@[3QCCGY>>YQWJ1?$.C,Z;;^'=(FX'U
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M%0/K0NW]?UH#=]?Z[_J<]IB^([T7[SSZF8/M'DVRLC*'@:)LGYE#'#8^8X/
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M1(DBA)40E1YI8[2 P.[KR,+QSSZ;10AO6XR&/R8$BWN^Q0NYSEC[D^M/HHH
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MBB@#E= \"VN@:Z^L_P!L:SJ-X]L;7=J-R)ML98-@':#U'KCDUU5%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !2!0N< #)R<4M% !1110 4444
M(J*N=J@9.3@=32T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 55U#4]/TF!9]1OK:SA9M@DN
M)5C4M@G&6(&< \>U6J\K^/G_ "(MC_V$X_\ T5+0!W'_  FGA7_H9=&_\#XO
M_BJMZ?X@T75IV@T[5["\F5=YCM[E)&"Y SA23C)'/O7ENH^%= D\.W%O'I&C
M^:NB"Z06\N+[S=@.[9_<SWSSTKE_@'_R/5]_V#)/_1L5#TDX_P!=5^@+6*E_
M71_J?1=%<IX]\0ZCH.CP#1HHYM4NIMD$;KD$*I=SC/\ =4_F*:/B#I0TR>]:
M*Y=+>Q@OI/+53E)20 N6'((.<XH6H'6T5YK?_$C4(?$\FG1:3=&"#4DM3L@W
M-,IB9B%^;[Q(!';;S6[)\0])73;&\AM-1N6O(Y)5MX( TL:1G#LXS@!3P>3[
M9HZ7#K8ZVBN'UKXBV5O#<0Z=!?3RC3OMR74-N)(8XV5BK-E@?X>G'44Z3XE:
M?87L=EJ.G:K"WV=IS<M;J(F15R7&')P3P..I H_K^ON [:BN2'Q"TTVH;[!J
M8O3<"V&GF ?:-Q7>#MW8QM^;.>GOQ1I/B34=1^'D^NPVPN+X)<-#"$*[RCN$
M&WKG &10]$WV!:V7<ZVBO+M*\=ZA/I-W<MK-C>K'+;)OBM#'+"[R!'C>)F''
M/#9]>O2NGM_'VEW6LQZ=%::A^]EFABN3"!#*T0)?:V[)Q@CIU]N:;0'545QE
MG\2M,OH2\.EZP6:W6YAB^R@M.A8)\F&(X8X)) [YQ4$/Q'BO=;TJVL]-O#:W
M45PT[O$-\31'!4X;'!')YZKZTMOZ_KL!W5%<H_Q!TE+!+PP7OEOIAU0#8N?*
M! Q][[W/3I[U#%\2-*>2!)-/U6 2;#*\UL%%N';;&TGS<!CTQGCDXIV=[!YG
M8T5S^B^+['7M2N+.SM;[;"7'VEXAY3E6VD @D@Y[,!GMFN@I>8>045%<K,]M
M*MO(L<Y0B-W7<%;'!([C/:O.X->\60:=XHO;O4=/F71A-$J)9E2[K&'#9W'C
MGI^M*X[7/2:*X*/XA17$FG0F.ZLY_M$<=W'<6PRR-"T@9<-PIVG!Y/&,5T'A
MOQ5:>)XI);2SOH8E"LDEQ$ LJGH5921^!P1W%58FYNT5SB^--.?Q!<:0MO>L
M;9BLUTL0,,;!=Q#$'<..Y7';-4X?B/HTME<7)M]0B\M8WABD@ >Y21ML;1#/
M(8\#./?%(9U]%><:[\2Y;1H8[32M0@62TN99'GM<O"\?&"NX @'D\XY7!YXV
MXO'NF"_@L9([QBS10RWBP?Z.DSJ"J,V>"<CL0,CFA:@]#K**Y?3O'6FZEK::
M7':7\3R3301SRP@1/)$3O4,&/.!GIT]^*37/'NF>']3FL;JTU"0P)%)-+!"'
M2-9&*J2<YZC&,9YXSS@[>8'4T5R=G\0=*O)Y;<6M_#/#'<22Q31*K1^3MW _
M-U(8$?KBEC\?:9/?6-I!9ZC-)=P0SYBA#>2LOW=X#9^NT,!WH ZNBN5\,^*K
MCQ!HVJWDEC+:/:7$T48D3 (3..YR1CGWK'T7XHV3Z)9OJ]M>Q:A-;))&BP "
M\9B%Q"-W/S''./7IS1_P/Q#^ON/0J*Q+;Q3IMQX<N-<8S06UL)/M"3)B2)D.
M&5E&>01VS6=_PG]BMDLSZ7JZ7+SB"*Q:V GE8KN!4;MI&WG.>.] '645QUU\
M2='MK.UN4M=1N4N+>6XVPP M&L;!9 X+#:5).?H?;*GXD:.-/N[PVFI!;:2!
M3&8 '=9O]6ZKGD'\#[46 ["BN"?XC6QUFW#+-:64,%TU_#<PXFB>+80, GJ'
M[9SD4Z[^(Z>?ID-II&H":XOUM;F">$"2$%-PX#8R001ST#=QBA*X/0[NBN3'
MQ#T3SKM9!=PP6\<LB7,D6(K@1'$GEG.6(/'(&>V:=X9\4S^(-=U:!K2XM;>U
MAMWCAN8MDJEPQ.<$@C 4C%"U!Z'545YGHWQ,E:[U/^TK+492+F5;:SMK$;XH
M8R=[LV_G&1GT/3.:ZBW\;:=>Z]:Z396M]=-<6Z70N8H@84C<$JS-G(Z8Z=2*
M%K:W]=0>E[G245SC^-=,BNGM9(KE9TO_ + R%5R&V;]_WON;><]?:J4/Q(T>
M:SN[DVNHQ1P6K7D?FP!3<PJ<%XLGD=.N#R* L=A17(:I\1=,TO4?L!L-3N;D
MF)5CMH5<N9$9U &X$\*<UMW^O6NF76G074<T?V]F1)"HVHP0MA^>"0#C&>E'
MF!J45QK?$O1EAMYOLFI-#)"MQ+(L (MHF8JKR8;@'&1C)QR0*JK\28XM=U73
M[C2K^0V]PL%HEM"&>X^3<Q&6 Z?-V^7'<XH [RBN3\0^-$T_P;;>(-+MI+V.
MZDB6,*G(#L!DC(Y[8_O8%2OXZTN/65TY[>^7]['!)<F']S%,X!6-FSPW([$#
M/6BVM@Z7.GHKD?$GBV?P_P")K"U-G<7=I-9S321VL0>7*%>>2   3FI+#X@Z
M)JFI6]I9_:98;AA%'>"+]P92F\1[LYW[>V,=LYH6NP/0ZJBL+7_%5GX?G@MY
M;6]N[B9'E$-G%YC+&N-SD9' R/?T%4;GX@Z/:ZBUJ\-\T2,D<EVL'[F.1EW+
M&S$Y#$$=L#(R10%CJZ*Y7_A/M*^Q)=>1>;'TMM5 V+GR@0"/O?>YZ=/>LFY^
M)T3:EI]C9:1J1EGNXXIEF@ 98W4LK* W<#(SV#<<4[.]@Z7/0**Y,?$/1/.N
MUD%W#!;QRR)<R18BN!$<2>6<Y8@\<@9[9IWACQ3/XAU[5H&M+BTM[6*W:.&Z
MBV2J7#$YP2",!2,4EJ#T.JHHHH **\ZU;Q-XFM+_ ,1WMI-8MINB31A[62 [
MY4**S8<-P>3CBMN]\=V5EJ(L7T[4R[J?*E\@".5_+\S8I)R3COC&>,T7TO\
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MDE\  =Z[NL/QI_R(OB'_ +!ES_Z*:@#2TS4(M6TFSU&!76&[@2>-9  P5U#
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MZ;H\CVH#7L[+;VJ$9W2N=JY]A]X^P-:M9UUI7VO6[&_EFS%9I(8X-O\ RU8
M;\^H7< ,?QF@"32=-BT?2;73X"2D$87<W)<]V/J2<D^YJ[110 4444 %%%%
M!1110!D>)=2FTW19&M,&_N&6VM%(R#,YVJ2/0?>/LIJWI6G1:1I5KI\!8QV\
M80,QRS'NQ/<DY)]S45SI7VO7++4)9LQV:2>5!LZ2-@;\^H7<H'^T:T: "BBB
M@ HHHH **** "BBB@ HHHH **** "N'^+_\ R2W6?^V'_H^.NXKA_B__ ,DM
MUG_MA_Z/CH [BN'^+_\ R2W6?^V'_H^.NXKA_B__ ,DMUG_MA_Z/CH [BBBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K#\:?\B+XA_P"P9<_^BFK<K#\:?\B+XA_[!ES_ .BFH /!?_(B^'O^
MP9;?^BEK#^+_ /R2W6?^V'_H^.MSP7_R(OA[_L&6W_HI:P_B_P#\DMUG_MA_
MZ/CH [BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K#\:?\B+XA_[!ES_ .BFK<K#\:?\B+XA_P"P9<_^BFH
M/!?_ "(OA[_L&6W_ **6MRL/P7_R(OA[_L&6W_HI:W* "BBB@ HHHH *RM?\
M-Z3XHL$LM9M/M-NDHF5/,=,. 0#E2#T8_G6K10!P_P#PJ#P)_P! +_R;G_\
MBZ/^%0>!/^@%_P"3<_\ \77<44 </_PJ#P)_T O_ ";G_P#BZ/\ A4'@3_H!
M?^3<_P#\77<44 </_P *@\"?] +_ ,FY_P#XNC_A4'@3_H!?^3<__P 77<44
M </_ ,*@\"?] +_R;G_^+H_X5!X$_P"@%_Y-S_\ Q==Q10!P_P#PJ#P)_P!
M+_R;G_\ BZ/^%0>!/^@%_P"3<_\ \77<44 </_PJ#P)_T O_ ";G_P#BZ/\
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M_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZ[BB@#A_^%0>!/^@%_P"3<_\
M\71_PJ#P)_T O_)N?_XNNXHH X?_ (5!X$_Z 7_DW/\ _%T?\*@\"?\ 0"_\
MFY__ (NNXHH X?\ X5!X$_Z 7_DW/_\ %T?\*@\"?] +_P FY_\ XNNXHH X
M?_A4'@3_ * 7_DW/_P#%T?\ "H/ G_0"_P#)N?\ ^+KN** .'_X5!X$_Z 7_
M )-S_P#Q='_"H/ G_0"_\FY__BZ[BB@#A_\ A4'@3_H!?^3<_P#\71_PJ#P)
M_P! +_R;G_\ BZ[BB@#A_P#A4'@3_H!?^3<__P 71_PJ#P)_T O_ ";G_P#B
MZ[BB@#A_^%0>!/\ H!?^3<__ ,71_P *@\"?] +_ ,FY_P#XNNXHH X?_A4'
M@3_H!?\ DW/_ /%T?\*@\"?] +_R;G_^+KN** .'_P"%0>!/^@%_Y-S_ /Q=
M'_"H/ G_ $ O_)N?_P"+KN** .'_ .%0>!/^@%_Y-S__ !='_"H/ G_0"_\
M)N?_ .+KN** .'_X5!X$_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZ[BB@
M#A_^%0>!/^@%_P"3<_\ \71_PJ#P)_T O_)N?_XNNXHH @LK.#3K"WLK6/R[
M>WB6&),D[448 R>3P!UJ#6-'L-?TJ;3-3@\^SFV^9'O9=V&##E2#U [U>HH
MX?\ X5!X$_Z 7_DW/_\ %T?\*@\"?] +_P FY_\ XNNXHH X?_A4'@3_ * 7
M_DW/_P#%T?\ "H/ G_0"_P#)N?\ ^+KN** .'_X5!X$_Z 7_ )-S_P#Q='_"
MH/ G_0"_\FY__BZ[BB@#A_\ A4'@3_H!?^3<_P#\71_PJ#P)_P! +_R;G_\
MBZ[BB@#A_P#A4'@3_H!?^3<__P 71_PJ#P)_T O_ ";G_P#BZ[BB@#A_^%0>
M!/\ H!?^3<__ ,71_P *@\"?] +_ ,FY_P#XNNXHH X?_A4'@3_H!?\ DW/_
M /%T?\*@\"?] +_R;G_^+KN** .'_P"%0>!/^@%_Y-S_ /Q='_"H/ G_ $ O
M_)N?_P"+KN** .'_ .%0>!/^@%_Y-S__ !='_"H/ G_0"_\ )N?_ .+KN**
M.'_X5!X$_P"@%_Y-S_\ Q='_  J#P)_T O\ R;G_ /BZ[BB@#A_^%0>!/^@%
M_P"3<_\ \71_PJ#P)_T O_)N?_XNNXHH X?_ (5!X$_Z 7_DW/\ _%T?\*@\
M"?\ 0"_\FY__ (NNXHH X?\ X5!X$_Z 7_DW/_\ %T?\*@\"?] +_P FY_\
MXNNXHH X?_A4'@3_ * 7_DW/_P#%T?\ "H/ G_0"_P#)N?\ ^+KN** (+*S@
MTZPM[*UC\NWMXEAB3).U%& ,GD\ =:GHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HKQ;XN^//$OA?Q9:V6C:E]FMWL4F9/(C?+EY 3EE)Z
M*/RK@?\ A;_CO_H._P#DI!_\10.Q]3T5X%\./B/XLU_Q]IFF:GJWGV<WF^9'
M]GB7=B)V'*J#U [U[[0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;)(D,;22.J1H"S,QP
M !W)H =15+2=6LM<TZ/4-/E\ZUD9E20# ;:Q4D>V0:/[5M/[;_LC>WVS[/\
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M]ZT:;36XIPE!\LE9A1112)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI>GS&:RTVSMI2NTO# J$CTR!TX%7:)-/8BO4C.=X[?D%%%%28A1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!1U.P>^CMS#,L4UO,)HV=-ZY (P1D
M=F/>L.;PC<36]O:/J,,EG;P+#''):DE2!AGR' R>G3@$@=3GJJ* \CF+;P9;
MV]R6:ZDDMA<--%#RAC4QA @92#@8X]L#MFF:CX1N+^ZN'35!;0W!(E$,!5Y$
M9=I1B'"MQG#%=PXY..>JHH#S,S1='&BPW%O'</+;O,98U<<Q[L%AGOELGH.M
M:=%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>card4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 card4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0, Q\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** $9E1=S,%'J3BEHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#"U/QAHVD:O%IEW/(MP^S<5B9DBWG:F]@,+D\#-+9>+M&
MU#5KK38+D^?;!RS.A5&"'#[6/#;3P<=*YCQE>3W7BJQTF31=4DTI6CGN[FSL
M6E\]U;,<9<# 4'YB<^WK69X<T&ZN?$MOI^H:9<"VT\:@MT\T1$4ZSR@H%)X8
M%>>/3FB.OXA+3\#L)/'>BIH\>JQFZN+.262)9+>V:3)0D$_*#\O'6M>PUBSU
M+1(M7@=A9R1&97D4J=GJ0?I7$+I^H0?#V^TNWL;F&2\U66WV1PL"D$EP07
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 1E5U*L RD8((R"*@M+&TT^(Q65K!;1EBQ2&,("3WP.]6
M** "BBB@ HHHH **** "BBB@ HHHH KW>GV5^J+>VD%RJ-N431API]1D<&K
M&!@=*** #I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4=834'TBZ&E3)%?^63 TBAE
MW#H"/0]*O44FKH:=F>&>#_'WCWQ-XOBT5Y+:)8W)NS]F ,2*<-^.>![FO7_$
MFJ/HGAO4-4CC21[6!I51S@$CUI;#0--TW5=0U.UMU2ZU!E:=QW(&./3U/O4V
MKZ9#K.D76FW+2+#<QF-VC(# 'TR"/TI]$A+XK]#D]!\<W6JWMI;2064BS7SV
MOVFSE9X7 A,N4) R01M-6;/Q;<W?C*[T8MI\45O<F'8QD\YQY8?<,#;W[GM6
MOK'AR#5TL=M[=V$EE(9(9;,HK E2I^\K#&">U9]OX*%M/<RQ>(M;'VDEIT\R
M';(Q0)N/[O.< 'ZBG<#)7XAW4VD:O=PZ<H>TN$$&[<RM;.Q43L%!;;\K$@#M
M43_$*\\K2L-H\?VR"65IVFD>)MCA1L* GD'.",C&#6FGPUT.U$;:8]UILJ1*
MGF6CJI=E8,KME3E@1]#N.14B> ;: VTEKK.K6MS$)0]Q#)'OF,CAW+;D(Y8#
MH!0K?U_7S C\3>+YM#UC3+!9=-A^V0-)YMX[A2P90%7:"<G=W]*AA\::DSV]
M[-86JZ3>W$MM:LLK&8.@?#.,8VMY;=#D9%=.-(A_M>WU-I9FN(+9K8;B,,K%
M22>.N4'MUXK(A\#V$5_Y_P!LOGMDDDF@LFD7R8)) 0S*,9S\S8!) R>*3V^_
M]?\ @ O/R(+CQ-JLVD>&YM-M+-KS6%!V7$C+&G[DR'E03VQTJROBS=X%?Q ;
M8"=8V'V8-G,P8IL![Y<8S[U3C^'T45M90)XCUT"Q(^RMYL.80$*8'[KIM;'/
MM6G/X0TJYT"TT2596T^WD60Q%@?.().)"1R"QR>F33E9WM_6O^7X@NERIH/B
MN76+O3;=[9(FN+*::=0Q)BECD6-D^F2?RJC#XTU%I+>]EL+5=(O;B:VM665C
M,&0/AG&,8;RST.1D5/'\.]/L[L7&EZGJ>F;2^R*T>((BOM+* R' R@/US5B#
MP-807HF^VWTEO&\DL%F\BF*&20$,ZC;G/S-@$D#)P*3UV!>9S^G_ !0EU.RM
M6M=/B-Y<01@0.Y79.\H0!CCA,$-G&2*ZK0=7O=6TV]WMI<E[;2M"&L[GS868
M#(SCYEY."#SQ6</AOH:$O&]VDIM(+82I(H8&$@QR A?OC:.>G'2MG0M AT**
MYV7-S=3W4OFSSW!7<[8"]%  & .@INVHE<Y6U\>:A;S6\FM0Z=;V4E_/8M)"
MTC%6C#Y.".A*@#ZU%IOQ$N]3U*UMU&F6Z31Q2#SFDW2;W=<)@$=%'7'6NHMO
M"EC:W%O,DMP6@O9[U0S+@O*&# \?=^8X[].35&T\"6^GW:7%CK.K6N$2-TCD
MBVR*K,PW9C)_C8<$<4+I?^MO^".76Q5\;>-;GPO>V\%O'8,)+:2XQ=S,AD*,
MH\N/ .7.[@>U9=A\2+Z\T34M3:#3XVM8)I19,T@F4HVT!^-H]\&NZETBVFUN
M#5GWF>"!X$4XVX9E8G&,YRH[^M8:^!;=;.]L3K.K-8W8E#6K21;$\QBS%?W>
M<Y)QDFDO/^M?\ALYQOB=>1VZ/(-'6)KOR!?B:0VK#RR_!VYW @ C!&2*V-1\
M7ZK!]JDL;.QN(--LH[N_=I67S ZEML7']U2<MZ@5KQ^$;"'75U6*:Y1Q/]I\
M@,OE>88S&6QMSD@\\]0#ZY9K/@ZSUJ^DN7O+VV%Q$L%W%;R!4N8P3A7R"1U(
MR"#@D4=A+S.;\._$Q]9O=SQ6+6)BGE<P2.9;=(R<-*I& & &.>]2KXYUF?PD
MNKPZ=9PW,5RMO=6L[OE"[((R,#^ZZDYK3G^'6CRV,-I'<7MO'&LT;&%T!EBD
M<NT394@KD\8P1ZU,O@'1(8+RVLTEL[6Z>&1X+<JJ!XFW!@"#@G !]0.U/3^O
M5?I</Z_/_@,HCQ;K,DQTN.SL3JS7[6:$R.(0$A61G/&X_>P!]*QHOBRYOM0T
M^XT^**[M%$9PY*-.)"CH#@=AN'? /I76WG@ZSN7GFBO+RVNY+PWJ7,+KOBD*
M",A<J1M*C!!!ZUG'X8Z"UK-"[W;M,\4KRM(I<R1NS;\[?O,7;/;!XQ0K7U_K
M;_@A+9V_K?\ X!O^(]4DT7PYJ&IQ1K));0M(J.<!B.QKC[_Q]JNEW:Z;?VVE
MV]\)U1Y3+(T'EM&SJW"[LY0C&*ZR[T,ZGIFK:??WD[6]^S!=C#="A51M4D8Z
M@GD'K64W@&U9HY_[9U<7Z3>=]N\V,S$A"@7E-NT*QX"CK20,K7?BK6;2_P!.
M0II+V=U:/=M.'D&$C52^ 1_M<?K18>-[R]\*"^.G)%JK7:68M'<A5=R-A8]<
M;65C6GJ?@VSUB"UCOK^_E:"WDMS+O0-*CE=V_P"7&3M X X)J(> -$AM[R"R
M26RAN6BD"6S!1#+&<K(G'#=,YR#@<4>O]:_Y:!VM_7];F??>-KW091;:_:VE
MK.;2XF1HY&=)70J$V\9 8,>#R,59U[QG)HVCZ->K9K-)>A)9T#'$4(4-(_\
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MZS+#0--TW5=0U.UMU2ZU!E:=QW(&./3U/O4QTE=C>L;&G1110 4444 %%%%
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M9 ]-R#<?89)["FC7;0Q-+Y.H;58*0=.N,Y.>@V9(X//0<9ZBM*BBZ[#YJ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$[@Q//EGG-96E_$&8HEMXAMO[3@5/+6Y#;+J-?9_XQ[-GZB@9T/S!,HV"&8
MAO7KCMTQWS@?@.R^&6!XFN /F/V-R6 ZG>A^N,$?D?QYH64%_;_VAHEY%JEK
MM5I?+!$L)Z#S(^J=^>G!YQ72_#'(\1SC& ;)CUSQYBXQ^9^AH ]7HHK-\0:Q
M#X?\/W^K3D!+6%I #_$W\*_B<#\:!&-!X]TV?Q_/X1",MS''N$Q8;7<*&* >
MH!)_X":ZNOE!;75].T>P^(0N':[EU60%F[L &#'ZD2 CV%?4VGWT&IZ=;7UL
MVZ"XB66,^JL,B@"S17DOQA\:Z_X4U'24T:^%ND\<C2J84?<01C[P)'4]*[OP
M=XIM?%_AJWU: "-CE)XLY\J0?>7Z<@CV(H WZ*\-7XKZQK/Q3LM.TRZ6'1'O
M4MO+6-'\]=V"Y8@D;NV",#'?FO5O&6H76E>#=7O[*7RKJWMGDB?:&VL!P<$$
M'\: -RBOG_3/%'Q3U#PI/XHM=7MKFQM7<30F"(. @!8D;!Q@]CG@UZUX"\5C
MQEX5@U1HTBN S0W$:'Y5D7&<>Q!!QVSWZT =-17F6B^+-;N_C5JOA^>]WZ7!
M$S1P>4@VD!"/F W'J>]>FT %07UTMC87%VR,ZP1M(57J0!FO.=:\6:W:?&K2
MO#\%[LTN>)6D@\I#N)#D_,1N'0=Z[KQ)_P BOJV,_P#'G+T_W#0!S'_"S]."
MAVL+K9ZK@UTVB^(-.UZ!I+&4ED^_$XVNGU'^%<Y\-H8IO#-XDB)(C7C;@R#G
M]W&.??&/IT[5C>&$2V^(]S;Z> +19)E(CQ@J03V[!L#\O:@#U"BN(^(&OZEH
MC6 TZZ,!F$F\^6K XVX^\IQU-=O0 45Q?A'7-2U/7]4M;VZ\Z*')C7RU7 W8
M&,#GCWJQX\UF^T73;6>QN?(:24H6VJV?E)'W@?3MS0!UE%9^B7,]WI$$]PVZ
M5MVXX Z,1T'M6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !61XCEUB'27?18XWN0>=PR0O?:#P3]?UK7HH ^
M?]2EOIKR2347G:Z!Q)YV0< <#!&1W'3_ .O5[ CIM^55].X/7']<]:]UUGP[
MINNPE+R %\$"5>'7CUKS37O FJ::&EA)O;?=G?$AWK@=2!R.F,C(QCCC% SB
M/&((\ VW.5_M+C/IY1_ICK]>]>;UZ1XQP? 4!  SJIZ#'_+,]NW7\.G:L/1O
M =_?VZ7NHRII=BZ^8CSJ3+*OK'%]YAR.>!SUH P='NM4M-4ADT:2Y2^)VQ_9
ML[VS_" .N?3O7T3\,S=O(7UVUM;;6S ^%A.V1HMR;C-&/E1\[?0G)R!@YXBT
M?3]$C-MH%HUFICVS7LC;IY0>Q8<(#QPN/H<5U'PR8GQ).22=UFQ!(/(WICK]
M3Z=N* /5Z\=^.^N_\2_3_#5H6>ZNI1/+''R2HR$7'?<QR/\ <KV*O.$^'-]=
M_%1O%NJ7=K-:I)O@MEW%EVKMCZC Q@-QWH$>:SWWB^?P''X2/@.\6SC0!919
M3[PX;=OZ8R3G/U-=W\#/$7V[PY<:'<2L;K3Y"T:.>?*;T[\-D>V17JU>;:1\
M-KW0OB;/XDT^]METZ=I#);,&WX<9('&.'Y'L*!G+_'15?Q+X95E#*P<$$9!&
M]:R_%GAGQ)X.\07NC^%EO'TG7D 6.%"0A+<IGL1TS_=;FO1/B'\/[[QCJ^D7
MEI>6\"66=ZRALME@>,#VKT&@#YZO_#-KX3^*W@G2[9%#+#;/.X_Y:2F5]S?I
MQ[ "O8/B%_R3W7O^O.3^58_B3P'>ZW\2-%\30W=O';V"1*\3AM[;)&8XP,=&
M%=/XGTJ77?#&I:7#(D<MU T2N^<*2.IQ0(^?O"%UXXOO!%SX=\.Z0LNGW<DB
M3797GY@JLH9B%''L3SQ7N'@'PH/!WA2#3&=7N68S7#K]UI&QG'L  /PJ'X=^
M$[KP;X9;2[NXAGD-P\V^+.,$*,<_2NMH \9\._\ )QNN?]<7_P#08Z]FKR?5
M_AKXHD\<ZAXDT/7;6PDNCA258L%P 0?E([5UW@S1_%&E?;?^$EUR/5/-\O[/
ML7'EXW;NPZY7\J .#\1?\G&Z'_UQ3_T&2O4_$F/^$7U;<I8&SF! [_(:Y;5/
M E[?_%+3_%:7=NMK:QJK0L#O. PXXQ_%78ZI:/?Z3=VD;*CS1-&K-T4D8S0!
MYGX4T#5=7TFX:SUF6Q@^T%'C3<-QVH2<9'8X_KV'>:!X7L/#RNUN&>XD&))7
MZGIG'H,C-,\)Z#+X=TR:TEF24O<-*I3. "%&/TK>H \V^*N1)IF"1F.?//WL
M;#Z?7\ZT?^$<\8\_\5&GWL@Y;ICTQZ\_A5WQEX4G\2M:-;S0QF%9 ?-!YSMQ
MC'N/Y>E=70!YO\.UD3Q'K D;<Y!#DGJP?!(]1G(Z=NW2K_Q/_P"0-: GY?..
MX9 R-I[G_/\ *M'PWX8N=%UK4;V:>&1+K[HC!!7YB<'/7J?S/7K4_BWP]<>(
M;.WAMIT@>*0MO;/3&,#'^>* +OAP,-!MMQR?F_\ 0C6I5+2+)]/TN&UD*EDW
M9*].6)]!ZU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\
M_7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\
M^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?
M_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_
M /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_
M /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\
MW_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P"
M_P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7
M_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBB
MO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\
M@/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[
MU_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](
MHKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__
M (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[
M^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /
M2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U_
M_P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX
M._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@
M#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]
M?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X
M^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7
MH ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._
MO7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A
M>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\
MUZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#
MO[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_
MX7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __
M ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/_P#7H ](HKS?_A>/
M@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7CX._O7__ (#_ /UZ
M/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]>C_A>/@[^]?_ /@/
M_P#7H ](HKS?_A>/@[^]?_\ @/\ _7H_X7CX._O7_P#X#_\ UZ /2**\W_X7
MCX._O7__ (#_ /UZ/^%X^#O[U_\ ^ __ ->@#TBBO-_^%X^#O[U__P" _P#]
M>C_A>/@[^]?_ /@/_P#7H ](HJAHNKVNO:/;:I9;_LURN^/>N#C..1^%7Z "
MBBB@ HHHH *9(D;#,BH0/[PZ4^N/^*?_ "376O\ KDO_ *&M*3LKCBKNQU2P
MVS?=CB/T44OV:#_GC'_WR*\4\*+X?/C;0I? D=T$2*3^UV'F^5MV< [^^[/3
MVKJ-.^)&IS>&+KQ)?:+##ID2M'"(Y]TDTV\(%QCA3GK[&J:_KYV_'H):_P!?
M/_AST/[-!_SQC_[Y%'V:#_GC'_WR*Y31_%.LOKZ:'KVEV]E>7-L;FT>"8R(X
M'56X!#"L_2O'VJZOKG]@Q:*D6J6S3?;_ #';RX57[A4X^;=D8Z4@.[^S0?\
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MS.Y%U-J&]([I=GW%#,P8D].E*.KL$M(W_KH>XB"W.<11''7Y11]F@_YXQ_\
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M7]'M[:\&GR7]IY$Y=) @RR-D9#"CI<:5W;^NG^:.X^S0?\\8_P#OD4?9H/\
MGC'_ -\BN*T_Q7XIU#PRFL)X?LU%SY1M@]X%5$;.Z20GH!QP 3S7*:_XZUO6
M- 1+2.TCGMM9BM+B2TNRT4W0J%;&2K'(/T_"BVMA=+_UU_R/8/(MR2/*BR.H
MVBC[-!_SQC_[Y%<39ZU::=XH\4WEYIZP7%G86\]Y-'*S^9\A.T \#&" 1U[T
MFF>.=8:]TG^VM%@M+'60?L4L4Y=D;;N59!@<D>E']?G_ ) ]/Z]/\SM_LT'_
M #QC_P"^11]F@_YXQ_\ ?(KSG3_B3K%U9:3JLVB6T>E7M\+%W6X)D5RQ4,%Q
MC;QZYSFO2Z=NH/1V(OLT'_/&/_OD4?9H/^>,?_?(J6BD!%]F@_YXQ_\ ?(H^
MS0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\ /&/_ +Y%2T4 1?9H/^>,?_?(
MH^S0?\\8_P#OD5+10!%]F@_YXQ_]\BC[-!_SQC_[Y%2T4 1?9H/^>,?_ 'R*
M/LT'_/&/_OD5+10!%]F@_P">,?\ WR*/LT'_ #QC_P"^14M% $7V:#_GC'_W
MR*/LT'_/&/\ [Y%2T4 1?9H/^>,?_?(H^S0?\\8_^^14M% $7V:#_GC'_P!\
MBC[-!_SQC_[Y%2T4 1?9H/\ GC'_ -\BC[-!_P \8_\ OD5+10!%]F@_YXQ_
M]\BC[-!_SQC_ .^14M% $7V:#_GC'_WR*/LT'_/&/_OD5+10!%]F@_YXQ_\
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M$1Y5VD !\[>>AZ&@#/\ ^$+\*_\ 0M:-_P" $7_Q-'_"%^%?^A:T;_P B_\
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MH P_^$+\*_\ 0M:-_P" $7_Q-'_"%^%?^A:T;_P B_\ B:W** ,/_A"_"O\
MT+6C?^ $7_Q-'_"%^%?^A:T;_P  (O\ XFMRB@##_P"$+\*_]"UHW_@!%_\
M$T?\(7X5_P"A:T;_ , (O_B:W** ,/\ X0OPK_T+6C?^ $7_ ,31_P (7X5_
MZ%K1O_ "+_XFMRB@##_X0OPK_P!"UHW_ ( 1?_$T?\(7X5_Z%K1O_ "+_P")
MK<HH P_^$+\*_P#0M:-_X 1?_$T?\(7X5_Z%K1O_   B_P#B:W** ,/_ (0O
MPK_T+6C?^ $7_P 31_PA?A7_ *%K1O\ P B_^)K<HH P_P#A"_"O_0M:-_X
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M,82Y>%3(OT;&10G9K^NPGJFOZZEZBBBD,**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445@^,XM6G\)W
M\>B,XOR@V>6VUR,C<%/9BN0#ZTF[#2NS8M[6WM!(+>WBA$CF1Q&@7<YZL<=2
M?6H)-(TV:TGM)-/M7MKAS)-$T*E9&/)9AC!)]37!^"=1AAN]56QFUKS8K42-
MH>K9$RN"?G21VQM;IZ=Z>?B?/;V>JO<Z7:R7-@(&,=G?"96$K[-I8+PZ^E.W
M07F=ZVG6+Z?_ &>UG;M9; GV<Q*8]OIMQC'M4LD$,UNUO+%&\#J4:-E!5E(Q
M@CIC':L'P]XBN]4U;5=+U#3DLKNP,;8CF\U720$J<X'/!R*Y6?1Y=?\ &OBT
M-K&JVC6*6YM?LUVT:1L8LD[>AY H?GVN-+M_5SM[3PQX?L+E+FST+3+:X3.V
M6&TC1ER,'! R.*DM_#^C6DADMM)L(7)8[H[=%/S?>Y []_6N#T#QLKV\>L:D
MD[2Q: +J=DF^1RLC*<1XP&)7[V>^*MQ?$[997INK"W-]%'#);P6EXLRR^:VQ
M5+8&U@V,\'%-K6Q*>ESL(/#VBVME/9V^DV,5K<?ZZ&.W14D_W@!@_C7-:WX!
MFU2ZDB@O[2WTN6)(/(_L]#)!&N,I%(""JMCH0<4U_']W8C6(M5T40WFGK;JL
M4-QY@N))B0JJ2HP,XY/OZ<['A_Q%=ZCJ-[I6JZ<MAJ5HB2LD<WFH\;YPRM@=
MP01BA;W'>QH3:!HUQ<FYGTJRFN&55:62W5F(!! )(SP0/RJ0:/IBR7<@T^T#
MW@Q<MY*YF'3#\?-^-8_CS5;O1_"-U<6,GE74CQP1R_\ /,NX7=^&<U6L/#%U
MX9NI+^PU74;Z 6K":QNI_-,\HY#*[D!#U![<TN]]OZ8=DOZZ'2V.GV6EVHMK
M"T@M8%)(B@C"*">O J-='TQ'1UTZT5TE:=6$"@K(WWG''#'N>IKSC6/&]YJO
MA_6K)HX+2]L_LLGF6%]YR@/*H*E@!AA@@CWJ+QCJ5_-K%]IFGPW&'U.R@G;^
MT7C\P,F0BX7* ]"0>V:-6P/29-!T>6&WADTJQ:*W<O"AMT*QL3DE1C@YYXH_
ML'1_+$?]DV&P((POV9,! VX+C'0-SCUYKE]0\;7.E37T=IHS76FZ,L:7]P;G
MYT)4$A 0=Y4$$DD53;XE7W]EZGJ\6@+)IEE<FV647?S3/YBH,+MX&&S]>/>F
MM=@]3T2BO/-6\77$NE:]::II;VMSITEL2MK>D;TE<;2'"@@CN,<]*T=?\;7.
M@ZY#:S:?;?8Y)HH5=[Y1/)O(&Y(L$E5)YR0:2U!Z'945QWQ N6@@TE)[RXLM
M*EO E_<P2&,HFUMH+CE06V@FN6LKI]7\"KJ>J^([^#3M,EN828I&CFNB&Q"6
M<$$D#'&.2>:5]&^P[:I=SUJBO+-8G\61>&_"DMY>"W3S[-;L D3S2,^"K$<!
M0,9]2:U/B);7$$,FIC7+Z";RE@TRQM',9>Z+<$X/SYX&",  U35OOL):_=<[
M^BO/M6F\0Q>.?"HO+R..QDE:/[/ 2#*XA)9I.WWL@#VS7H-%M/O ****0!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@FP5Z6Z"1&1NC#!K/T70M/\ #]F]KIT+1H\AED9W9V=SU9F8DDT[ZW_K^O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2!9)B1&I_B(&3^E $M%%% !145O<PW<(F@D$D9) 8>H)!_4&I: "BD) !).
M.I-06]]:W;,MO.DI5%<[3GY6&5/T.* +%%%1P3Q7,0EA<.A) (]C@_J* )**
M*K)?VDEN)UN(_*,GE!R< ONV;?KNXH LT444 %%%% !113)IHK>%YII%CB12
MS.QP% [DT /HHHH **BAN8;AYDBD#M"_ER ?PM@'!_ C\ZEH **9'-%*TBQR
M*[1-L<*<[6P#@^^"#^--GN8+;;YTJ1[\A0QQNP"3CUX!/X4 2T4R&:.X@CFB
M8/'(H=&'0@C(-/H **BAN8;@RB*0.8G,;X_A8 ''ZBI: "BBB@ HJM%J%K/=
M7-M%,K2VV/.49^3(R 3TSCG'TI;>^M;MF6WG24JBN=IS\K#*GZ'% %BBBB@
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M[F$,)F2-MP=H&&75"0,M@'.0,]:T=2\4-IVI75O_ &;+-;VB127$Z2J-@D)
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M1PE8I58J7;:">>@YS]#1>[!K0XV*TOS>6\-]#J\D\6HPBRR)FC6W2<Y+G[O
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MUR=]/T'&R?-\_P!?Z_X)3TSPMJ>H_8-0O1;6>+!+7RH79BJ^2ZA^5&&S)T[
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M1I+437-I<QD!F*I)-+YF =OW1TSC/M79T4+0;5U80< "EHHH **** "BBB@
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M=PPG&>?3BGJP90RD$$9!'>O!M8UK4$NO%%I=WKZ7;7$<TK!44^?<?9X1Y)+
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MM"DM%L;^6UF$#7 0^6J2X91M)96+'!/RKCU)&*2UM;J.VMCT6F22QQ*&DD5
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M[]LLUB4&R$38CP=N?G7@Y)SG(Q6IX2\3:M=^+K;3SJBW%H!Y8A?;EX1"K+*
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M_5]2MIH-%&J1KIT]LK&2-?)F<IL?YB.F"<CI2#R_K<[_ 'Q,1\R$AL#D=?\
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M#:2[H@I ;>NW*8W*><<&LB#X701PZK;/?1F"[BDB@*6JB2,.^_+N22^" ,#
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MT#LEMGRBDSQLH(VD94@D$<$=Z@L_"6A:>L$=K9>6()UN8QYSG$BIY8;EN<*
M,=/QJKJ[;)M[J1D^)/'#Z!KUO8"S@FA<QJ["9O,5G)"_*%( X_B(SGC-9=A\
M2-2N'M6N-$MHH)OLCNR7A9E2X.U"!L&2"#D9Z=S75:CX/T/5M2_M"\M'DN/D
M)VSR(K%#E255@"1DX)'>F6_A3PZ8D\BT5HXQ!&I6=R (&)C&=W\)S]>^:4;=
M1R\CE_\ A:%S*TGV;1/,5YUBM6:5U5\S"+YV*84G.X8+<>XJ/5?'VJW&B7EO
M9:=%#J4-K>/<N+D[81"VPM&=OS')! ('2NJ3P/X>CNI+D6!\QY5FYF?",'\S
MY1NPHWC<0, GK3;_ ,#^&[V,BZL3L+RR,5N)$W&0Y<$A@2"><=.*GH4FN:YS
MB^/M729+2#2+:XQ)]E6:6[*%Y! )B6 0X&,]SS4G_"SC)<V:V^DO)#+;033D
M,Q:,RKD8 0@@<9)(Z\9Q730^%]!8I<0VJMF7[0CK,Y!8Q^5N'S8^YQZ=^O-0
MMX(\.B6UF-CM^R0I%&//<+L0'9N&[#%<G!.2*J7]?B3';^O(Y"[^(6OW6CQO
M;Z9:VEU,ME<Q$7)<&&:39@Y3@Y&.^ V>HK:\6>*]1\.>(;,^1')IJZ?/<SQJ
M^'=E*@ <=BRCK_$3VYUF\'>';NP2%;3=;FVBMT:.X?\ U4;;HP&#=CSGK[U<
MU/PWI.L303:A:^<T$;Q+N=@"CC#*P!^8' Z^F:';IW_S!>?];%#2O$&H:A:Z
MO!<6$-MJNG  Q).7B8LF]#NV@]\'CC%<1H/CGQ%')'>ZC#%=6SVEDT^)]OE^
M;(Z;U4+@DY4D< 8[UZ%I>F:'H.FNMFT<=M</EI9;@N96(P,NQ)/  '/:J]KX
M'\/6=K);0V+>5((PP:XD;B-RZ#EN &)Z?3I0K)W#[-BCX:\;GQ!JMS;G3VAM
M561X;C+$$(^TA\J ">H )X^E<GH'Q*F:7Q+=RW45\BP/?V5L'QY2([)Y9/8D
M!&_X%7>P>%M T^ZNGC@\J34%>)E,[\ALLZQC=\N3DG;CUJ2\\):'?V=K:7%B
M&@M8&MX565UVQLH4KD$$C '7TI+IZ#T_$YVT\>ZB^J"SO='MX5%Q);,\5V7Q
M(L/G# *#Y=O!/KVK.F\=ZGJ%E8*]HNG37+V-U$T,_F;X)9@C*V5&#UXYX-=G
M-X5TEWDFCM=MPTK3K)YCG$IC\K=C./N\8Z?C6;H7P_T;2=)M[::#[1<(L!DF
M,K_,\1W*5RWRKNYVCCFJ5KDN]CSO_A(O$6HZ[?V^EW>OR7,6?LD,.R6$.)Y%
M/G$J J848Z=.IKK(O%>K67B#5+2ZA$UC)J)M(YA/AX7^SB0*J[<;<@\YZMTK
MK]+\-:1HMW<76GVGDS7'^M;S';=\S/T)('S.QX]:27PSH\TSS26>7>Y^UL?,
M?F79Y>[K_=XQT]LU/V;>175LXC7-9U.;PIX-EL[C51)J#)YPLY4-Q(#"6QN8
M!2<C).!4.E>-KFPM(KC4IKRZDM;.]:6)G56W1S*JI( N#( P!8'')X-=O>^#
M]#U#2['3;BS<VEAC[,B7$B&/"[1\RL&/'')IL/@SP];0+#'IJ>4L$L&UY';*
M2$%PV2=Q) .3D\=:;:NV)=+G.:A\0]1TRTN%NM%ACO+6X6*Y(G=X(U:/>K%U
MC)&?N\K@'J<5'J?CF_N]&U:ZLM/ TZVC:,W<%\JRK((A)E05(*_, ",GOC%;
MT?@?PU-IR0Q6[M$9#*)TNY#(Q*[3^\#;B"ORXSC%++\/_"\TCN^EKM:+RC&L
MKJ@&W9D*#@-M&-PYQWH5NH(P-0^)LEA<ZC'%I+3P622)YN]\F1$#G=\FT*>F
M<YSVYJT/'6JO.=-71;;^V#=>0D/VP^5M\GSMQ?9G.WC&.O?%:\W@WPSJ-Y=W
M$EHLTDRF.=5N'VY*A2=H;"L5P,C!Q4]_X.T+4?.-Q9MOFE65Y$F=&W*FP$$-
MD?+P<8SWI= 1AWGQ GM=:AT]=%EE(CA:Y2-R[H\@)"KM4JP&.26'7C.*M^&/
M&4NOZ7J5Q+:0P7-DNYK=)'+K\I.UU=%8'C'0@]B:N77@[PTT]M<7%C$@A1($
M0R,L;!>$5DSM8C)QD$\U<T;PWI>@+,-/@=#,%#M),\IVJ,*H+$D* < =!0]4
M_F';Y'':9J]YI&@0>*=2\0RWHN]/:[DTR38-S?*1Y. "JKNP<[NM7#XXU<7D
M6E?V);?VL;L6SQ?;#Y0#1&4,'V9Z C&.M:\/@KPQIWVR?[!$D<\31RB:5FC2
M-CEE4,<(">>,58L/".AZ=]G>VM&WP3&XCD>=W;>4V9+%B6^4XP<@4[J_D#V.
M9/Q*GM8I;F_TA4M"MU]G:&XW-(\#[2&!4;0>,')[U)/X]U:"8:>=$M?[6%SY
M#Q&]Q$%,)E#!ROH"""*NZ7X'T72+>ZEU00W$MR\ZR232,(]DLA8J%8X!((!(
MP3BK]OX2\-V?D6RVRF02/,@EN'=W8H4))9B6&PXYR *70?4Y*X^(6L7^BW;6
M-G:0WL%U:+N2=GC:.9\##,@R>,$@$<Y!.*LVWCF]MM-VV]@U[<1B\NKC[3=@
M;(89BI"L$Y/H,# ')K>M?!/A@Z?=6EO \D,_EI*PO)7;,1R@#%B5V]L8Q2S^
M$/"MU8(CV\9MK9Y266Z<8WMND5F#9*D\E2<>U/3H(S[/QY<WFNQ6ZZ9&--EO
M5LUN?//F;VA$JG9MQC'!YJ.]O=6M/&\XM=6EO(HX)9[FS$:B&UB$?[L$]?,9
MP3UY&>!70KH>@K=Q2)#$)GN1>Q@3-\T@38' STV\8''M3(_".AVVMS:VEK(M
M]*Q>60W,I5B5VG*%MO3CIQ2?EY_D"\_(\Z'B#Q2OA+57@U;S98[*TOWN)U&^
M,2H2R1[0!U QGH":W=-\0ZE<?$::"YNKN.R%T]E#$%C,#E80^#_&'ZMNZ=!7
M2V/A#P]!HUU86MH&L;X R@3.V]<< -G(4#H <"K2>&=(37CK2VF+XC[^]MN<
M;=VW.W=MXW8SCBJNN;^NW]?F+H<5:W>KWOQ"U.(S>()+2UU".-1:20BVC78C
M$2!AN(Y.<=C5BY^)%Y;QS7/]CQ?8S%=RVS_:3O<0,%.Y=ORY/N>*Z23P5H,N
MLOJ[6DPO7E69W2[F4,XQ@E0^T]!VJA-\/])?7Q?1PA;:6*XCNK9G<K)YNW.T
M9PG().,9)J5LD5I=LYWQGXYU*T@N?[.B:&XL[EX583 *X^R^;N8%3G&>!QR!
MSVK;'C.\M=0L](N["(ZA<K:F(+,2)!)GS&SC^#8Q]^.F:T1X"\-BU:V:P>2-
MG9V,ES*S,QC\LDDMD_(<?_7J*+PS$OB_3[TSVY@TNR,-I!\S3#=@%G9F)(P"
M!QW--6V_K83V,AO%6K66LZC9V]NE_+-J[6MND\YC6)1;+)U"GC(/;O5K2?'-
M[KES:"QT>-H#!;RWC/=!6B\TL!L!&'V[23R">PS6Q'IGAR;53-$;=[[[2UT0
MMR2WF^7Y9;;N_N\8QC\:J0^%O".^VO((H"NG!45ENF*+L)*[_FPQ4DD;LXH5
MM+@^MC!_X6A<RM)]FT3S%>=8K5FE=5?,PB^=BF%)SN&"W'N*S]9\=:[(N4MD
MM88K2^^U)!<_.)(7"Y1RA]1C(_B.1QSV%IX2\*SW$MW:P1S,TRRDQW+,J.'\
MSY0&POSC<0, GK4UWX'\/7PQ/8L06F8A9Y%W&;F3.&Y!/..@[8H6EKCNKLY_
M4OB2=)FN;273O,NK1W:2,2\F 1JR2=/XF=5^N?2I[SQ5?7_PXUW4D@>POK..
M159-V"0H(="ZJ2.>XZ@UT%[H'A^:ZN)[VV@,]W:_8Y6DD(+Q#)V]?J<CGCKQ
M4=CH/A]M"N-'M@EQ972EIU^TM(TH;C+/NW'.,9SVI/5,2T:.#M]9\0V6B3WL
MESJZV!O;%8)-558IFW.!,.@^0C&"1WK7MOB1=W%A>.FEV[W4-Q:Q1HERWEN)
MVVK\Y0=/4 @]B:[/4M$T[6--73K^U6>T4HPB9B!E2"N<'GI^-9=EX-\-6GF6
M]O;EFW0R.'NY'8>4Q,75B0%/0=.,=JJZ;U_K873S,?5/%NL2^#/[0LK6"WU"
M/4UL9XS+N0$3>6=K%>0>!G' )/:KNB>,Y]5UBWMYM-6"SO?/%G,L^YF,+;7W
MK@;<\D<FMB?PQI%QI5QIKVK?9;B<W,BK*X)D+;RP;.0=W/!JC-X%T0I?FVMS
M!->1/$T@D=A&'Y8HN["DGDXQD]:2\_ZT7ZC?E_6I!XR\8OX5-N4M8+A&4R2J
MTQ5P@('RJJL3UZG"C'6L^^\>:I#K-Q8VFC6LT:73VD<DEV4+.L(ER0$.!MSW
M/-;NL^&O#^MW4$6IIYDXA,:H+EXVDCR"00K#<,@'GH:E;P[H37YD:W3[4TS7
M6/.;)<Q^4S8W?W<#T_&ET^\9R]Y\39(=._M*WT?S;*WL[>ZO2UQM>,3?="#'
MS8[Y(IMK\1[^6TC,VBP1W5W#:RV<:W197$[E!O.P;<$9. >*Z*;P+X;N/LHD
MTX%+:)(43SGVLB?=#C=\^.V[.*IZSX-TNXTS^S]/6VM[O[/%!")W=QY43;E&
M X;@G[P(8>M-M7$A]MXQ<>$-2UR_L!%)82S1/;PR[PS1MMX8@=3WQ6!JGC3Q
M ;NUT]+&VM+N.]\F[5;C>K(T!D7:VS/0$G@<J!T-=/X=\*0Z5X6DT6^\FZ2X
M>5YU52(SYC$E0"2<#..234:^$?"Z01V'EC,=R)QF[<RF4+@9;=N/R<8)Z4FO
MZ^7^8TSEM+^(NHV/AVU34[!);Y[2TDMY//9A/YI*[I,)E3E22 &ZUO>'/&5_
MXAUD6:Z.MO!%;K+<R2RL'1F+J JE06!*<$XX/2M"Z\(^&UL-L]LL5O';16ZR
M&X=?+CC.Y,-NX()SNSGWJYHN@Z/I(\_2H%3S84C,BRL^]%+$<DG)RS'/4YYJ
MFTVV3;30X6^\3^*1XQEM($MWBBU4V\,)G**Z?9B^'(4G'1N_/';-.A^(5_<Z
MW:)I^GF:74K6!T@N+O9%$Q25FQA"?^6>">_' KM3X5T8ZVVL&U8WK2"4OYS[
M=X0INVYVYVDCI4-KX+\/V=W:W5OI^R:U14A;SI#M4!@!@M@\.W7U^E2MDBGN
MSF_^%E74]M#=6FCQ- L-J]T9+DJT;3OM 4;?F P<GBMCPWXPEUO7M0TNXLX[
M26VW%8FD;S=H8KEE9%&#P<J6'/6LC5?AY;7>KV26$]E;65HD(>(B1ID1'WC!
MWX.>1EP2.<5NMX'T58-02TA>"2\B>%G\YV$2L=S!%+83)YPN.::MN)]BIXJ\
M22^']7,J)+,L.E7%UY/FA8W*,@&1M)SSUSQSP:J#QUJKSG35T6V_M@W7D)#]
ML/E;?)\[<7V9SMXQCKWQ72:IH.CWZ-+J4*NHM7M6=Y60>4V"P.".NT<]>*@O
MO!VA:D)C<6;%II%F:1)W1MRIL!#!LCY>.,9'6ET&<[-\0]1@BOII-$ACC@N(
MK-,W6\F=U1L'8I^4!CRN<XX'-$7Q(E>]TJ%]+2)+J2.&96E?S8W=V0$+LX7*
MY!8J2#P*Z/\ X0[05TR?3H[ 16L\B2LL<CJ0ZA0K*0<J0%7ICI55? _A>VNK
M206GERQLAB7[5(H=T)96*[L.PY.3D\FFK7)>Q@3?%"6WGOK:?3(HKJ*988+=
MY9!(27*@NOEYVX&[*;_3K5[6/%6K2>!;36--M!;7DUW%#)%.2NW,H0XRN<$X
MP<#AL]>*TV\ ^&V\\FQ?,W3_ $B3]U\V_P#=_-^[^;YOEQS5N?P]HC:''H$D
M06R)&R+SF5RP.\$-G<6R,YSFDMM?+_@E/?3S.)TWX@:CI.G3OK%F+B+-[);S
M+/EW,4VW85V_*/F !R>E=/IOBV:[\+ZAJMQ8I;SV1=61Y&2*0@ @AW53M.0,
MD=<]:N'P=H#6ZV[:>&B59D"M*YXF.9.IYR>?;MBI(/"VCP:'<:.MLS6=R29A
M)*[O(3W+D[L\#G/&!1T#J<:GQ1O9[>Z6WT:"6[L8IY[H-<.B>7&%Y0M&&).\
M<$#IUY%7O^%@7CWL8CTF(V+70LS,UP0XE\GS3\FW[O;.?PJMXF^'%A+;(MA<
M6EE'(9%GEOI)9'9I JE@YD!+?*/E;*DX.,TMQX-LH/&,%[=ZIIL5M$RR^4Q9
M)W(C,8!^?;CON"[C@#-&XAI^)=_%9Z;--H2&2\M_MGE0S/(?(^4#&V,Y<DG@
MX''7FIX?B+=2R"8Z5;QV$T-U+;2R7>QF$#!2'!7"9/N?SKH;GP9H%Y;V$$MD
M3%8QB*!5F<?NQCY&P?G7Y1PV>E<_9_#6+^W[R[U%K26QE2=%@@21&;S6!.[Y
MR%QC^ +R<]:;M?[PZ%*7X@ZI<6VFW,-I!"B:G):WRJ[8=4B,GR;D#8(R>0.5
M Z'-;_A?QE-XAL+VXFTTVQ@B6>/!<HZ,I(&YE7YAC!QD<C!-6O\ A#?#L-B(
MVMV\F.Y^VL\EU(Q,H7:69BV3D<$$X/.:GT;0-"T;3[AM.15M;A/GD-PT@* $
M !F)PH&< ' I/9V#JCF;'XC7LT-NUWH\,+7*6<L(CN2X,<\FS)^48(ZXY^M)
M?_$B]MHY)(-'AE6%;N27?<E,)!*(R1\IR3G../K70/X4\,SV\5I]G3:]K'!"
M%N7#>5&=R;3NS\I.=PY]Z>O@CPZMJ;8:>?*:*6$@SR$E)6#.,[L\D YZ^E4[
M7 XR?Q[KO_"1RB/3H0=.M;E[NT^UGRV"")PZMLR6VOC& ,D\UM6/Q$_M'6Y+
M6WTQVLP&59\MN#K'YGS#;M"G[N=V<]N:U+WP#X;O[J6ZN+!S/*29'6YE7=D*
M"" V,$(H(]O>K2^$]#BU635%L]MPZD-B1@@RNTL$SM#;0!D#.*E[!U_K^NYE
M0>,+\^#K/6KC2H4N=0EACL[9+G*MYN A=MOR]3G@]*RK7Q)K.N^,]%M!']C@
MA-TM[#%<9#2Q,JGG;\R_,I XSN.>G/72Z)HLWAV'27BC.F(B1PKYI^4+C9M?
M.<C P<YJ&WT?P]H,UFR"&VF@21(&EN#N(<@N3N;YB2 23DU6G-?H+[-CD_%?
MCN]M)=>TF.!;*:"UE:VF:5EE<J@;>H*;6')'#$C'(JS/X_U"RTZZ%QIEHFH6
MLXB>,W;,KJ8A*"N$+,V#C 7@\YQ6_=^"/#U_>7-U<V)D:Y#>8OGR!"67:S!0
MV Q'!8 &GWW@S0=0EDEN+-_-DD$CNEQ(C$A/+QE6'!48(Z'O4Z\MNI6ESF$^
M)=W-I]QJ$>CQ"U$L-O S7#%FEE1' 90A(4!SDC)XX%3W?Q%N+6TTBYDTD6\5
MYN$TET\D:1LK[-H;RSR>6!?:"*W3X2\.6ND2Z9]F6&TFDC8C[0X82*%5"K%L
MA@%4#![4DW@;P]/;VL#V+>7;(8U"SR+O0MN*OAOG!;DALY-5I?R)Z'1 Y&:*
M ,# Z45(PHHHH **** "N=\:ZC=Z7X?\^TG-L&N(HY[H(&-O$S@/)@@C@=R,
M#K715!>7=M8V<MU>31PVT2EI))#A5'N:3&CS#0GN]<\::!=WFH2745NE\+:9
MHD N(TD15D^[U(;J,?=&.ISJQ^(+\^--2M7U65;F&62.VT<6P998A"&63<!N
M7+9^;)';%=EI&LZ;KED+O2KR&ZMP=F^(Y (['TJ]M&[=@;L8S3?;U_'J*_7T
M_ \>M?%>NW-FJ0:[-.9C8_:)Q!&&LYY9MDD(&W' [,"1CWJ!_$WB6&;3X/[?
MN6^VSO;ES%%F,1W:0AE^3&2K'.<\U[0 !G  R<G%+335]@>QY%:^)O$UK;74
MB:C-?S&QOFCCDA0[6@G$:L J@D[22<YR:EMM>UC4+JUT^R\27$]C+J!ACU-(
MHM\J_9FD91\NT[6&,X]NU>L57BO+5[V6QCE3[1"BO)$.JJV<'\<'\J0'FVL^
M*=7C^'GA[4QJ8M[FX7=<.&2)IB$/ =D9%.1G:<;N@-4-4UN_M?$DFH1ZI=6I
MO-,L6D,L29@A:0B23;@X*]3U +G/08]7N;RT@FMK>XE19+ERD*-_&P!; _ $
M_A5@JI.2H)QCIVIWUN'E_6YY)_PEFJ,EFMWXAFL['_2?LNHK:JYOBDJK&"N/
MFRI/"X+=15_X::C>MJM_8WDK1V^^XELH0H"RC[0_F,>^X$@8[ CUKT2UN[2_
MC=K:1)4AE:)BO\+J<$?4&K-"=@>IX_XK\9ZS9^)=2MM,U*8>6L\7V=A'F,I#
MO5E3:6QD'YBW/( XJ+6-=DUJ]ANAK;_V=!K"Q0O'MV$-:9QG'.6W#_@1]L>R
M;1DG R>I]:KWEW::?:^?=R)# K*H9AP"2 H_,@5-M+#OK<\ATK6]:T7P[:6:
M:K+]DDTVPG:=HD)L8W<H[+A>@4#ELXZUJ:;K.MZM>VEL=9F-FL%[*LPAC_TV
M.*151FRN,$$C(QFO4R 1@C(J)KB".>.W:5%ED!*1Y&Y@.I ]!D?G52?-?S_X
M(EI;^NQX7J'C74-.T_28]-\0M:SQ:5!--:>1'Y;.RJ%2-0F<X)8]@ .*Z!/%
M&JR:#8M<Z[Y-C+J$L+ZI&$D8((MRJ6,80Y?Y<A<'IUS7K--"(%"A5VCH,<"B
M6M_,%I8\GM;(W_A7X<(UPZQFZ&Y0BD,1&[ D,#_=Q_P(]\8@NO&&OQQZH\>J
MNUVEO>O<6?DJ!IYC;$)'RY^8?WB<YS7K-G>VVH0&>TF66(.R;EZ;E)5A^!!%
M/@G@N [P21R ,49D(/S#@@D=QTH;N_Z\@_K\SC=9>\TX^%DDO#=7!GF+7,]N
MK,3Y$C @*O&.!\HR0,=ZX1?'.N?V*^=<D,D4ZF2<2PA908V;;'*8MJG(SY;@
M-VSFO<JJWMU9Z?:F:[>.*#>H+,.-S, /Q)(I?U^(+9'G.I^,M0@O4B^W2V[7
M4&FR6T4L2J[;Y2)N,==N ?2L6?QIK=QKTUG9ZU.D5Q.J#<L1>W/VI8B FWY/
ME;HQ8G@\9KVG SG STS2,R1(\C850"S'^M.ZO=A;2QY,_BC5H7AM;_Q%/90P
M2WD:7HM4D>YECF"I&RA<,=I/RK@FM7P'XDUG6/$=[#J%TKJ$D:6U( :V=9-J
MC 0;05[,Q)QD=Z[=M6TTZ?;7[7,1M;AHQ!*>CER F/J2/SJ:RO+2_A:XLY4E
MC+LA=/[RDJ1^!!%"TW!Z['E%WXUU=;:\ABU1A>VMKJ3S)L7=&R3 19&.RGCU
M%6+O7]8L;F;3;WQ!/%9QWZQRZDT4>]%:V$BI]W: 7XZ>U>K@ 9P ,\F@@,,$
M CKS2Z6'?6YXMX7\1ZS;S>&]-ANUAM_L]L([=\8N5<MYAQL+$C'4$!<<\&N@
MEDU34?AEXHOKG5KF61_M21($0>4L<CC:N!DY P<\^E>DE5+!B!D=#CI2D9&#
M3EJG_74$[-,\8T74=2TRYEOM,U26]BGU);?R"J%+C-FK!\A<[LJO0@>W-=)X
M"\0ZKJ^DZI->7ZW?E0)(KC!:*4H2R'"*!@@?+R1T)Z5WTT\%I#YD\L<,8(7<
MY"C). /Q.!4-M/9:I92-:R)+ [/$S)Q\P)5A]<@BE)MIV["5E8\>M?$.H:SI
MUBL^K/J<3/ID\[M&J_9[@S@&,;0.P!P<GOWJTWC;5VN/$GV;5)72/3[F>)9!
M'OMY(Y0H&P+\G!Z,6)X/&:]8TW3[;2M.M["T0I!;QK&@)R< 8&3WX%5+WQ%H
MVEZE#I]W?PPWEP5*1'.6W':.GJ>.:IM7T!;:G#ZC=Z@_@KQQ87]_+?&SB CF
ME1%;#PJY'R@#@DXXK/;Q;K&FZ;<ZC::G-JNF65TMNLIC0&4R0\+\JC[DI4<>
MI!SBO7:S=5T2RU86WVSS?*MIA.(TD*([ Y&\#A@",\]ZGU\OZ^X%_7]>IP?Q
M$ADC\,:!!JEQ TRLWGW=Y&'A\SR'SN4#&23\O3!Q]*Y[5%EEU.PV6\L6KR6N
MFG3DD&9D0+)YH!]A][IVS7L>GZE8:U9_:K&>.YMBQ4.HRI(/;/6K9"YW$#('
M4]J'U\P73[CR7P#>6=K9W\%DZQ&ZL;:")44C?>K YE'^_P #/O[UBZ6EI_PC
M<[Q1H-'232AJ V?N]ZG]_O'K]W=^M>QP76DZG>(MO-#<36P%PHC;(4.&4/QP
M<_-S]:T-B[2NT8/48ZU3=W?^M_Z_ /+^OZ_X)X/H4>-7TL/&?M;W-HVE97YA
M:B>8OL_V=F,^V/:NO\7>(]0L/&\=@M_(;.2-(_LD.P-\X;+%&3+KT^9&^7'(
MKMH?$&C7%[]EAO87N%G:V"K_ ,] "2@/J IS]*U"JE@Q W#H<=*EZI+^MK#O
M9M_UN>,:7KNI:'X:M[-]8N1!+I=C-%)MB7[,9'*%0Y7"K@#YF#8Z\UJ:-XA\
M0:O%HC)J4OF"QO+B1(T1OM3PS!44G:.HX) &?:O4I618G:3&Q02V>F*CM+J"
M^M(;NUE66"9 \<B]&4\@BG)WN_ZZ_P"?X"6EOZ[?U\SQ(>-_$3:*)VUY"F]'
M=@Z(X<QLS1"0P^6N" 0C?-VS7:>,/$MU:>$M'N8+VYL9[U _F,L<1)$1;:Y8
M,%).. "2>!7>^6F"-BX)R1COZTI .,@'!SS2>JL"T=SQ_5?%GB0:;+JUIJ4B
MR6VFZ=="T2%&2>29B&!^7=@^@(K3^'FHR:IXJN+J;57U"X?2+<SET5?)D+N6
MCPH'W2>_(]:].I  HP  .O%5=7;M_6O]?(.EOZZ'CVF:)?OX1\2:E9VFFF9G
MODAEAM"+W/FL"/-SR,9& /2JNJ-H<]EJTGA**%-/3P_*E\;>/8GF97RPW R^
M-^>_K7KMUK>FV5W]EN;R..?Y#L;K\[;4_-N*O*JKG:H&3DX'4U/3^NUAWU_K
MO<\Q\%6LFE:QKJ7,-A8WZZ?$\4&GV_E0RQ88B7!)RVXE3Z8]ZR-4\5ZWI7A;
M1;IM?N7OKJS%^?,6&-'SL&S[A+8R?E !YR2,5Z_>7EOI]G->7<JPV\*EY)&Z
M*!U)JII&NZ1X@A:?2KZWO$B;:QB;)0^_<4[W=_3\V)*R_KLCQ7QI).FI>(K<
M:FYDDO'<QO'&Q2/[&S#:2N5!P4R.P^M;%_J-SH'B*WTQ-3_LS338VJW&I1VT
M0>/Y)BH)VXPS #'Y8S7L> "2 ,GJ:&4,,, 1Z&A:*P/5GDOB'Q9J:ZKIEI::
MS<HTT5JD@:&.#S1-D&18V5F)Z'J IP.<UD^'-;O;'07:UU#Y5L]/CN+WR49[
M5&ED$A)V\[!Q\V<=?6O:;RZMM/M9;V[D2*"%"TDK=%7O4R[#&-H&PC(P.#FA
M/<.QY#-XD\0W-FQM]=G2*WLK^YANDACS=K"ZB-V!7&""<X S^-=9XJUN[M=+
MT.0ZBVEVEXW^F7Z(I,(\LLH^8$#<V!DCV[UV@  P!@5G6>MZ3JEW=6=G?VUS
M/:MMGB1PQC/N/J*3VL'F<)X*%]JOC,ZOJ<K_ &MM%MV*-$J@;F<9'&5SMW8S
M_$?;')6SWUM?7\UIKMRM[80ZK,S;8V8%)D(5@5Z-PQ[\\8%>XV-_:ZE:K=64
MZ3P,642(<@D$@_J#5)_$>AP:E<:<^IVD=Y!&9IH3( R*!DD_AS]*;=GIV_X/
MZC7GW7^1Q&@^*=;U#Q\+2XND6%F*M9''$7E!ED "9&6/WBV#G&,BL_7-2O?^
M%A/XFBM)WTS1[J*PDNED01HA!$V5)W$[I%Y Q\E>CP>(=%N;*WU"#4+:2WN9
M1;Q3*V0[DX"#WSVIL?BC0Y=8.D1ZI;-J(8H;8/\ /N R1CZ"CJO+^OR_,GH_
M/^OS_(\YD\;:T$N(;6^,U];6^HM+#Y8+(4F41$C'9"2!W[YKF=;NGN+35S9:
MN]^LMXV+TQ1EY MBQ."%P.FW*@'&:^@@ ,X YZ^] 4!=H "XQC'%(J^IY[XA
M:S;0_",^HSK>:"LJ->S2J&C<>40C2 #!7=CMC.*QK_Q##INF6R^';JXT71VA
MNKBT8PAA=7"N-D:A@V$;)(48)'3%>ME5*;"HVXQC'&*"JD $#CIQTIMW;]?Z
M_P" ):)>7]?\.>3S:WXDNM7=#K-U9"2]:U:WCCB(B M!,<%E)SNR.2>*B;Q+
MXBOA93IK,UMNMM,+I%%&59KAV1V^93SW';->O4477870\)GU34-2L=8:]U)H
MVM+BSC>[6*-9&1;N5-SL%YP #Z9'3DYN1ZYJ6B^&?*M=;D ?6;R.YNY6C4Q%
M=Q122A W$!NG.<#&17M) 8$$ @]C2%$((*J03DC'4TNGW%7U/)-'UO7/%&OM
MHNM7,:0W2-#<6*C'[KR0PD53'N7).=S$#G&,BMK3_$-^OQ1FT>2^DFM"SQQV
M\6S;"JH"-Z% X[_.&93D"O0MJ[MV!NQC..<4;5W;L#<1C..:=]43T/(_$'C+
M7=,\3ZU;VEY)<%(Y1!!$$(@"HIW/&4#C')WY96X%9NM>)-;'AO2M3M[E-0N;
M;4IUMKA2')3[.V6)"*KE<L<@8XQUS7MVU=Q; W$8SCFA555"J  .@ I+1%-Z
MGDZ>*=4;P_9/=:^;>PDU"6&35H@LC+&L1906\L(27XR%YQC.<UG:5J%Y'XO+
MC4'U"[EOA*L<]LJ,P-DS*RJ1NCR?EX/08]<^T>6FS9L7;_=QQ2X )( R>IIW
M%TL>/6WBO7KJR"6^O33M,;'SYQ!&#9SRS;)(0-N.!V()&/>NIM=:UF'X?:U=
M1S/>ZC83W4$,KQ@LXC<@,54 $@>@YQ7<  9P ,G)Q2T/;^OZ\@6]SQ[S[GQ#
MJNC0/K4NI:;!K2+;WABCQ-_HY=@?EP=K C('\1[@87Q?+I\7Q.NS?W6A0+]A
MM]O]K67V@-\SYV<_*?\ ZU>O@!1@  >@I:+V:\O^ !Y7:ZCKU]!ICKXBNHUU
M+5+JWS'%%^ZBB$V N5/7:O)STK-C\8:Y=W.BQS:M-_IMI$C16PC5][A@9"C)
M\XR <HV%QR*]FI"JE@Q W#H<=*3VM_6P[GE8N!_PHFSB-SYZW$<=M+<2GY;;
M<^&9L#HA]?3FM?X6ZC%J7ABYT]X$S:S/'*P?<EP7RS2* H 1B3@#M7>[5V[=
MHV^F.* H7H /I3;NY>8NB\CQ^UAN=!M]:N(;Z51IU_'I,-TR!C8V197=AD$9
M <#)'11Z4MSXVU:RTQY9=68P-9WZV5VT:K]J>-U$+CC!;&[IP<9Q7L! (P1D
M4FU>.!QTXZ4AWUN>-67BKQ3%HR:@NJ37DUW:7[+"\*$1-#( K+M4$D GKG-=
M5X2U>;5++Q(AUB75;6W*I;W$B*I*F$$_=4 \D\XKM;VSAU"RFM+@,8ID*-M8
MJ<'T(Y!]Q5+1-!L]!@FCM6N)&GD\R6:YF:61VP ,LQSP !0]4UW0+2S/+1XG
MT2;X5Z)9QZE"UQ8O8O<Q@G,2K*F2?I5[Q.]OXX\5:2F@MI&I1O8W49>]5GC3
MF/+* ,[QD8Z?6O6**;?,[OU_"Q*TV_K6YY]XMO+KPEX0T?3K?59X9T3R1<@H
M@D,<1(#,X8+D@8 !)Z"LOP=XQU;5/%ME!>Z@]PEW;AO(A"!8CY*M\\90.O.?
MG#%3D 5ZH0#C(!P<\T;5W;L#<1C..:$]6V%M+(\AU>.4ZAXFMO[3F\]M>T\H
MI"DPAC'M<#'X#.1\OUJ*^\7^)+1K>T&J;?(GNHH[B8*INGCF"*C 1G<=I^ZH
M!.<]J]CP 20!D]3055L9 .#D9'0T+2Q3UN"DE 2,$CD4M%%(04444 %%%% !
M7->.K.YO/#JFVMWN?L]W!<26\8W-+&D@9E [G Z=\5TM% 'FFJW<^J1I>PZ)
MJUAH\M\?MCVD;QW5THBPCE% <*'P/< 'I65_9GBBZ^S27QUL7"1:>A,4LJC#
M2N)<[3@L(R-QZCKQ7L%%-60/4\6OWU6".RL+AM?\];34!;16[S>:76<"!GP<
ME0-O+<<C/%-U\^+)-3NC;VVM+<^1)#-Y(G=6_P!'!5E*_NP"X. H+9ZGG%>R
M-9VSWJ7K0H;F.,QI*1\P4D$CZ$@?E4]"Z7'U/(]637?#=M?W=G)J3I:7T<=N
MEU-(WFK/ $."Q^;$I!]B#6GXTT:[T[0=,^PMJ$MVB)%/)%Y\GG;$;:)#$PD'
MS$D$ C<?FKO;W2K#49K66\M(IY+63S8&D7/EOZCWJY2Z"6C.,U7^UYK7PO)'
M!>QR'<;N-&9BF;=^)".OS8&3WQWKCXK#Q%8Z5$I_MY[>:QL9K\,\SRY\P^<J
M9.5;;C*KSBO8Z*=];@MK'AXL_$=M!;I:1:W;6KW-T]M^YF:7S3,"C2 ,N<IW
MD.T_-FI+2;Q'=6U])HTFL27H2_6Y=VD,1 EQ&(LG;N&& "\]?:O;*@M+.VL8
M3#:PI#&79]J# W,22?Q))I=+!YGF-AI^L:AIVD6TLFL_87U*;<1Y\+K#Y+8!
M8L9-F_H6(ZX]*R+FU\07EE81ZI:Z[/<_9['[,JI*4!67]\90.-V I^89Z$5[
M913OK<.ECQ9+7Q7=7ES#.^M*SWD:W8B295 -R,,C[L "//W !MZ\UL:'I5[;
M^,]'GO8=6:.WDU"VAEE,KA4$@,6\G^$J6P3UP.N!7J-%$7:P/6YY?KNGZX/^
M$BOX&U7)U**((KS%?LFV,N8T4@GG.2G.-V*YVXN-;MXXO[1N-;,BBT%DZF2-
M8T:X(83#<>2NT#?R1COFO<JS+SP[H^H:I;ZG=Z;;37MOCRIW0%EP<CGV/2E'
M1KY?U_7=@]4_F>8:DOB2*#3I%AUF69+JZ*P;9U#_ .D';\Z'Y6V=/,4IMJ*7
M3]7T_P .FUM8=7AA76+LW>Q9W<@[C$R["&93\IRIP6QGO7L]%'2W]=!WUO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)Y7W[57D^'&E3-IR37=]+;6$<<:6\CJRMY8PISMRI]=I4'N*[&BETL!RNF>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4<\$5S \$R!XW&UE/<5)10 4444 %%%% !1110 4444 %%%% $<EO#+-%
M*\:M)"28V(Y4D8./PH2WACGDG2-1+*%#N!RP&<9^F34E% !1110 4444 %%%
M% !1110 4444 1S013A!*@<(X=0>S#H?PJ2BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
